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ATP-sensitive  potassium  channels  (K atp)  are  present  in  the  plasma  membrane  o f   a 
number  of tissues  but  are  also  present  on  endomembranes  such  as  the  endoplasmic 
reticulum (ER) and mitochondria.  They are involved in a number of physiological and 
pathophysiological processes and form a link between cellular metabolism and membrane 
excitability.  Ischaemic  preconditioning  describes  the  phenomenon  in  which  a   short 
period  of ischaemia protects against a more  prolonged  one.  The  ability  of potassium 
channel  openers  such  as  pinacidil  and  nicorandil  can  mimic  this  phenomenon,  with 
inhibitors such  as glibenclamide to abolish this response,  led to the suggestion that the 
final effector in this process was the sarcolemmal  K atp channel as it was able to shorten 
the cardiac  action  potential  reducing the energy  requirements of the cell.  However,  a 
number  of pharmacological  observations  were  not  compatible  with  this  hypothesis  as 
diazoxide,  which  does  not  activate  the  sarcolemmal  channel,  was  able  to  mimic 
preconditioning.  The focus of research then turned to the potential involvement of a K Atp 
channel present in the mitochondrial inner membrane called the mitoKATP channel.
The molecular identification of this channel would be important and there is controversial 
evidence to suggest that Kir6.1  may be a major component of the mitoKATP channel.  I 
examined  the  hypothesis  that  the  localisation  of Kir6.1  is  functionally  significant  in 
cardiac  and  skeletal  muscle  because  it  generates  important  K+   flux  in  intracellular 
membranes  such  as  the  ER  and  perhaps  mitochondria.  Colocalisation  studies  showed 
that transfected  Kir6.1  was located in the ER with a small but significant proportion  in 
mitochondria.  However,  Kir6.1  was  ER  retained  and  not  trafficked  to  the  plasma 
membrane  when  co-expressed  with  its  regulatory  subunit,  the  sulphonylurea  receptor 
SUR1.  Immunofluorescent staining also detected the presence of endogenous Kir6.1  in 
these cell  lines using antibodies specific to Kir6.1.  The distribution of Kir6.1  suggests
•  •  O x
that  it  may  play  a  role  in  reactive  oxygen  species  (ROS)  production,  calcium  (Ca  ) 
handling in the ER and perhaps cellular respiration in mitochondria.
2ROS production is often associated with K atp channel opening and protection against cell 
death  at  reperfusion.  My  results  showed  that  diazoxide  induced  ROS  production  in 
C2C12,  HepG2  and  HEK293  cell  lines  with  glibenclamide  abolishing  this  effect. 
However,  in the absence of Kir6.1, the same response was still observed.  This suggests 
that Kir6.1   is not involved in the mechanism that is responsible for ROS production.  The 
functional  role  of  K Atp  channels  were  also  examined  in  mitochondria  by  measuring 
flavoprotein  and  NADH  autofluorescence,  an  index  of mitochondrial  redox  state  and 
mitochondrial  membrane potential (Avym )  in  C2C12 cells and  rat ventricular myocytes. 
In  myocytes,  flavoprotein  oxidation  increased  when  cells  were  treated  with  3- 
nitroproprionic acid (3-NPA) and diazoxide.  Glibenclamide did not reverse this effect. 
However, this phenomenon was absent in C2C12 cells.  Given these observations, 3-NPA 
and  diazoxide  did  not  affect  the  Avj/m   in  C2C12  cells  whereas  glibenclamide  caused 
mitochondrial  depolarisation.  The A\ym  could  not  be  measured  in  myocytes.  A  large 
proportion of Kir6.1  resides in the ER and I examined whether Kir6.1  would alter ATP- 
induced Ca2+  transients.  Upon ATP stimulation, C2C12 cells released Ca2+ from internal 
stores via the P2Y  purinergic signalling pathway.  The use of dominant negatives (DN) 
for  Kir6.1  showed  that  ATP-induced  Ca2+   transients  were  affected  by  the  absence  of 
Kir6.1.  However,  on  closer  inspection;  it  was  revealed  that the  presence  of eGFP  to 
identify transfected cells seriously perturbed the Fura-2 signal.
In conclusion, the  K Atp sensitive channel subunit Kir6.1  is predominantly distributed  in 
the  ER  with  a  small  but  significant  proportion  in  mitochondria.  1   also  report  that 
pharmacological  compounds  such  as diazoxide and glibenclamide are  not always truly 
‘selective’  for  the  activation  and  inhibition  of K Atp channels.  I  have  not  identified  a 
specific  role  for  Kir6.1  but  my  data  suggests  that  Kir6.1  is  not  part  of the  mitoKA Tp 
channel and  Kir6.1   is not involved in ROS production and mitochondrial  function but it 
may still have a role in Ca2+ handling.
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4List of abbreviations
A Anion
K+ Potassium
Na+ Sodium
Cl Chloride
Ca2+ Calcium
K,r Potassium inwardly rectifying
SUR Sulphonylurea receptor
ABC ATP-binding cassette
KCO Potassium channel opener
NBD Nucleotide binding domain
ATP Adenosine triphosphate
NDP Nucleotide diphosphate
IPC Ischaemic preconditioning
APD Action potential duration
PKC Protein kinase C
PIP2 Phosphatidylinositol (4,5) bisphosphate
PIP3 Phosphatidyl inositol (3,4,5) triphosphate
DAG Diacylglycerol
IP3 Inositol triphosphate
PLC Phospholipase C
PI3K Phosphatidylinositol-3-kinase
NCX Na+/Ca2+ exchanger
sarcKA TP Sarcolemmal K Atp
mi  to Katp Mitochondrial K atp
SDH Succinate dehydrogenase
5-HD 5-Hydroxydecanoate
ANT Adenine nucleotide translocator
PIC Phosphate carrier
3-NPA 3- Nitroproprionic acid
ROS Reactive oxygen species
KO Knock out
GFP Green fluorescent protein
ER Endoplasmic reticulum
SR Sarcoplasmic reticulum
siRNA Small interfering RNA
DN Dominant negative
MBP Maltose binding protein
FCCP Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
NaCN Sodium cyanide
A y. Mitochondrial membrane potential
TMRE Tetramethylrhodamine ethyl ester, perchlorate
TMRM Tetramethylrhodamine methyl ester, perchlorate
CCD Charged-coupled device
(Ca2+|, Intracellular Ca2+ concentration
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nM TMRM.  The cells were treated with  100 pM diazoxide,  10 pM glibenclamide and  1  
pM FCCP.
Figure  3.52.  An  experiment to show the changes  in Avj/m   in  C2C12 cells  loaded  with 
20nM TMRM.  The cells were treated with  1   mM  3-NPA,  100 pM diazoxide,  10  pM 
glibenclamide and 1   pM FCCP.
Figure 3.53.  An experiment to show the changes in Avj/m  in C2C12 cells loaded with 400 
nM  TMRM.  The  cells  were  treated  with  1   mM  3-NPA,  100  pM  diazoxide,  10  pM 
glibenclamide and 1   pM FCCP.
Figure 3.54.  A graph to show the Ca2+ transients in C2C12 cells stimulated with just  10 
pM ATP (n=26).
Figure 3.55.  A graph to show the Ca2+ transients in C2C12 cells stimulated with  1   mM 
caffeine and 10 pM ATP (n= 20).
Figure  3.56.  A  graph  to  show  the  Ca  transients  in  differentiated  C2C12  cells  (48 
hours).  The cells were stimulated with 1  mM caffeine and 10 pM ATP (n= 40).
Figure  3.57.  A  graph  to  show  the  Ca2+  transients  in  differentiated  C2C12  cells  (96 
hours).  The cells were stimulated with 1   mM caffeine followed by 10 pM ATP (n= 22). 
Figure  3.58.  The  Ca2+  transients  in  figure  3.57  were  separated  according  to  their 
response.  A. A graph to show the Ca2 4   transients in C2C12 cells in response to  10 pM 
ATP (n= 9).  B.  A graph to show the Ca2+ transients in C2C12 cells response to  1   mM 
caffeine and 10 pM ATP (n= 13).
Figure 3.59.  A graph to show the Ca2+ transients in rat ventricular myocytes in response 
to 1  mM caffeine (n= 7).
Figure  3.60.  A  graph  to  show  the  Ca2+  transients  in  C2C12  cells  transfected  with 
DNG->A, these were stimulated with  1   mM caffeine and  10 pM ATP. (Non transfected 
cells = 7, transfected cells = 6).
Figure  3.61.  A  graph  to  show  the  Ca2+  transients  in  C2C12  cells  transfected  with 
DNG— >S, these were stimulated with  1   mM caffeine and  10 pM ATP. (Transfected cells 
= 9, non transfected cells =11).
Figure 3.62.  A graph to show the Ca2+ transients in C2C12 cells transfected with eGFP 
these were stimulated with  1   mM caffeine and  10 pM ATP. (Transfected cells = 9, non 
transfected cells = 13).
151.0  INTRODUCTION
1.1  Transport through cellular membranes and membrane potentials
Each  cell  is  highly  compartmentalised  by  the  plasma  membrane  and  intracellular 
membranes.  The  plasma  membrane  is  composed  of a  phospholipid  bilayer.  This  is 
impermeable to  most  ionic and  polar substances and the specific transport of ions and 
solutes is achieved through an array of channel and receptor proteins that are embedded 
in  the  membrane.  Two  transport  processes;  facilitated  diffusion  and  active  transport 
control  the  movement  of ions.  Facilitated  diffusion  is  a  passive  process  by  which 
molecules  or  ions  will  equilibrate  in  their  environment  by  flowing  down  their 
concentration gradient.  Active transport involves the specific action of carrier proteins 
where molecules or ions are transported against their concentration gradient, using energy 
from the hydrolysis of adenosine triphosphate (ATP).
The  semi-permeability  property  of  cell  membranes  allows  charged  ions  such  as 
potassium  (K*)  and  chloride  (Cf)  to cross  easily  whereas  sodium  (Na+)  do  not.  The 
intracellular compartment also has a high protein content, phosphate groups from ATP 
and organic molecules which, at physiological pH, are negatively charged and contribute 
to  the  intracellular  anion  (A )  pool.  The  presence  of  anions  in  the  intracellular 
compartment will  upset transmembrane osmolarity,  but a balance  is maintained  by the 
action  of the  Na+ /K+  ATPase.  The  high  intracellular  content  of impermeant  anions 
produces  an  unequal  charge  distribution  across  the  membrane  with  excess  negative 
charge on the inner surface of the membrane compared to the outer face.  This difference 
in charge is known as the membrane potential.  The ionic composition of extracellular (i) 
and intracellular (2) compartments is determined by two principles:
1.  Electroneutrality in bulk solutions where:
[K+]i = [Cf]i  Equation 1   [K.+h = [Cf]2 + [A h  Equation 2
162.  The  Donnan  equilibrium  where  the  product  of  permeable  ions  in  one 
compartment is equal to the second:
[K+]i [Cl ]i = [K+]2 [Cl ]2  Equation 3
The net result of these forces determined  by equations  1-3  is that the concentration of 
permeable  cations  (e.g.  K+)  is  greater  in  compartment  2  and  the  concentration  of 
permeable anions (e.g. Cl ) is greater in compartment 1.  Furthermore, these forces yield a 
greater  solute  concentration  in  compartment  2  compared  to  compartment  1.  Osmotic 
balance is achieved by the accumulation of an impermeable ion (e.g. Na*).  Thus, there 
will be equal anion and cation concentrations in both compartments.  This is an important 
condition  because  the  two  solutions  must  have  the  same tonicity  to  maintain the  cell
volume so  that there  is  no  net  movement of water across  the  membrane.  Na+   cannot
leave the cell passively but is actively pumped out of cells through the action of the Na- 
pump, which is often referred to as the Na+/K+  ATPase.  The Na-pump moves three Na+  
out of the cell in exchange for two K+.
At equilibrium, the inside of the cell membrane is more negative then the outside of the 
membrane.  The  asymmetry  of permeable  ions  such  as  K+   leads  to  the  difference  in 
charge or potential difference across the membrane which is also known as the membrane 
potential.  This can be summarised by the Nemst equation.  The Nemst equation allows 
the theoretical equilibrium potential to be calculated for a particular permeable ion when 
its transmembrane concentration gradient is known.  Below, is the simplified equation at 
a temperature of 37 °C:
E  = iilo g   IM  
m   z  [* |]
Em = equilibrium potential in millivolts (mV) for ion X 
Xq  = concentration of ion outside cell 
X\ = concentration of ion inside cell 
Z = valency of ion (+1 for Na+ or K+)
17If the membrane is permeable to a single ionic species, the membrane potential can be 
calculated from the Nemst equation.  The concentration of K+ is higher inside that cell 
than outside for example, if it is  150 mM inside compared to 5 mM on the outside, the 
equilibrium potential for K+ is -90 mV.  For Na* because the concentration inside the cell 
is for example is 10 mM compared to 144 mM on the outside.  The equilibrium potential 
for Na+ is thus calculated to be + 70 mV.  The resting membrane potential of most cells 
in the body lies between -65 mV to -85 mV.  This value is near to the E* value because 
the membrane is much more permeable to K+.
1.2  Potassium channels
Ion channels regulate a number of functions.  These include electrical excitability, ionic 
homeostasis,  control  of neurotransmission  and  hormone  secretions  (Hille  1992).  Ion 
channels can  be  in open  or closed conformation and the equilibrium  is determined  by 
voltage  and  concentration,  depending  on  the  channel.  The  physiological  role  of 
potassium  (K*)  channels  is  largely  based  on  their  ability  to  stabilise  the  plasma 
membrane potential.  The action of Na+/K+ ATPase maintains a high  K+ concentration 
inside the cell relative to the outside.  When potassium channels open, the membrane is 
hyperpolarised  (the  membrane  potential  becomes  more  negative  than  the  resting 
potential) and this decreases excitability in cells.  The potassium channel family contains 
a variety of diverse proteins that can be classified into particular subfamilies depending 
on their structure and functional properties.  The types of K+ current can be classified by 
their  electrophysiologica!  properties  (Fujita  &  Kurachi  2000).  Potassium  channel 
families  include  the  six  transmembrane  domain  voltage  gated  potassium  channel  (Kv 
family),  two  transmembrane  domain  inwardly  rectifying  (K ir  family)  and  four 
transmembrane domain two-pore channel (‘Twin pore’ channels).  Kv and K ir channels 
exist as tetramers whereas twin  pore  channels  are dimers.  There  is also  the calcium 
(Ca2+) activated or dependent channel  (Kca family) and tandem pore region  potassium 
channels.
181.2.1  Inwardly rectifying potassium channels
Inwardly rectifying K+ channels are so called because they allow more inward flux of K+ 
ions than outward flux with the same driving force but it is the small amount of outward 
current that is important physiologically because it causes membrane hyperpolarisation. 
Inward rectification was first demonstrated in K+ depolarised muscle by Katz in 1949 and 
subsequent  studies  have  identified  potassium  channels  in  different  cell  types  such  as 
starfish egg cells and neurones (Katz 1949).  The first members of this potassium channel 
family  were  initially discovered  by  cloning  mRNAs  from  rat  kidney  (ATP dependent 
KirI.I/ROMK) and from mouse macrophage cell line (Classical Kir channel IRK/Kir2.1) 
(Ho et ai 1993; Kabo et al 1993).  Several members of the Kir channel family have been 
identified and named as Kir subfamily (Kir  1.0  - 6.0) based on  unifying nomenclature 
(Chandy &  Gutman  1993).  The inwardly rectifying  K+ channel  family  (Kir) contains 
seven family members, these are characterised by the degree of their inward rectification 
in response to extracellular stimuli, see Table 1.1
Table 1.1.  A table to show examples of native inwardly rectifying K+  channels.
K n C h iiie b Name Original name Nomenclature
IK , channel Classically inwardly rectifying K+ IRK1 Kir2.1
channel IRK2 Kir2.2
IRK3 Kir2.3
IRK4 Kir2.4
Ko Channel G protein activated K+ channel GIRK1 Kir3.1
GIRK2 Kir3.2
G1RK3 Kir3.3
GIRK4 Kir3.4
KA T r channel ATP-sensitive K* channel uK -atf-! Kir6.1
BIR Kir6.2
ATP-dependent K+ transport channels ROMK1 Kiri.la
channels Kab-2 Kir4.1
BIR9 KirS.l
The  Kir  channel  is  made  up  of tetrameric  subunits,  each  Kir  subunit  contains  two 
transmembrane domains called Ml and M2 with a pore forming loop (p) in the middle of 
the H5 pore region.  This is responsible for conferring K+ selectivity and the amino and 
carboxylic termini are located on the cytoplasmic side.  Please refer to figure  1.1.  Two 
thirds  of the  K«  channel  amino  acid  sequence  forms  an  intracellular domain,  which
19forms  the  pore  that  regulates  channel  activity  and  inward  rectification  (Ashcroft  & 
Ashcroft 1990).  Magnesium (Mg2*) and other cations interact with negatively charged 
amino acids in transmembrane domain 2 (TM2) at the C terminal end of the Kir subunit 
that induces rectification.  The majority of the Kir channels identified are eukaryotic but 
the 3D structure of the first prokaryotic Kir channel called KirBacl.l  was determined in 
2003 using high resolution X-ray crystallography (Kuo et al.  2003; Bicher et al  2003). 
K ir 1.0  family  members  are  important  in  transepithelial  membrane  transport.  K ir 1.1 
(ROMK1) is inhibited by acidification for example; H* can bind to the channel and cause 
inhibition.  The K ir2.0 family are responsible for controlling the excitability in the heart 
and brain.  The K ir3.0 family are known as the G protein inwardly rectifying K+ channel 
family  (G1RK) as the channel  activity  is regulated by the G  protein  Gffy subunit.  In 
general, the K ir 2.0 and 3.0 family members are strong inward rectifiers whereas K ir 1.0 
and K ir 6.0 members are weak rectifiers (Reinmann & Ashcroft 1999).
13  ATP-ae—itive potassium channels (Katp!
1.3.1  The molecular structure and basic properties of K atp channels
K atp channels were originally  discovered  in  the  heart  by Noma (Noma 1983).  K atp
channels are present in many tissue types with a variety  of important  functions and they
respond to  intracellular  levels of ATP thus  coupling cell  metabolism to the electrical 
activity of the cell (Rodrigo & Standen 2005).  They are inhibited by non hydrolysable 
forms of ATP and activated by nucleotide diphosphates (NDPs).  The K atp channels can 
also be activated by potassium channel openers (KCO) and inhibited by sulphonylureas. 
The K atp channel is an octameric complex comprised of four Kir 6.0 subunits from the 
inward rectifier family of potassium channels and four sulfonylurea receptors (SUR), a 
member of the ATP-binding cassette (ABC) family of proteins.  The SUR is the site of 
action  for  antidiabetic  drugs  such  as  glibenclamide  used  in  the  treatment  of type  2 
diabetes mellitus (Szewcyk & Marban 2003; Aguilar-Bryan & Bryan 1999; Ashcroft & 
Gribble 1998).  The structure of a K atp channel is shown in figure 1.1.
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Figure  I. I.  A diagram to show the topology of a K At p  channel.  A.  The K jR subunit B.  The SUR 
subunit C.  The pancreatic KA Tp channel is composed of Kir6.2 and SUR l  subunit.
The pore forming subunit Kir6.0 has two different members called Kir6.l and Kir6.2 that 
share 70 % amino acid identity.  Recently, a new member of the Kir subfamily has been 
identified  and  characterised  in  zebrafish  called  Kir6.3  (Zhang  et  al.  2006).  The 
regulatory subunit,  SUR  is encoded by two distinct genes,  SUR l  and  SUR2 (Aguilar- 
Bryan & Bryan 1999; Bryan & Aguilar-Bryan 2003; Higgins,  1992).  The SUR1  protein 
was first cloned  in  1995  in  protein  purification  studies and  expressed  in  pancreatic  p 
cells, the SUR1 cDNA sequence encoded a protein of 1582 amino acids with a molecular 
mass of 177  kDa (Aguilar-Bryan et al  1995).  A  few years later, the SUR2 gene was 
identified with two splice variants named SUR2A and SUR2B, these differ by 42 amino 
acids in the C terminus (Chutkow et al.  1996; Inagaki et al. 1996; lsomoto et al.  1996).
The SUR regulatory subunit contains three main transmembrane domains, TMDO, TMD1 
and TMD2 which are composed of five, six and six transmembrane regions respectively. 
The  topology  of  the  complete  full-length  SUR1  was  predicted  using  membrane 
impermeable biotinylating reagent called biotin malemide (Conti et al.  2001).  The SUR 
subunit contains 17 transmembrane domains in total with an extracellular N-terminus and 
intracellular C terminus.  There are two nucleotide binding domains (NBD) which are 
located between TMD1  and TMD2 in the C terminus (Grover & Garlid 2000; Bryan & 
Aguilar-Bryan  2003;  Aguilar-Bryan  et al  1998).  The NBD  contains three consensus
21nucleotide  binding  motifs  called  Walker  A,  Walker  B  and  a  characteristic  linker 
sequence.  These  contain  specific  sites  where  Mg2+  bound  nucleotides  can  bind  to 
(Walker et al.  1982).  The Walker A and B motifs form a binding pocket which houses 
the MgATP complex and  interacts directly with  Mg2+ and the phosphoryl  group whilst 
the role of the linker motif is likely to stabilise and facilitate nucleotide hydrolysis.  The 
Kir6.0 subfamily does not contain these motifs so ATP sensitivity was originally thought 
to be determined by the SUR subunit.  Introducing mutations  into the  Walker A  and  B 
motifs  can  alter  ATP  binding  to  SUR1.  Specific  mutations  of the  lysine  residues  in 
Walker A (K719R and K719M) and Walker B (K1385M, K1835R) motifs in the NBD-1 
of hamster SUR1  abolished channel activation (Ueda et al.  1997).  These mutations are 
not vital for K atp channel inhibition but NBDs are responsible for MgADP activation.
The  stoichiometry  of  K atp   channels  has  been  determined  by  using  cDNAs  encoding 
tandem dimers of SUR 1   and Kir6.2 (Clement et al.  1997).  This group demonstrated that 
the Kir6.2 and SUR1  tandem dimer exhibited electrophysiological  properties similar to 
native  pancreatic  B-cell  K Atp   channel  where  a  1:1  stoichiometry  was  sufficient  to 
generate  functional  channels.  However,  the  triple  fusion  protein  consisting of Kir6.2, 
Kir6.2 and SUR1  did not produce functional channels.  Our laboratory have carried out 
biochemical and functional experiments with these subunits and found that K atp  channel 
complexes containing SUR1, SUR2 and Kir6.2 could not form, even after overexpression 
in  HEK293  cells  (Giblin et  al.  2002).  However,  SUR2A  and  SUR2B  are  C-terminal 
splice  variants  and  differ  by  about  40  amino  acids  there  is  a  possibility  that  these 
channels  can  still  form  and  possess  channel  activity.  The  glycosylated  form  of 
Kir6.2/SUR1  channel  was reported to be a protein complex of 950 kDa suggesting that 
the K atp channel was an octameric protein with 4:4 stoichiometry (Inagaki et al.  1997). 
Shyng  and  Nichols  confirmed  that  the  K atp   channel  pore  consisted  of  four  Kir6.2 
subunits and each Kir6.2 subunit required an SUR1  subunit to form a functional channel 
in an octameric or tetradimeric structure (Shyng & Nichols 1997; Shyng et al.  1997).
221.3.2  Chromosomal localisation of SUR and Kir6.0 genes
The human  Kir6.2 and  SUR1  genes are clustered at  11 pi5.1  where the  Kir6.2  gene  is 
approximately 4.5  kb downstream of SUR1.  There  is about 71  % amino acid  identity 
between Kir6.1 and Kir6.2 {Inagaki et al.  1995a).  The SUR1 gene contains 39 exons and 
is more than  100 kbp in length (Aguilar-Bryan et al 1998; 1995).  The human Kir6.1 and 
SUR2 genes are also close together with Kir6.1  gene at 12p 11.23 and SUR2 gene located 
at 12pl 1.12 (Chutkow et al.  1996).  The proximity of the Kir6.0 and SUR genes (Kir6.2 
and SUR1,  Kir6.1  and  SUR2) suggests that each  gene pair may have derived from the 
same loci  but during the course of evolution they duplicated and diverged to different 
positions on the chromosome.  In the rat heart, the mRNA level of SUR1  was expressed 
at low levels indicating another isoform was also present.  This was later confirmed to be 
SUR2A.  SUR2A is expressed at high levels in rat and mouse hearts and has 68 % amino 
acid identity to SUR1.  The other isoform of SUR2, SUR2B is composed of 1546 amino 
acids and only has 67 % similarity to SUR1  but 97 % identity to SUR2A; the differences 
exist in the C terminal part of the protein {Chutkow et al.  1996; Inagaki et al.  1995a).
1.3.3  K^tp channel isoforms
Different combinations of Kir6.0 and SUR genes can create various  K At p channels with 
distinct  electrophysiological  and  pharmacological  properties  (Seino  &  Miki  2003a; 
Yokoshiki et al.  1998).  The different types of channels are displayed in table  1.2.
Table 1.2.  A table to show different combinations of Kir6.0 and SUR genes create distinct KA T P  
channels in various tissues.
Channel Type Tissue References
Kir6.2/SUR1 Pancreas/Brain Inagaki et al, 1995a; Sakura et al. 1999
KM.2/SUR2A Cardiac muscle Inagaki et al 1996
Kir6.2/SUR2B Smooth muscle Isomoto et al 1996
Kir6.1/SUR2B Vascular smooth muscle Yamada et al 1997
23The  Kir6.2/SUR1  isoform  is  present  in  pancreatic  B  cells  and  has  been  studied 
extensively  by  many  groups  (.Ashcroft  &  Gribble  1998;  Inagaki  et  al.  1995b).  The 
Kir6.2/SUR2A isoform forms the cardiac sarcolemmal channel and is mainly expressed 
in  heart  and  skeletal  muscle  {Babenko  et  al  1998a;  Inagaki  et  al  1996).  The 
Kir6.1/SUR2B  isoform  constitutes  the  channel  found  in  vascular  smooth  muscle  and 
Katp  channels  in  non-vascular  smooth  muscle  are  predominantly  composed  of 
Kir6.2/SUR2B and Kir6.1/SUR2B channels.  It is vital that functional KA tp channels are 
trafficked to the plasma membrane.  For example, the  Kir6.2 contains an  ER retention 
motif at the C terminus which is composed of three amino acids, arginine-lysine-arginine 
(RKR).  SUR1  also contains an RKR sequence in the intracellular loop between TMDO 
and NBD1.  This mechanism prevents SUR1  surface expression in the absence of Kir6.1 
or Kir6.2 (Zerangue et al.  1999).  When  KA tp channel subunits coassemble to form the 
octameric protein, the ER retention motif is masked, allowing the complex to exit the ER. 
The truncation of the C terminus of Kir6.2 (Kir6.2AC) eliminated the ER retention motif 
allowing channels to  form  in  the absence of SUR  {Tucker et al.  1997).  The authors 
found that the channel was inhibited through Kir6.2, which contains the ATP binding site 
and not SUR.  Furthermore, deleting seven amino acid residues from the C terminus of 
SUR1  clearly reduced the surface expression of KA tp channels {Babenko et al.  1998b). 
The trafficking  of KA tp  channels  to  the  cell  surface  is  a complex  process  because  in 
contrast, the deletion of the furthest amino acid  sequences at the C terminus of SUR1 
allowed KA tpchannels to be expressed at the cell surface {Sakura et al.  1999).
1.3.4  Biophysical properties of K atp channels
Single channel conductance measured in the inside out configuration in pancreatic B cells 
recorded inward current from 50 to 75 pS whereas cardiac cells measured 70-90 pS  in 
140  mM  K+  recording  solution  {Nichols  &  Lederer  1991).  A  characteristic  of KA tp 
channels is that channel openings occurred in bursts with relatively long closed periods in 
between {Trube et al.  1984).  A study investigating single channel recordings made from 
ventricular cells isolated enzymatically  from  guinea-pig heart showed that the channel 
was inhibited in the presence of ATP {Kakei et al.  1985). More importantly, the results
24showed  that  when  ATP  concentrations  increased,  the  number  of openings  decreased 
whereas the duration of the closed-intervals increased, resulting in the overall decrease of 
the open-state probability.
1.3.5  K^jp channel regulation by ATP and nucleotide diphosphates
The expression of Kir6.0 and SUR subunits in different combinations reconstitutes KA Tp 
channels with distinct electrophysiological properties and characteristics in native tissues 
(Seino & Mi  hi 2003a).  One of the characteristic properties K At p channels possess is the 
dose  dependent  inhibition  by  ATP.  This  inhibitory  effect  can  be  mimicked  by  non- 
hydrolysable  analogues  of ATP  and  also  ATP  in  the  absence  of  Mg2+  i.e.  channel 
inhibition does not depend on ATP hydrolysis.  ATP sensitivity varies in different tissues 
but channels are usually  inhibited  in the micromolar range.  For example, in pancreatic 
cells,  the  Kj  is  ~  30  pM.  The  other  factors  that  regulate  KA jp  channels  include 
intracellular  nucleotides,  phospholipids,  protein  kinases  and  phosphatases.  It  was 
originally thought that the SUR subunit mediated the direct hydrolysis of ATP and this 
was a required element for channel inhibition (Kakei et al.  1985; Cook & Hales.  1984).
One study showed that the truncation of the C terminal (26-36 amino acids) of Kir6.2 
(Kir6.2AC) without the SUR subunit generated K+ currents which were inhibited by ATP 
but not activated by MgADP, this suggested that the Kir6.2 subunit does not confer ATP 
sensitivity {Tucker et al.  1997).  Other studies showed that equivalent mutations of the 
Walker A and B motifs of rat SUR1  when heterologously expressed with Kir6.2 did not 
affect the inhibitory effect of ATP on channel activity {Gribble et al.  1997).  When the 
last 36 amino acids from the C-terminus were deleted from Kir6.2, MgADP, KCOs and 
sulphonylureas of low concentration had no effect on channel activity, suggesting that the 
SUR  subunit  was  the  site  of drug  action  {Reinmann  &  Ashcroft  1999).  COS  cells 
expressing  Kir6.2  and  SUR2A  have  a  conductance  of ~80  pS  and  like  cardiac  and 
skeletal cells, they are generally less sensitive to intracellular levels of ATP compared to 
the Kir6.2/SUR1 type channel {Inagaki et al. 1996).
25NDPs such as ADP, UDP and GDP, in the presence of Mg2+ stimulate channel opening 
and reduce the inhibitory effect of ATP.  In the absence of NDPs, the maximal block in 
(3-cell  K atp  channels  is  around  60-80  %,  suggesting  that  sulphonylureas  such  as 
glibenclamide  can  act  as  partial  antagonists.  Intracellular  MgADP  will  modulate 
sulphonylurea  block  and  enhance  the  inhibition  of Kir6.2/SUR1  ((3-cell)  channel  but 
decrease the inhibition of Kir6.2/SUR2A (cardiac-type) channels {Reinmann et al. 2003). 
The NBDs  in  SUR1  in  particular are  responsible  for channel  activation;  MgADP  will 
activate the K atp channel by interacting with the NBDs in the SUR subunit {Gribble et 
al.  1997;  Shyng et al  1997).  In  SUR1,  there  is  strong  ATP  Mg2+  independent  high 
affinity binding at NBD1  which is antagonised by MgADP at NBD2 (Ueda et al.  1997). 
The SUR subunit has other important regulatory roles apart from NDP activation.  For 
example, the energy status of mitochondria may be linked to  K atp channel activity and 
during metabolic stress; adenylate kinase may transport ADP from the mitochondria via a 
phosphorelay network linking mitochondria to  K atp channels on the plasma membrane 
{Carrasco et al. 2003).
1.3.6  Kfrff channel regulation bv potassium channel openers and inhibitors
The SUR subunits are so called because they form the crucial target for the interaction of 
therapeutic drugs such as sulphonylureas but they also confer sensitivity to activation by 
a group of potent channel  activating drugs called  potassium  channel  openers  (KCOs). 
Examples include diazoxide, pinacidil, cromakalim and nicorandil, these are known as 
pyridines the latter, nicorandil is an antianginal agent and can be used as a vasodilator to 
lower  blood  pressure.  KCOs  are  a  diverse  group  of drugs  and  will  stimulate  K Atp 
channel  opening  which  generates  an  outward  current  that  changes  the  membrane 
potential.  This  is  important  because  it  modulates  cellular  function  by  reducing  the 
electrical activity of a cell {Seino & Mild 2003a; Ashcroft & Gribble, 2000).  KCOs can 
have  different  effects  on  various  tissues,  as  the  different  SUR  subunits  will  confer 
varying sensitivities to KCOs.  Diazoxide is used in some hypoglycaemic conditions for 
its hyperglycaemic actions by strongly activating K+ currents in pancreatic cells whereas 
pinacidil  have no  major effect  on  p  cells {Gribble et al.  1998;  Inagaki  et al.  1995b;
26Garrino et al.  1989).  Other sulphonylureas such as glibenclamide and tolbutamide are 
hypoglycaemic  agents  that  stimulate  insulin  secretion  by  closing  the  K Atp  channel 
(Tucker et al.  1997).  Glibenclamide can  inhibit the channel  by  binding directly to the 
SUR  subunit and  block  K atp  channels  resulting  in  membrane  depolarisation  and  Ca2+ 
influx (Koster et al.  1999).
1.3.7  K^jp channel regulation by other factors
K atp   channel  activity  can  also  be  closely  modulated  by  other  intracellular  factors. 
Protein  kinase  A  (PKA)  has  been  shown  to  stimulate  K Atp   channel  activity  in  native 
tissues such as rabbit arterial smooth muscle (Wellman et al.  1998; Quayle et al.  1994; 
Beech  et  al.  1993;  Ribalet  et  al.  1989).  In  pancreatic  B-cells,  Kir6.2  can  also  be 
phosphorylated by  PKA (Yamada et al.  1997).  Phosphatidyl inositol (4,5) bisphosphate 
(PIP2) and phosphatidyl inositol (3,4,5) trisphosphate (PIP3) are membrane phospholipids 
and  have  been  shown  to  modulate  the  ATP  sensitivity  of  K Atp   channels.  PIP2  in 
particular decreased the ATP-sensitivity of K Atp  channels and it prevents the inhibition of 
the channel  in the presence of tolbulamide by stabilising the open state of the channel 
{Koster et  al.  1999).  Finally,  K a tp   channel  activity  can  also  be  modulated  by  GTP 
binding proteins (G<Xj),  pH, or protein kinase C (PKC) and cytosolic factors such as C1‘ 
{Hu et al.  1996; Kayano et al.  1993; Kirsch et al.  1990).
PKC can activate K atp channels in rabbit and human myocytes by decreasing sensitivity 
to  intracellular  ATP  {Hu  et  al.  1996).  Rat  ventricular  myocytes  with  tolbutamide 
sensitive K atp currents were studied and purinergic receptors were shown to be coupled 
to K atp channels via G proteins with three different types of Ga, protein reducing channel 
sensitivity  to  ATP  {Kirsch  et  al.  1990).  Furthermore,  Ga,i  could  stimulate  both 
Kir6.2/SUR1  and  Kir6.2/SUR2A  channels whereas Gc^ stimulated  Kir6.2/SUR2A  but 
not Kir6.1/SUR2B channels {Sanchez et al.  1998).  K Atp channels in guinea pig cardiac 
ventricular myocytes were closed by internal ATP and activated by lowering the pH (7.6- 
6.0) in a dose dependent manner.  This is due to the decrease in sensitivity of the channel 
to ATP {Kayano et al. 1993).
271.4  The physiological roles of K a t p  channels
K atp  channels  have  many  important  physiological  roles  and  have  been  identified  in 
tissues such as the kidney, brain and skeletal muscle and pancreatic p cells {Inagaki et al. 
1995c).  For  example,  when  K Atp  channels  in  p   cells  are  closed,  cell  depolarisation 
stimulates  insulin  and  growth  hormone  secretion  {Bemardi et  al.  1993).  In  resting  p  
cells, blood glucose is 2-3  mM (fasting period) and the role of the K Atp channel is to set 
the membrane potential close to the K+ equilibrium potential reducing excitability which 
inhibits insulin secretion.  After a meal, blood glucose increases and is transported to the 
B-cells via the glucose transporter {Seino &  Miki 2003b).  The  increase  in  intracellular 
glucose  stimulates  glycolysis  and  subsequently  ATP  production.  This  increase  in 
intracellular  ATP  closes  the  K Atp  channel  followed  by  depolarisation  of the  plasma
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membrane.  There is an increase in intracellular Ca  mainly through the activation of L-
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type voltage gated Ca  channels.  Rapid cytoplasmic Ca  in turn stimulates the release 
of insulin from insulin containing vesicles via exocytosis.  Insulin stimulates the uptake 
of glucose from the blood to the tissue causing plasma glucose levels to fall.  The adenine 
nucleotide levels normalise allowing membrane repolarisation therefore inhibiting insulin 
release.  In Kir6.2 knockout mice, the membrane potential of 6-cells has been reported to 
be permanently depolarised at approximately -  40 mV {Miki et al.  1998a).
1.4.1  Genetic mutations affecting K a t p  channel subunits
Familial persistent hyperinsulinaemic hypoglycaemia of infancy (PHHI) is characterised 
by  persistent  insulin  secretion  in  newborns despite  severe  hypoglycaemia {Kane et al. 
1996; Thomas et al.  1995).  This can be caused by a mutation in the gene encoding SUR1 
or in rare cases in the pore-forming subunit, Kir6.2.  Thomas et al originally identified 
three mutations in SUR1  gene in patients with PHHI and later studies identified further 
mutations  in  Kir6.2  {Nestorowicz et  al.  1997;  Thomas et  al.  1996).  Although  these 
mutations have been  identified  in  K At p channel  subunits,  mutations  in the glucokinase 
gene  and  glutamate  dehydrogenase  gene  can  also  cause  PHHI  {Glaser  et  al.  1998; 
Stanley et al.  1998).  Dilated cardiomyopathy is a disease of the heart muscle that causes
28the heart to  become enlarged.  The muscle  becomes  weak  and  the  heart cannot pump 
blood efficiently around the body.  Two mutations in ABCC9 gene, which encodes the 
regulatory  SUR2A  subunit  of the  cardiac  K atp  channel  have  been  linked  to  dilated 
cardiomyopathy (Bienengraeber et al. 2004).
1 .4.2  The physiological roles of K a t p  channels in other tissues
K atp  channels  also  play  important  physiological  roles  in  tissues  such  as  non  vascular 
smooth muscle, neurons, endocrine cells, renal cells, vascular, endothelial and follicular 
cells of the ovary (Seino & Miki 2003b).  For example, cromakalim induced K Atp channel 
opening  and  hyperpolarisation  in  rat juxtaglomerular  cells  of the  vas  afferens  in  the 
kidney  which  increased  renin  secretion  (Ferrier  et  al.  1989).  Diazoxide,  unlike 
cromakalim  and  pinacidil  cannot  activate  cardiac  sarcolemmal  K atp  channels  but  has 
cardioprotective properties (Babenko et al 1998b; Nakayama et al.  1990).  Some studies 
have demonstrated that glibenclamide reduced basal coronary blood flow in anesthetised 
dogs, suggesting that K atp channels may act to regulate background K + conductance and 
therefore vascular tone (Imamura et al.  1992; Samaha et al.  1992).  K Atp channels also 
have  vital  roles  in  smooth  muscle.  For  example,  glibenclamide  can  cause 
vasoconstriction in arteries, which supports the fact that K atp channels are important in 
regulating resting membrane potentials and vascular tone {Samaha et al.  1992; Clapp & 
Gurney 1992).  In vivo studies conducted by Quayle et al also reported that diazoxide and 
pinacidil  promoted  vasodilation  through  K Atp  channel  opening  with  glibenclamide 
affecting  smooth  muscle  membrane  potential  by  significantly  increasing  vascular 
resistance and arterial diameter {Quayle et al.  1997).
The exact role of K atp channels in skeletal muscle has not been clearly defined but the 
opening of KAtp channels in isolated fibre bundles from myotonic human skeletal muscle 
prevented  after-contractions  and  spontaneous  mechanical  activity,  which  would 
otherwise  happen  in  myotonia  congentia  {Quasthoff  et  al.  1990).  In  the  brain, 
hypoglycaemia or local  hypoxia opens neuronal  K atp channels.  This reduces the firing 
rate of a subset of neurons that express K atp channels, for example in the hypothalamus,
29nuclei of the vagus nerve and dopaminergic neurons (Miki et al 2002; Muller et al. 2001; 
Liss & Roeper 2001a and b).  Finally,  K ATp channels also play a protective role in the 
heart during  metabolic  stress.  K atp  channels  were  initially  discovered  in  the  cardiac 
sarcolemma where they  were expressed at high density and opened  in the presence of 
cyanide or under hypoxic conditions {Noma et al  1983).  The cardiac action potential is 
the electrical activity of individual cells in the electrical conduction system of the heart.
The  cardiac  action  potential  has  five  phases  (0-4);  phase  4  is  the  resting  membrane 
potential and is the period where the cell is not stimulated.  Once the cell  is electrically 
stimulated, usually by an electric current from an adjacent cell,  it begins a sequence of 
actions  involving  the  influx  and  efflux  of multiple  cations  and  anions  that  together 
produce the action potential of the cell.  See figure  1.2.  Phase 0 is a rapid depolarisation 
stage  where  Na*  channels  opens  resulting  in  a  rapid  influx  of Na+  ions  into  the  cell. 
Phase 1   of the action potential occurs with the inactivation of the fast Na+  channels. The 
transient  net  outward  current  causing  the  small  downward  deflection  of the  action 
potential is due to the movement of K+  and Cf ions.  Phase 2, the plateau stage is mostly 
maintained by the influx of Ca2+ ions through the L-type Ca2+ channel and the outward 
movement of K+ ions via the slow delayed rectifier K+ channels Iks-  During phase 3 of 
the action potential, the L-type Ca2+ channels close, while the slow delayed rectifier K+ 
channels remain open.  This outward flow of K+ ions promote other  types of K+ channels 
to open such as the rapid delayed rectifier K+  channels (Iki) and the inwardly rectifiying 
K+  current,  Iki•   This causes the cell  to repolarise.  The delayed  rectifier K+  channels 
close  when  the  membrane  potential  is  restored  to  -80  to  -85  mV,  while  Iki  remains 
conducting throughout  phase 4  to  set the  resting  membrane  potential.  K Atp  channels 
were recognised to have a cardioprotective role by shortening the cardiac action potential 
duration (APD) and preventing Ca2+  influx  in the cytosol to reduce muscle contraction 
and conserve cellular ATP.  This is thought to act as a protective mechanism that adapts 
local energy expenditure to local energy supply in cardiac muscle cells during periods of 
interrupted blood supply {Suzuki et al 2001, Flagg & Nichols 2001).
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Figure 1.2.  The cardiac action potential may be divided into a number of phases:
Phase 0 - rapid depolarisation.  Phase 1   - early repolarisation.  Phase 2 - plateau phase.  Phase 3 - 
late repolarisation and phase 4 - diastolic phase.
1.5  The phenomenon of ischaemic preconditioning
Ischaemia results from a situation  in which tissue is deprived of blood  leading to tissue 
damage and irreversible necrosis.  Myocardial ischaemia affects the heart muscle and can 
be caused by a number of factors such as atherosclerosis, thromboembolism and surgical 
interventions; these include heart bypass operation,  percutaneous transluminal  coronary 
angioplasty  (PTCA)  and  heart  transplants.  Ischaemic  preconditioning  (IPC)  was  first 
described by Murry in  1986 where brief ischaemic episodes would protect the heart from 
a subsequent lethal  ischaemic  insult (Murry et al  1986).  This original study examined 
dog hearts which were subjected to four to five minute episodes of ischaemia and these 
were reported to have less necrosis from a sustained 40 minute coronary occlusion when 
compared  to control  hearts.  In  Murry’s  study,  it  was  also  noted  that  preconditioning 
delayed  cell  injury  by  slowing  the  rate  of  ATP  depletion  therefore  limiting  the 
accumulation of harmful catabolites such as lactate during reperfusion.
Other groups have used  this protocol  to  investigate how  IPC  can delay cell  injury and 
death in  ischaemic myocardium.  For example,  hearts can be protected  from  ischaemic 
and or reperfusion injury by subjecting the organ to one or more short ischaemic periods 
(usually  3-5  minutes)  with  regular recovery  phases  before  prolonged  index  ischaemia,
31which usually lasts about 30 minutes (Gross & Peart 2003; Cohen et al.  2000).  This is 
the first window of protection which will last for  1-2 hours and is known as ‘classic IPC’ 
followed by the second window of protection which is less effective; this occurs 24 hours 
later and lasts 72 hours.  The second window of protection has been extensively studied 
however;  I  will  only  discuss classic  IPC  (Yellon  &  Downey 2003;  Bolli  2000).  How 
protection is memorised is unknown at present and subject to speculation.
IPC  evidently  reduces  tissue  necrosis  induced  by  a  subsequent  prolonged  ischemia 
(Hanley & Daut 2005;  Cohen et al.  2000).  The cardioprotective effects of KCOs have 
been reported in a variety of species such as dogs, rat, mice, rabbits and humans (Yellon 
Downey 2003; Cohen et al. 2000;  Yao & Gross 1994a,  1994b; Grover et al.  1992).  It 
is widely accepted that preconditioning activates intracellular signalling mechanisms that 
increase tolerance to injury (Yellon & Downey 2003; Dzeja et al. 2001).  These signalling 
mechanisms are complex  and  are  linked  to  a  variety  of factors  such  as  mitochondrial 
function, cellular metabolism and electrical activity of the cell (fVang et al.  2005; Dzeja 
et al.  2001).  Although  preconditioning studies  predominantly  focus on  the  heart,  this 
protective mechanism has also been studied in the brain, skeletal muscle, kidney and liver 
(Jaeschke 2003; Cochrane et al.  1999; Pang et al.  1997).
1.5.1  Ischaemic preconditioning: The events that occur
In a normal cell,  K a tp channels are inhibited by high intracellular concentration of ATP 
in the pM range but open when ATP levels are low.  In ischaemic myocardium, firstly, 
the  lack of oxygen  cannot support oxidative  phosphorylation  so  pyruvate  is converted 
into lactic acid.  The anaerobic generation of ATP is not sufficient to keep up with the 
requirements  of the  heart  and  eventually  ATP  levels  fall.  Anoxic  mitochondria  may 
consume  ATP  to  maintain  their  membrane  potential.  The  ischemic  cell  will  become 
acidotic as  lactic acid  is  increasingly  formed  in the hypoxic, ATP-starved  cell  (Cohen 
2004).  There are three main steps in preconditioning which are hypothesised to lead to 
the activation of K a tp channels.  The first in the sequence is the trigger, which activates
32the second, the mediator that initiates a series of signal transduction pathways before it 
activates the end effector.  Ischaemic myocardium will rapidly consume ATP to form the 
trigger adenosine.  Other triggers  include bradykinin, opioids,  reactive oxygen  species, 
Ca2+ and acetylcholine which also confer cardioprotection {Cohen et al.  2000;  Thornton 
et al.  1993).  The consensus is that these triggers activate intracellular mediators such as 
PKC,  receptor  tyrosine  kinases  (RTK)  and  mitogen  activated  protein  kinase  (MAPK) 
signalling  cascades.  The  final  effectors  in  ischaemic  preconditioning  include  the 
mitochondrial  K atp  channel  (mitoKATP  channel)  and  or  mitochondrial  permeability 
transition  pore (mPTP) {Ardehali &  O'Rourke 2005; Javadov et al 2003,  Cohen et al. 
2000;  Garlid et al  1996).  Whether the  K Atp  channel  is the end-effector or  is  simply 
another  element  in  a  complex  signalling  pathway  remains  debatable.  The  protective 
effects of exposing the myocardium to brief periods of ischaemia can also be mimicked 
by a variety of drugs in a phenomenon known as pharmacological conditioning.  These 
agents  include diazoxide,  volatile anaesthetics such  as  isoflurane and agonists of G(i)- 
coupled receptors such  as adenosine and opioids (Riess et al.  2004;  Patel et al.  2002; 
Cohen et al. 2001).
1.5.2  The receptors and intracellular messengers involved in ischaemic preconditioning
During ischaemia, ATP is metabolised to AMP and subsequently converted to adenosine. 
Adenosine and other triggers will bind to and activate their appropriate receptors which 
couple to mediator phospholipase C (PLC) (Simkhovich et al.  1998).  For example, at the 
cellular  level,  the  release  of adenosine  will  bind  to the  Al  receptor and  activate  a  G 
protein.  The G protein is composed of three subunits (apy) and upon activation, the ai 
subunit  will  dissociate  from  the  complex  and  activate  PLC  (PLCp  subtype).  PLC 
catalyses  the  hydrolysis  of  PIP2,  generating  secondary  messengers  inositol  (3,4,5) 
triphosphate  (IP3)  and  diacylglycerol  (DAG).  The  latter,  DAG  will  activate  its  target 
PKC.  PKC is a serine/threonine kinase which can be categorised into three groups.  The 
conventional or classical PKCs (api, Pu, y) require Ca2+, DAG and phospholipids for their 
activation.  The novel PKC isoforms (8, e, q, 0) are not dependent on Ca2+ as they lack
33the Ca2+ binding domains.  Finally, the atypical  group (<^, i, A .,  p) do not bind to Ca2+, 
DAG or phorbol esters because they lack the Zn2+ finger motif needed to bind to DAG 
and phorbol esters so instead, they may be activated by 3’phosphoinositides {Cohen et al 
2000).  There is substantial evidence in the literature to show that PKC is a key mediator 
in preconditioning {Miki et al.  1998b;  Ytrehus et al.  1994).  The mechanism may be by 
the  direct  phosphorylation  of effector  molecules  or  the  activation  of kinase  cascades 
{Hudman  &  Standen  2004;  Baines  et  al.  2002).  There  is  no  doubt  that  PKC  is  an 
essential trigger of preconditioning and it has been shown that specific isoforms of PKC 
do exist and will act at different points during preconditioning {Simkhovich et al.  1998). 
For example,  the  Ca2+  independent novel  isoform  of PKC  (PKCe)  is activated  during 
ischaemic  injury  {Gray et al.  1997).  Despite  this,  some  studies  have  shown  that  the 
involvement of other intracellular messengers such as PKA and its mode of action may 
be  through  the  inhibition  of  Rho-kinase  {Sanada  et  al.  2004).  This  observation  is 
supported  by  the  fact  that  protection  can  be  mediated  through  p-adrenergic  receptor 
agonists to PKA {Lochner et al.  1999).
The  signalling  mechanism  that  leads  to  protection  also  involves  MAPKs  and 
phosphatidylinositol-3-kinase (P13K) {Armstrong 2004;  Fryer et al.  2001a;  Tong et al.
2000).  In  quiescent  myocytes,  the  majority  of PKC  is  present  in  the  cytosol  and  the 
activation of cytosolic PKC by lipid cofactors has been shown to be accompanied by its 
translocation and kinase activity to the membrane cytoskeleton {Liu et al.  1994,  Yuan et 
al.  1987).  More importantly, upon activation, PKC is translocated to membranes such as 
the plasma membrane or mitochondria where it can initiate signalling cascades and many 
groups believe is an important downstream event that leads to the activation of m ito K ATP 
channels and ROS production {Armstrong et al.  1996;  Yoshida et al.  1996;  Ping et al. 
1997; Liu et al.  1999; Albert & Ford 1999; Fryer et al. 2001a).  However, glibenclamide 
and K atp channel blocker 5-hydroxydecanoate (5-HD) application during diazoxide pre- 
treatment or preconditioning period can block the cardioprotective effects of IPC {Pain et 
al.  2000).  Using  these  results,  they  concluded  that  the  timing  of m ito K ATP  channel 
opening was more compatible with the channel performing as trigger rather than an end- 
eflfector role.  In contrast, a study by  Fryer et al  suggested that the  m ito K ATP  channel
34acted as a trigger and downstream effector {Fryer et al.  2001a).  At present, both views 
remain  controversial.  A  schematic  diagram  to  show  the  pathways  involved  in  the 
mechanism of preconditioning is shown in figure 1.3.
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Figure  1.3.  A  diagram  to  show  the  proposed  events  which  occur  during  ischaemic 
preconditioning.  It  is clear that  K Atp channels,  whether as end effectors  or signalling elements, 
are originally important in the cardioprotective mechanism.
1.6  The evidence for Katp channels in preconditioning
1 . 6 .1   The sarcolemmal and mitochondrial  K a t p  channel: The story so far
It has been more than  2 3   years since the sarcolemmal  K a tp  channel  (sa r c K ATp) was first 
discovered by Noma in cardiac myocytes {Noma 1983).  The role of K Atp  channels in the 
heart  has  not  been  clearly  defined  but  pharmacological  evidence  has  shown  that  the 
opening of these channels  protects  the  heart  against  ischaemic  injury.  KCOs  such  as 
nicorandil and pinacidil  mimicked IPC with inhibitors such as glibenclamide abolishing 
this  effect.  The  protective  effects  of  KCOs  exerted  during  ischaemia  in  rat  hearts 
following  recovery  of  contractile  function  during  reperfusion  is  accompanied  by
35conservation of ATP  (Baird et al.  1996;  McPherson et al.  1993).  However,  it  is not 
certain  if protection  exerted  during  ischaemia  is  a  direct  effect  on  reperfusion  injury 
because KCOs such as aprikalim and cromakalim did not confer protection (Auchampach 
et al. 1991; Grover et al.  1990a; 1990b).  These observations led investigators to suggest 
that the sarcKATP channel was the final effector in IPC (Mizumura et al.  1995; Gross & 
Auchampach 1992).  It monitors the metabolic status of the cell and is sensitive to ATP 
concentrations  causing  APD  shortening  which  conserves  ATP  levels  (Findlay  1994). 
The first study to dispute this reported that a low dose of bimakalim was cardioprotective 
but this did not affect APD shortening whereas the higher doses were required to cause 
significant APD shortening (Yao &  Gross 1994a).  Furthermore, Grover et al described 
similar  observations  showed  that  there  was  APD  shortening  but  protection  was  still 
observed with cromakalim treatment (Grover et al.  1995).  The authors also reported that 
dofetilide,  the  class  III  antiarrhythmic  compound  prevented  APD  shortening  in 
preconditioned canine hearts which did not antagonise the cardioprotective effects of IPC 
(Grover et al.  1996).  The other pharmacological evidence that questioned that role of the 
sarcKATP channel showed that:
1.)  The  sarcKATP channel  inhibitor,  HMR1098  did  not  eliminate  the  preconditioning 
response induced by KCOs (Sato et al. 2000).
2.) The specific  m ito K ATP  channel  inhibitor 5-HD could block the anti-infarct effect of 
diazoxide and IPC (Hu et al.  1999).
3.) Diazoxide protected hearts from reperfusion injury without causing APD shortening.
These observations lead to the alternative hypothesis that the  K atp  channel  involved  in 
cardioprotection was mitochondrial  (m itoK ATp)*  This channel was first identified in the 
inner mitochondrial membrane by Inoue in  1991  but research turned a new comer when 
influential  papers  from  Gar  I id’s  and  Marban’s  groups  were  published  (Garlid et  al. 
1997a  and b;  Inoue  et  al.  1991).  Since  its  discovery,  pharmacological  studies  have 
reported  that  activation  by  diazoxide  and  inhibition  by  5-HD  are  the  hallmarks  of 
mitoKATp channel.  For example, mitoKATp channel activity was assayed  by measuring 
the  changes  in  flavoprotein  autofluorescence  in  rabbit  ventricular  myocytes  where
36diazoxide  selectively  opened  and  5-HD  inhibited  the channel  (Liu et al.  1998).  Later 
studies conducted by Garlid’s and by Grover’s groups showed that diazoxide, nicorandil, 
and  BMS-191095  activated  the  mitoKA TP  channel  in  perfused  rat  hearts  and  were 
protective with little effect on cardiac or smooth muscle sarcKA Tp channels (Garlid et al. 
2003;  Grover  et  al.  2001).  These  studies  support  the  notion  that  m i t o K A T P   channel 
opening is an important event that confers protection.  However, there is much debate on 
the precise role and existence of mitoKA Tp channel opening as it has been suggested that 
channel opening may act as a trigger but it also has a prominent role as an effector after 
index ischaemia (O'Rourke 2004; Liu & O'Rourke 2003; Gross & Fryer 1999).
1.6.2  Basic principles of mitochondrial function
Mitochondria are responsible for generating cellular ATP and are involved in a number 
of important  intracellular  signalling  processes  such  as  the  modulation  of intracellular 
Ca2+   levels {Jacobson &  Duchen 2004).  During aerobic  respiration, glucose  is broken 
down into pyruvate via glycolysis which occurs in the cytoplasm.  Pyruvate is taken up 
into mitochondria and converted into acetyl CoA and fed into the Kreb’s cycle.  During 
of breakdown of acetyl  CoA  into other substrates, decarboxylation reactions occur and 
the reaction generates a supply of reduced  nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2) from oxidised forms NAD* and FAD2*.  ATP is 
also formed during these steps but the majority of ATP is formed in the final step called 
oxidative phosphorylation {Mitchell 1967).  See figure 1.4.
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During oxidative phosphorylation, oxygen  is required by the electron transport chain to 
reduce  oxygen  to  water.  The  electron  transport  chain  translocates  H+  across  the 
membrane  to  set  up  the  mitochondrial  membrane  potential  (A\\im )  which  usually  lies 
between  -150 to -200  mV.  It  is the A\|/m   which  provides  the driving  force  for proton 
influx across the inner mitochondrial membrane through the ATPase; this energy is used 
to generate ATP.  Mitochondria can sequester excess Ca  ions and the driving force for 
mitochondrial Ca2 +   uptake is dependent on Av|/m , but the route of entry is mostly through 
the  uniporter  (Jacobson  &  Duchen  2004).  Ca2+  is  then  redistributed  between  the 
mitochondria and cytosol through the action of Na+/Ca2+ (NCX) exchanger.
1.6.3  Evidence for the existence of mitoKATP channels
The study which discovered m i t o K A T P  channels was first published in  1991  by Inoue et al 
where  they  identified  K+  specific  currents  with  a  conductance  of  10  pS  from  giant 
mitoplasts prepared from rat liver mitochondria (Inoue et al.  1991).  The mitoplasts were 
prepared by homogenising the tissue and chemically dissociating mitochondria from their
38outer  membrane  before  they  were  ruptured  and  reformed  into  mitoplasts.  Channel 
activity  was  inactivated  by  ATP  and  inhibited  by  4-aminopyridine  and  glibenclamide 
applied to the matrix  side  under  inside-out patch configuration.  In  Hanley and  Daut’s 
recent review on  m i t o K ATP  channels,  they  noted  that  in  Inoue’s  study there  may  have 
been some experimental flaws to the work {Hanley & Daut 2005).  The problem with this 
procedure was that the sample  may  have been contaminated with other  K atp  channels 
from sarcoplasmic, endoplasmic  reticular as well as mitochondrial  membranes.  At the 
time of the study, the authors did not employ strict controls to ensure that their mitoplasts 
were not contaminated but the block by 5-HD and inhibition by ATP characterised this 
channel  as  the  m i t o K AT P  channel.  However,  diazoxide  had  no  significant  effect  on 
channel activity therefore it may not be a mitoKA jp channel but in fairness, this remains 
an  important  study  as  it  was  advanced  at  the  time  and  provided  an  insight  into  the 
existence of mitoKA TP channels.
1.6.4  Studies investigating the mitoKAn> channel in liposomes and lipid bilavers
After single channel studies in mitoplasts, the majority of research on mitoKA rp channels 
focused on the technique of channel  reconstitution  in  liposomes and  lipid bilayers.  A 
high A\|/m  is essential for oxidative phosphorylation and it is the influx of K+ (‘leak’) that 
uncouples the respiratory chain causing changes  in mitochondrial  matrix  volume.  The 
Avj/m  is maintained by the ejection of H+ across the inner membrane through the K*/H+  
antiporter.  Paucek  and  colleagues  provided  further  insight  for  the  existence  of this 
channel designed to facilitate the uptake of K+ into mitochondria {Paucek et al.  1992).  A 
highly purified inner membrane fraction of isolated rat liver and beef heart mitochondria 
was reconstituted  into liposomes or lipid bilayers and exhibited channel activity with a 
conductance of around 30 pS.  This channel was purified using DEAE cellulose column, 
the main protein in this fraction had a molecular mass of 54 kDa which was a similar size 
to  the  mitochondrial  Ca2*  activated  K*  channel  identified  in  cardiac  muscle  with  a 
molecular mass of 55 kDa {Xu et al. 2002; Paucek et al. 1992).
39The liposomes  in  Paucek’s study containing this reconstituted protein were loaded with 
the fluorescent K+ indicator PBFI to measure CCCP dependent electropheretic K* uptake. 
In comparison, Inoue et al reported ATP inhibition from mitoplasts in Mg2* free medium 
and that a high concentration of glibenclamide (5 pM) was required to inhibit the channel 
electrophysiologically {Inoue et al.  1991).  On the other hand, Paucek et al found that K+  
influx was inhibited by a much lower concentration of glibenclamide with an IC50 value 
of ~50 nM {Paucek et al 1992).  Although the majority of this work was carried out using 
rat liver mitochondrial  preparations, the studies using the beef heart mitochondria were 
virtually  identical  with  respect  to  K+  specificity  and  inhibition  by  ATP  and 
glibenclamide.  Paucek argued that this variation in the data may be due to the presence 
of Ca  in the solutions used by Inoue et al as their preliminary studies indicated that the 
presence of such divalent cations will lead to a high binding affinity for the K atp channel 
and slow dissociation constant.
The effects of several factors such as diazoxide, glibenclamide, 5-HD, MgATP and ROS 
were examined on mitoKATp channels from bovine ventricular myocardium reconstituted 
in planar lipid bilayers {Zhang et al. 2001).  The channel had a unitary conductance of 56 
pS with  symmetrical  150 mM  KC1; this was substantially  inhibited by  1   mM  MgATP 
applied to the trans (matrix) side of the bilayer.  Diazoxide (10 pM) increased channel 
activity and 5-HD (10-100 pM) reduced the open state probability in a dose dependent 
manner but HMR1098, the specific inhibitor for sarcKATp channel did not inhibit activity 
of the  reconstituted  channels.  However,  MgATP  had  no  effect  on  the  cytosolic  side 
despite the fact that Yarov-Yarovoy et al reported that the regulatory sites on mitoKATp 
channel faced the cytosol {Yarov-Yarovoy et al.  1997).  Garlid’s group reported that the 
proteoliposomes  containing the  mitoKATp  channel  was tightly  regulated  by  KCOs  and 
inhibitors as well as nucleotides and  Mg2* {Paucek et al.  1996).  These channels were 
reactivated  by  cytosolic  GTP  and  long-chain  acyl-CoA  esters  inhibited  K*  flux.  The 
authors  noted  that  channel  inhibition  may  depend  on  how  it  was  activated  and 
experimental  conditions used.  In contrast, the mitoKATp channel  ffom  active respiring 
mitochondria  was  entirely  insensitive  to  glibenclamide  and  5-HD  under  experimental 
conditions in which the open state of the channel was stimulated by the absence of ATP
40and Mg2+ (Jaburek et al.  1998).  However, K+  influx was inhibited by glibenclamide and 
5-HD when the open state was induced by either diazoxide, ATP, Mg2* or GTP.
Biological membranes are not just physical barriers but are rather complex and dynamic 
environments and  K Atp channels residing within these environments control the flux o f 
ions across the membrane through conformational changes through the pore (Tillman & 
Cascio 2003).  Any changes caused to these membranes may directly affect the behaviour 
and activity of the ion channel in question.  The studies investigating the characterisation 
of mitoKA TP  channels  have  provided  valuable  insight  into  mitoKA Tp  channel  activity. 
However,  there  is  variation  in  the  data  when  one  considers  the  parameters  that  were 
investigated  such  as  molecular  mass,  drug  sensitivity,  ion  selectivity  and  channel 
conductance  because  the  various  purification  methods  and  techniques  may  have 
influenced  the  results.  The  methods  for  isolating  and  reconstituting  native  or cloned 
channels into these lipid bilayers are technically difficult (Favre et al.  1999).
1  -6.5  Studies investigating mitochondrial matrix volume in isolated mitochondria
There  is  evidence  to  show  that  mitoKA -rp  channel  opening  facilitates  changes  in 
mitochondrial  bioenergetics  (Kowaltowski  et  al.  2001).  Many  groups  agree  that 
mitoKA Tp channel opening is accompanied by an increase in matrix volume which will 
activate components of the respiratory chain (O'Rourke 2004;  Garlid 2000).  However, 
there  is  much  debate to  what occurs  in  the  mitochondrial  matrix  as a consequence of 
mitofCA TP channel opening.  Garlid and co-workers focused their work on the changes in 
light  scattering  where  an  increase  in  K+  influx  and  mitochondrial  matrix  volume  was 
observed as a decrease in light scattering {Garlid et al.  1996, Beavis et al.  1985).  They 
reported that mitochondrial swelling was inhibited by adenine nucleotides ATP, ADP or 
AMP and KCOs such as diazoxide and cromakalim increased light scattering; this effect 
was inhibited by both glibenclamide and 5-HD {Jaburek et a ll998; Garlid et al 1996).
These experiments were conducted  in  K+ and not tetraethylammonium medium, which 
selectively blocks voltage gated K+ channels therefore the changes observed were due to
41K+   influx through  the  mitoKATp channel.  However,  Halestrap’s  group  were  unable to 
reproduce the same changes in light scattering by administering  K C O  such as diazoxide 
and pinacidil and blockers such as glibenclamide and 5-HD (Das et al  2003; Lim et al. 
2002).  They reported no increase in light scattering in response to ATP and ADP, which 
disagrees  with  the  original  results  obtained  by  Beavis  et  al  providing  evidence  that  a 
putative  K atp  channel  does  exist  in  the  mitochondrial  inner  membrane  (Beavis et al. 
1993).  Guanine  nucleotides  such  as  GTP  and  GDP  had  no  effect  on  matrix  volume 
whereas carboxyatractyloside, an inhibitor of adenine nucleotide translocator (ANT) was 
found to inhibit K+  influx.  Whilst Garlid and Paucek’s work showed that the changes in 
light  scattering  were  due  to  changes  in  the  mitochondrial  matrix  volume,  Halestrap’s 
group disputed this theory as the changes observed in Garlid’s studies were probably due 
to the physical changes  in the morphology or shape of mitochondria (Garlid &  Paucek 
2003; Das et al 2003).
More recently, other aspects of mitochondrial function such as oxygen consumption, A\j/m  
and ATP synthesis have been examined in  isolated heart mitochondria under ischaemic 
conditions with the build up of ADP causing transient depolarisation.  This was followed 
by an increase in oxygen consumption and light scattering, an index of matrix shrinkage 
(Korge et al  2005).  Furthermore, Korge et al found that mitochondria under metabolic 
stress had a decreased ability to maintain Ai|/m  but this was rescued by ions such as K+, 
Na+  and Li+.  The application of valinomyocin and diazoxide also improved the recovery 
of A\|/m   and  promoted  matrix  shrinkage.  In  conclusion,  K+   influx  controlled  matrix 
volume and swelling with external factors becoming more significant when mitochondria 
become under stress such as under high ADP load.  The authors noted that caution must 
be taken  with  respect  to  light  scattering  measurements  as  mitochondrial  swelling  and 
conformational  changes  of the  ANT  have  been  postulated  to  be  responsible  for  the 
published changes in mitochondrial matrix volume.
421.6.6  Other mitochondrial channels
The mitoKATp channel  opening  is a  important event  in  protection  against  necrotic  and 
apoptotic  cell  injury  after  ischaemia  but  many  other  mitochondrial  channels  exist  for
^ l.
example,  large-conductance  Ca  -activated  K  channels  (BKca)  were  discovered  in  the 
inner membrane of mitochondria (mitoKca) of guinea pig ventricular myocytes {Xu et al. 
2002).  Mitoplasts prepared from isolated cardiac myocytes were patch clamped and this 
channel  was  shown  to  contribute  to  background  K+   conductance.  The  BKca  channel 
opener  NS1619  also  protected  hearts  against  infarction  and  the  protective  effects 
abolished by BKca channel blocker paxilline.  The mitoKca channel  may be the primary 
target of BKca channel selective agents but these agents can also affect the sarcolemmal 
BK^ channel.  However,  this channel  has  not  been  identified  in  ventricular  myocytes 
(Gribkoff et al.  1996; Kenyon et al.  1995).  More recently, Sato and co-workers reported 
that mitoKca opening will  confer protection which  is  independent of mitoKATp channel 
activity.  They  demonstrated  that  cAMP-dependent  protein  kinase  induced  mitoKca 
opening which in turn depolarised the A\ym  preventing mitochondrial Ca2+ overload {Sato 
et al. 2005).
Finally,  Ardehali  et  al  recently  produced  highly  controversial  work  on  reconstituted 
mitoKATp channels in proteoliposomes.  They identified a highly purified fraction of the 
mitochondrial  inner  membrane that  formed  part  of a multiprotein  complex  containing 
SDH  (complex  II)  and  four  other  proteins  including  the  mitochondrial  ATP-binding 
cassette protein  1   (mABCl), phosphate carrier (PIC), ANT and ATP synthase {Ardehali 
et al. 2004).  This was shown to have similar properties of a m itoKATp channel as it was 
sensitive to KCOs and inhibitors as well as SDH inhibitors such as 3-nitroproprionic acid 
(3-NPA).  Their data suggested that 3-NPA increased K+ transport activity as well as 100 
pM  diazoxide  in  proteoliposomes,  this  was  reversed  by  500  pM  5-HD,  10  pM 
glibenclamide  or 2  mM  ATP  suggesting  that  SDH  has  a  regulatory  role  in  m ito K ATP 
channel activation.  .
431.7  The pharmacology of K a tp  channels
1.7.1  The pharmacology of sarcKA TP and mitoKA TP channels
To date, there are many pharmacological agonists that act on the sarcKA Tp and  m i t o K ATP 
channel.  See table  1.3 for the list of KCO and inhibitors.  The list of KCO is extensive, 
these also include: PI060, PI075 (pinacidil derivatives), minoxidil, KRN2391, sidenafil, 
desflurane,  isoflurane,  aprikalim  and  levosimendan  (O ’Rourke  2004;  Oldenburg et al. 
2003a;  Gross  2003;  Toller  et  al.  2000a;  2000b).  The  non-selective  KCOs  include 
pinacidil and cromakalim which will activate both the sarcKA rp and mitoKA Tp channel. 
However,  there  are  exceptions  such  as  diazoxide  and  nicorandil  which  can  be  used 
selectively to activate mitoKA Tp channels.  Glibenclamide is a strong inhibitor that binds 
to  KAtp  channels  with  high  affinity  however,  it  is  non-selective  and  will  block  both 
sarcKA rp and  mitoKA Tp channels.  The sarcKA rp and mitoKA jp channels have different 
responses to pharmacological agents.  The cardiac sarcKA rp channel cannot be activated 
by diazoxide unless at high concentrations.  Garlid’s early work reported that diazoxide 
opened  the  mitoKA jp  channel  with  a  Kj#  of 0.8  mmol/L  whereas  800  mmol/L  was 
required to activate the sarcKA rp channel {Garlid et al.  1997b).
Table  1.3.  A table to show the various compounds that activate or inhibit  KAtp  channels.  * 
Diazoxide will  activate sarcKA T P  channels at high concentration or when the concentration  of 
ADP is high. ** Nicorandil activates sarcKA T P  channels at high concentrations.
K4 channel openers Selectivity of K4 channel
and inhibitors Ooeners/inhibitors
K4 channel openers
Diazoxide 
Cromakalim 
Nicorandil 
Pinacidil (P-1075) 
BMS-191095
SarcKA TP *, MitoKA Tp 
SarcKATP, MitoKA jp 
SarcKA Tp **, MitoKA Tp 
SarcKA Tp, MitoK.A xp 
MitoKA TP
K4 channel inhibitors
SarcKATp. MitoK.A xp
MitoKA Tp
SarcKA Tp
Glibenclamide 
5 Hydroxydecanoate 
HMR1089
44One  study  showed  that  mitoKATP  channel  opener  diazoxide  increased  flavoprotein 
autofluorescence,  an  index  of mitoKATp  channel  activity  with  an  EC50  of 27  pmol/L. 
Interestingly, at this concentration, diazoxide did not affect sarcKA TP channel activity (Liu 
et al.  1998).  Furthermore, the protective effects of diazoxide and cromakalim were both 
abolished  by  glibenclamide and  5-HD  suggesting a role for the  mitoKA xp channel.  In 
cellular models of simulated  ischemia,  50  pM diazoxide decreased cell death by 50 % 
when compared to controls.  These results are agreement with  Garlid’s findings which 
suggest that the mitoKA TP channel  is  involved  in cardioprotection (Garlid et al  1997b, 
Garlid et al  1996).  Sato et al  subsequently  showed  that  100  pM  diazoxide  increased 
flavoprotein  autofluorescence  in  isolated  rabbit  ventricular  myocytes  without affecting 
sarcKATp channel activity (Sato et al.  1998).  The myocytes were also exposed to 100 nM 
phorbol ester phorbol  12-myristate  13-acetate (PMA) which potentiated and accelerated 
the  effect  of diazoxide  to  activate  the  mitoKATP  channel.  The  effects  of PMA  and 
diazoxide were blocked effectively by 5-HD.
Sato et al later examined the effects of KCO P-1075 and KA tp channel blocker HMR1098 
on  sarcKA rp and  mitoKA rp channels  in  rabbit  ventricular myocytes  (Sato  et al.  2000). 
SarcKA xp channels were activated in the presence of 30 pM P-1075 with no increase in 
flavoprotein autofluorescence.  SarcKA rp channel activity was completely inhibited by 30 
pM  HMR1098.  HMR1098  also  inhibited  sarcKA T p  currents  activated  by  metabolic
inhibition however, it did not abolish diazoxide (100 pM) induced flavoprotein oxidation. 
The cardioprotective effects of diazoxide was abolished by 500 pM 5-HD but not by 30 
pM HMR1098.  These results suggest that P-1075 selectively activates sarcKA Tp channels 
(without  altering  flavoprotein  oxidation)  and  HMR1098  selectively  inhibits  sarcKA xp 
channels. 5-HD is regarded as a specific inhibitor of mitoKA rp channels because it can 
abolish  the  protective  effects  of  ischaemic  and  pharmacological  preconditioning  in 
studies where infarct size was used as an indicator of tissue damage.  The specificity of 5- 
HD for the mitoKA rp channel was confirmed by Jaburek et al where mitochondrial matrix 
swelling  was  used  as  an  indicator  of K+  influx.  They  reported  that  5-HD  inhibited 
diazoxide  induced  K+  flux  (in  the  presence  of 0.2  mM  ATP)  in  isolated  rat  hearts
45{Jaburek  et  al.  1998).  In  contrast,  Tschida  et  al  reported  that  nicorandil  induced 
protection was abolished by HMR1098 and the authors also showed that PKC inhibitor 
calphostin C did not affect nicorandil  induced protection  suggesting that both  sarcKATp 
and  mitoKATP  channels  may  contribute  to  protection  {Tsuchida  et  al.  2002).  BMS- 
191095  is  a  benzopyran  derivative and  is  a  less effective  vasodilator than  compounds 
such as cromakalim but still retains its cardioprotective properties by activating mitoKATP 
channels  without  affecting  vascular  smooth  muscle  sarcKA Tp  channels  {Grover  et  al.
2001).  The  cardioprotective  effect  of BMS-191095  was  demonstrated  in  isolated  rat 
hearts and protection was abolished by glibenclamide and 5-HD {Grover & Atwal 2002).
1.7.2  The non specific effects of K ^  channel openers and inhibitors
There is an  increasing list of pharmacological agents that offer cardioprotection.  These 
compounds are structurally diverse but have the ability to partially impair the respiratory 
chain, which suggests that pharmacological inhibition of the respiratory chain may trigger 
cardioprotection  {Garlid et al.  2003).  For example,  pinacidil  and  volatile anaesthetics 
can  inhibit  NADH  dehydrogenase  (complex  I)  and  nicorandil  can  inhibit  complex  IV 
{Tanaka et al.  2004).  Diazoxide is routinely used at low concentration (30-100pM) to 
precondition hearts, it can also influence mitochondrial metabolism which is independent 
of its  K Atp  channel channel  opening abilities {Grimmsmann &  Rustenbeck  1998).  The 
cardioprotective  effects  of diazoxide  have  been  postulated  to  result from  inhibition  of 
SDH  and  a  decrease  in  respiration.  SDH  inhibitors  such  as  malonate  and  3- 
nitroproprionic  acid  (3-NPA)  have  been  shown  to  induce  cardioprotection  {Lim  et al. 
2002;  Hanley  et  al  2002;  Ockaili  et  al.  2001).  Diazoxide  can  inhibit  SDH  at  high 
concentrations (150 pM) and inhibit succinate oxidation in single cardiac myocytes {Lim 
et  al.  2002;  Ovide  Bordeaux  et  al.  2000;  Schafer  et  al.  1969).  Ovide-Bordeaux 
concluded  that  diazoxide  and  glibenclamide  at  high  concentrations  (100  pM)  did  not 
modulate mitochondrial functional or K At p channel activity {Ovide Bordeaux et al. 2000). 
Furthermore,  diazoxide  has  also  been  reported  to  act  as  a  protonophoric  uncoupler 
{Holmuhamedov et al.  2004).  The authors stated that the functional effect of diazoxide 
depends on respiratory substrates and do not appear to be related to K Atp channel activity.
465-HD is widely recognised as a mitoKATp channel inhibitor but it also possesses indirect 
effects.  For example, Notsu et al showed that 5-HD was able block the sarcKATp channel 
under  ischaemic  conditions  (Notsu et al.  1992a,  1992b).  This  compound  can  also  be 
readily converted to 5-HD-acetyl CoA by enzymes residing in the mitochondrial matrix, 
this has been confirmed recently by Hanley et al (O’ Rourke 2004, Hanley et al. 2002).  In 
agreement with this, some groups have shown that 5-HD could block both Kir6.1/SUR1 
and  Kir6.2/SUR2  surface  channels  implying  that  it  has  poor  mitochondrial  specificity 
{Liu et al. 2001; Sato et al.  1998; McCullough et al.  1991).  Low concentrations of 5-HD 
did  not  affect  matrix  volume  but  higher  concentrations  of  5-HD  (100  or  300  pM) 
produced an increase in matrix volume {Das et al. 2003; Lim et al. 2002).
1.8  The role of mitoKATp channels in preconditioning
1.8.1  The consequences of mitoKA rp channel opening
At present, the consequences of m ito K ATP channel opening and its protective mechanism 
is unclear.  However, there is a general consensus that mitoKATp channel opening plays a 
key  role  in  preconditioning.  It  has  been  shown  that  ischaemic  and  pharmacological 
preconditioning  is  linked  to  mitochondrial  depolarisation  {Minners et al.  2001).  K atp 
channel opening may uncouple mitochondria as a direct result of K+ influx and through 
the  action  of  the  K+ /H+   exchanger;  K Atp  channel  opening  will  tend  to  cause  the 
mitochondrial membrane potential (A'Fm ) to dissipate.  Without a proton gradient, there is 
an  increase  in  electron  transfer  which  decreases  the  driving  force  for  ATP  synthesis, 
producing an uncoupling effect (Liu et al.  1998).  This hypothesis is in agreement with 
several observations.  For example, KCO can induce membrane depolarisation in rat liver 
mitochondria  {Szeweczyk  et  al.  1995).  Furthermore,  in  isolated  mitochondria  and 
myocytes, mitochondrial  depolarisation has been suggested to be an  important event to 
decrease the driving force for Ca2+ influx and prevent Ca2+ overload {Holmuhamedov et 
al.  1998,  1999).  The  opening  of  m ito K ATP  channels  may  also  activate  protective 
mechanisms by increasing reactive oxygen species (ROS) production {Das et al 1999).
47Garlid  and  colleagues  opposed  the  original  hypothesis  and  stated  that  the  uncoupling 
effects  of diazoxide  and  other  KCOs  were  independent  of K Atp  channels  because  the 
same response was observed in  Li+  medium.  They reported that pharmacological doses 
of diazoxide and pinacidil (<50 pM) could open mitoKATP channels, which resulted in a 
decrease  in Avpm  but the magnitude of K+  influx (24-30 nmol  K+ min'1   mg'1 ) was only 
enough  to  depolarise  the  A\j/m   by  1-2  mV  (Kowaltowski et  al.  2001).  The  data  also 
suggested that  m i t o K . A T P   channel opening had little effect on respiration, Ai|/m  and Ca2+ 
uptake but K+ influx had important effects on the regulation of matrix and intermembrane 
space volumes.  K+   influx will  increase  matrix  volume  and  mitochondrial  swelling by 
shifting  the  balance  between  K+   uniport  and  K+/H+  antiport,  causing transient  net  K+  
uptake and matrix swelling due to a higher steady-state volume (Yellon & Downey 2003; 
Garlid  1988).  This  is  followed  immediately  by  uptake  of  phosphate  via  the 
phosphate/OH-  exchange  carrier  because  K+   uptake  is  always  accompanied  by  anions 
and  movement  of water  via  osmosis.  Another  study  confirmed  that  K+   influx  was
9 4 - insufficient  to  depolarise  the  A\|/m   and  making  mitochondria  resistant  to  Ca  entry 
(Terzic et al.  2000).  Garlid also suggested that perhaps the effects on mitochondria may 
be associated with the toxic effects of diazoxide because high concentrations of diazoxide 
will  inhibit respiration and  SDH  {Schafer et al.  1969).  Hanley  recently confirmed the 
toxic and non-specific effects of diazoxide {Hanley et al. 2002).
Recent  studies  have  been  conducted  to  demonstrate  the  significance  of mitochondrial 
uncoupling in the mechanism of protection {Brennan et al 2006a and b).  The authors 
reported  that  the  low  dose  of  mitochondrial  protonophore  FCCP  (100  nM)  was 
cardioprotective  whereas  higher  concentrations  (300  nM)  would  cause  mitochondrial 
depolarisation  and  exacerbate  injury.  Protection  was  observed  with  mitochondrial 
oxidation but this was not accompanied with mitochondrial depolarisation and sarcKA TP 
channel activity.  FCCP will induce mild uncoupling and activate protective mechanisms 
that  lead  to  protection.  However,  in  their  hands,  diazoxide  (30  pM)  did  not  alter 
mitochondrial  function  and  the  authors  concluded  that  it  must  elicit  protection  via  a 
different mechanism.  These studies are of significant  importance because they are  in
48agreement with  Garlid’s work that perhaps protection  is associated  with  mitochondrial 
function and signalling pathways rather than regulating K A t p  channel activity.
MUoK atp  channel  opening  may  also  facilitate  the  physical  contact  of proteins  in  the 
mitochondrial inner and outer membrane which was first described by Brierley {Brierley 
1974).  This interaction of proteins would promote ATP synthesis and this hypothesis is 
supported  by  recent data by  Ardehali  et al  where the authors proposed  that  SDH  is a 
structural and functional component of a multiprotein complex that exhibited mitoKA TP 
channel  activity  {Ardehali et al.  2004).  The authors  proposed  that  SDH  regulated the 
mitoKA jp  channel  by  means  of  its  physical  interactions  without  affecting  oxidative 
phosphorylation.  It  has  been  proposed  that  the  cardioprotective  effect  of diazoxide 
results  from  inhibition  of SDH  and  a  decrease  in  respiration,  rather than  opening  of 
mitoKA TP channels {Lim et al. 2002; Hanley et al. 2002).
In  the  high  energy  state,  such  as  in  the case of ischaemia,  mitoKA Tp channel  opening 
prevents matrix contraction.  This is a protective mechanism because there is no matrix 
swelling  and  contraction  which  prevents  the  rupture  of  the  mitochondrial  inner 
membrane.  Maintaining  a  constant  volume  is  important  so  that  the  rate  of substrate 
oxidation  is  regulated  preventing  energy  wastage  and  this  in  turn  facilitates  efficient 
energy transfer to synthesise ATP {Halestrap 1989).  Recently, Halestrap’s group showed 
that 50 pM diazoxide and two cycles of preconditioning increased mitochondrial matrix 
volume  in  isolated  mitochondria by  8 8  % and  58 %.  IPC  increased the  rate of ADP- 
stimulated  respiration  by  2 -oxoglutarate  and  succinate  oxidation  whereas  diazoxide 
caused a similar  increase  in  matrix  volume  but  inhibited  succinate and  2 -oxoglutarate 
oxidation however, 5-HD did not reverse this process but instead promoted further matrix 
swelling {Lim et al. 2002).  The authors suggested that the changes in matrix volume and 
respiratory chain activity might not be linked with protection.
491.8.2  MitoKATp channel opening and reactive oxygen species
ROS are group of messengers that are also known as  free radicals.  A  free radical  is a 
cluster of atoms that contains  an  unpaired  electron  in  its outermost  shell  of electrons. 
This configuration is extremely unstable therefore making the radical react quickly with 
other molecules or radicals to achieve a more stable configuration.  ROS are formed by 
several  mechanisms,  such  as  the  interaction  of  ionising  radiation  with  biological 
molecules,  from  enzymes  such  as  NADPH  oxidase  in  activated  leukocytes,  xanthine 
oxidase  and  as  a  by-product  of cellular  respiration  from  the  mitochondrial  electron 
transport  chain.  During  cellular  respiration,  electrons  are  fed  into  the  individual 
complexes of the  respiratory chain  and a very  small  percentage of these electrons that 
‘leak'  are used to  generate superoxide  ions at complex  I  and  111  from the reduction of 
molecular oxygen (Turrens  1997).  Ischaemia often results in an increase in ROS levels 
upon reperfusion and recent studies have shown ROS to cause significant damage to the 
respiratory chain (Lesnefsky et al. 2004; Petrosillo et al. 2003).
The  ROS  generated  from  mitoKATp  channel  opening  can  play  either  a  protective  or 
detrimental  role.  The  ROS  that  are  generated  during  the  preconditioning  phase  are 
protective, supporting a role for ROS in triggering protection {Forbes et al. 2001; Pain et 
al. 2000;  Vanden Hoek et al.  1998).  However, the ROS produced upon reperfusion have 
detrimental effects which can lead to irreversible cell injury and cell death {Droge et al. 
2002;  Ozcan et al.  2002;  Vanden Hoek et al.  2000, Zweier et al.  1987).  This burst of 
ROS  can  be  prevented  by  the  cardioprotective  mechanism  of  mitoKATp  openers  at 
reoxygenation {Ozcan et al.  2002).  The role of ROS has been confirmed  in ischaemic 
and  pharmacological  preconditioning studies  by  the  use of ROS  scavengers and  PKC 
inhibitors before index ischaemia {Novalija et al. 2003; Forbes et al. 2001; Baines et al. 
1997;  Chen et al.  1995;  Ytrehus et al.  1994).  Hence, the consensus  is that  m ito K ATP 
opening facilitates the production of protective ROS during preconditioning but decreases 
detrimental  post  ischaemic  ROS  production.  At  present,  the  link  between  ROS  and 
mitoKATp opening has not been fully elucidated.
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and the  ROS  produced  act as an  upstream trigger (Oldenburg et al.  2003b;  Yao et al. 
1999).  This conclusion was solely based on the assumption that diazoxide and 5-HD act 
selectively on  m i t o K ATP  channels.  Despite this hypothesis, Lebuffe et al postulated that 
the ROS generated during the trigger phase could in turn activate and open the m ito K -A T P  
channel (Lebuffe et al.  2003).  Based on these studies, some authors believe that there is 
sufficient evidence to show that K atp channels act both as a trigger and as a ‘distal’ end 
effector in IPC (Gross & Peart 2003; Gross & Fryer 1999).  The focus of research turned 
to mitoKATp channel activation and ROS generation.  K Atp channel opening was proposed 
to occur during index ischaemia and one group showed that exogenous H2O2 and ROS 
derived from mitochondria both induced preconditioning in cardiomyocytes triggered by 
hypoxia (Vanden Hoek et al.  1998).  Recently, the opening of the  m i t o K ATP channel can
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lead  to  partial  mitochondrial  depolarisation  which  can  reduce  Ca  entry  and 
mitochondrial  Ca2*  overload  or alternatively  increase  the  production  of mitochondrial 
ROS (Holmuhamedov et al.  1999; Das et al.  1999).
Although  m ito K ATP  channel  opening  is  often  associated  with  an  increase  in  ROS 
production,  the  link  between  the  degree  of  mitochondrial  depolarisation  and  ROS 
production is not clear.  In addition to this, diazoxide induced mitoKATp channel opening 
depolarised  the  mitochondria  by  1*2  mV  but  these  changes  were  too  small  to  affect 
mitochondrial  function  (Kowaltowski et  al.  2001).  The  use  of FCCP  to  collapse  the 
proton gradient will reduce the drive for ATP synthesis.  At low concentrations (100 nM), 
FCCP can bypass the mitoKATp channel and induce partial depolarisation in mitochondria 
{Brennan et al. 2006a).  The authors found that protection associated with FCCP was by 
dependent on  ROS but independent of K Atp channels because protection was abolished 
by  antioxidants  but  not  by  glibenclamide  or  5-HD.  FCCP-induced  mitochondrial 
flavoprotein oxidation  without activating the  s a rc K ATP  channel  {Brennan et al.  2006b). 
This  recent  study  provides  further  evidence  that  ROS  have  an  important  role  in 
cardioprotection.
511  -8.3  The sarcK-ATP channel and ischaemic preconditioning
The current literature suggests that the mitoKATp channel  is involved  is preconditioning. 
However,  there  is  also  solid  evidence  to  support  the  protective  role  of the  sarcKA Tp 
channel.  Jovanovic  and  co-workers  reported  that  COS-7  cells  co-transfected  with 
Kir6.2/SUR2A had channel activity when they were stimulated with pinacidil {Jovanovic 
et  al  1998).  In  addition  to  this,  later  experiments  showed  that  these  cells  survived 
metabolic  stress  such  as  hypoxia-reoxygenation  because  Ca2+ overload  was  inhibited 
{Jovanovic et al  1999).  The main finding from Suzuki’s study using Kir6.2 knock out 
mice was that I PC offered protection and shortened the APD duration in ventricular cells 
isolated  from  wild-type  (WT)  but  not  KO  mice  {Suzuki  et  al  2002).  However,  the 
authors noted that the importance of sarcKA TP channels may have been amplified due to 
the  fast heart  beat  in  the  murine  model.  In  another study, transgenic  mice expressing 
mutant  Kir6.2 did not respond to 1PC  with reduced ATP sensitivity suggesting that the 
sarcKA rp may play a role in the mechanism leading to protection {Rajashree et al 2002). 
The mechanism  by which sarcKA rp channel confers protection still  remains elusive.  It 
has  been  suggested  to  participate  in  preconditioning  by  acting  as  a  'trigger'  by  some 
groups whilst the majority of evidence has confirmed a role for the channel as a 'distal' 
effector, summarised in a review by Peart and Gross {Peart & Gross 2002).  PKC  is a 
key secondary messenger involved in I PC and its activation and translocation is reported 
to couple to the sarcKA jp channel {Light et al 2001).  This field is still controversial with 
strong  evidence  for  both  sarcKA rp  and  mitoKA jp  channels  as  the  possible  candidates 
involved in the mechanism that confers cardioprotection.
1.9  The molecular structure of the mitoKATp channel
1.9.1  T he evidence for and ag ain st K ir6.1  as a com ponent o f the m ito K ATP
The structure of mitoKA xp channel  is unknown.  Controversially,  it has been suggested 
that Kir6.1  may be a major component of the mitoKA jp channel {Suzuki et al  1997).  In 
this particular study, Suzuki et al identified a 51  kDa protein with a Kir6.1  antibody in a
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rabbit ventricular myocytes were compared with molecularly defined sarcKA TP channels 
expressed  heterologously  in  HEK.293  cells  {Liu  et  al.  2001).  Using  flavoprotein 
autofluorescence  as  an  index  of  mitoKA rp  channel  activity  and  electrophysiological 
recordings of currents from rabbit ventricular myocytes, Liu et al reported that HEK293 
cells expressing Kir6.1/SUR1  subunits had a similar pharmacological profile to the native 
mitoKA rp channel.  Finacidil  and  diazoxide  (100  pM)  opened  the  Kir6.1/SUR1  type 
channel, while P-1075 activated most of the heterologously expressed  K A t p   channels but 
it had no effect on  Kir6.1/SUR1  or native mitoKA Tp channels.  Glibenclamide (10 pM) 
blocked all channels whereas the mitoKA jp channel blocker 5-HD (200 pM) inhibited the 
native mitoKA jp and  Kir6.1/SUR1  channel.  The sarcKA jp channel  inhibitor HMR1098 
had  no effect on  these channels and  P-1075  could  not open  native  mitoKA jp channels 
either.  The  data  showed  that  the  native  mitoKA jp  channel  closely  resembled  the 
Kir6 .1/SUR1 channel expressed in HEK293 cells.
The  immunogold  labelling  work  by  Suzuki  suggested  that  Kir6 .l  was  a  possible 
candidate  of the  mitoKA Tp  channel  {Suzuki  et  al.  1997).  However,  recent  work  by 
Ardehali et al did not detect Kir6.1  in highly purified mitochondrial fractions {Ardehali et 
al. 2004).  Similarly, Hambrock and co-workers showed that Kir6.1  tagged to GFP alone 
or co-expressed with the SUR subunit did not translocate to mitochondria {Hambrock et 
al.  2002).  Furthermore,  Kir6.1  and  Kir6.2  have  been  shown  to  be expressed  at  high 
levels  in  rabbit  ventricular myocytes but one  study showed  that the overexpression of 
Kir6.1  (and  Kir6.2)  dominant  negatives  (DN)  did  not  block  diazoxide  induced 
flavoprotein autofluorescence in these cells, suggesting that neither Kir6 .1 and Kir6 .2  are 
part of the mitoKA jp channel {Seharaseyon et al.  2000).  Subsequently,  studies probing 
for  the  roles  of Kir6 .1  and  Kir6 . 2   demonstrated  that  diazoxide  induced  flavoprotein 
oxidation in Kir6 .1  and Kir6.2 deficient mice {Miki et al. 2002; Suzuki et al 2002).
531.9.2  Knockout mice studies
In  the  last  year,  research  in  this  field  has  been  focusing  on  the  potential  role  of the 
sarcKATP  channel  in  I PC  because  a  number  of studies  have  questioned  the  role  and 
existence of mitoKATP channels.  Studies conducted by Miki et al examine the importance 
of Kir6 .x genes in different tissues by generating Kir6.1  and Kir6.2 null mice (Miki et al. 
2002;  1998a).  Both  genes  have  vital  physiological  roles  because  functional  K Atp 
channels  protect  the  cells  against  acute  metabolic  stress  such  as  hyperglycaemia, 
hypoglycaemia,  hypoxia and  ischaemia (Seino  &  Miki.  2003b).  Miki  et al  found that 
Kir6 .1   knockout mice were susceptible to spontaneous ST elevation and atrioventricular 
block followed by sudden premature death.  In situ hybridisation detected Kir6.1  mRNA 
in  the  hearts  of wild  type  mice  but  none  was  detected  in  the  Kir6.1  knockout  mice. 
Kir6.1  mRNA  and  protein  are  up-regulated  during  myocardial  infarction  (Akao  et  al. 
1997).  Cardiomyocytes  from  wild  type  mice  showed  significant  K+  current  when 
stimulated with pinacidil, this was blocked with glibenclamide but cardiomyocytes from 
Kir6 .1  knockout mice had no response.  See table 1.4 for knockout (KO) mice studies.
Table  1.4.  A table to show knockout mice studies investigating the roles of Kir6.x and SUR 
subunits with the relevant references.
Knockout mice Reference
Kir6.2 7 Miki et al 1998
Kir6.1 7 Miki et al 2002
SUR1 7 Seghers et al 2000
SUR2 7 Chutkow et al 2001
Suzuki  and  others  showed  that  the  infarct  size  in  wild  type  mice  with  I PC  was 
significantly less than wild type mice without 1PC, however, there were no differences in 
infarct sizes between wild type and  Kir6.2  KO mice with  IPC (Suzuki et al.  2002).  In 
vitro experiments using Langendorff perfused hearts.  The hearts from Kir6.2 KO mice 
did  not  recover  from  an  ischaemic  insult  whereas  wild  type  mice  do  recover  from 
ischaemia.  Wild  type  mice  pre-treated  with  HMR1098  (sa rc K ATp  blocker)  were 
susceptible to metabolic stress, similar to the observations seen in Kir6.2 KO mice.  If the
54hearts of wild type mice were preconditioned (with their  m i t o K A T P   channels still intact), 
this  suggests  that  Kir6.2  and  sarcKATP  channel  and  not the  mitoKA Tp channel  may  be 
important in preconditioning {Suzuki et al.  2002; 2003).  In addition to this, the absence 
of Kir6.2  in  KO mice was found to negate protection of myocardium.  After ischemia- 
reperfusion,  IPC-induced energetic and  functional  improvements occurred  in wild type 
but not Kir6.2 KO hearts (Gumina et al. 2003).
1.10  Hypothesis and aims
This study aims to test the hypothesis that:
The intracellular localisation of Kir6.1  is functionally significant in cardiac and skeletal 
muscle  because  it  generates  important  K+  flux  in  intracellular  membranes  such  as the 
endoplasmic reticulum, sarcoplasmic reticulum and perhaps the mitochondria.  The study 
will  specifically  examine  the  role  of the  channel  in  ROS  production,  mitochondrial 
function and Ca2*  handling.  The aims are:
1.  To  examine  the  endogenous  expression  and  subcellular  distribution  of  natively 
expressed Kir6.1 and the subcellular distribution of heterologously expressed Kir6.1-GFP 
in HepG2, C2C12, HL-1 and HEK-293 cell lines.
2.  To examine the functional role of Kir6.1  in the regulation of free radical generation, 
mitochondrial redox state and Ca2+ handling by overexpressing Kir6.1 or by knocking out 
Kir6 .1   using siRN A or dominant negative forms of Kir6 .1.
552.0  MATERIALS AND METHODS
2.1  General molecular biology
Common molecular biology techniques were used in this project.  The data presented in 
this  study  required  these techniques  because  K atp  channel  subunits and  other plasmid 
DNA  were  manipulated  or reproduced  for specific experiments or  in conjunction  with 
other experiments.
2.1.1  Restriction di2est of DNA molecules
Restriction enzymes hydrolyse double stranded  DNA  molecules at specific palindromic 
nucleotide sequences.  These sequences are palindromes because they exhibit two  fold 
rotational symmetry.  Some enzymes cut the two strands of DNA in a staggered manner 
creating  ‘sticky’  or cohesive ends (e.g.  Bam  HI and Apa  I)  with  protruding 5’  and  3’ 
ends,  Bam  H\  cuts  at  the  5’  end  of the  axis  whereas  Apa  I  cuts  at  the  3’.  Other 
endonulceases such as Hae III cleave in the middle of their recognition sequence at the 
axis of symmetry and produce blunt ends.  The enzymes were stored on ice and added to 
the reaction mix last to avoid enzyme degradation and loss of activity.  The buffers for 
the restriction enzymes were supplied as lOx stock and BSA as lOOx stock (lOx BSA was 
used so pipetting small volumes was avoided).  The samples were mixed thoroughly and 
incubated  for  1   hour generally at 37 °C.  In some cases, two restriction enzymes were 
used to cut the DNA so a compatible buffer was used where both enzymes have greater 
than 50 % of their maximal activity.  Restriction digests were set up as follows:
2 pi DNA (20-100 pg)
2 pi  1  Ox BSA stock concentration (final concentration used 100 pg/ml)
2 pi enzyme buffer (1 Ox)
1  pi restriction enzyme (2 - 1 0  units)
16 pi Sigma grade molecular biology water
562.1.2  Agarose gel electrophoresis
Gel electrophoresis separates DNA molecules of different sizes.  Each nucleotide in the 
DNA  molecule contains a phosphate group;  therefore  it is negatively charged and will 
migrate  in the presence of an electrical  field.  Agarose gels are used to separate  DNA 
fragments  over a  broad  size  range  however;  its  resolving power  is  not  as  accurate as 
polyacrylamide gels which are used to separate smaller DNA fragments.  DNA exists in 
three  different  forms:  linear,  supercoiled  and  nicked  so  its  conformation  is  important 
because  it would  influence its migration  rate  in the gel.  In  most cases, a 0.7 % (w/v) 
agarose gel was made in  lx TAE buffer.  A 50x TAE stock solution was made using 2 M 
Tris Base {Sigma Aldrich,  UK), 50 mM EDTA pH8.0 and 5.71  % (v/v) glacial acetic acid 
{BDH,  UK) and (0.7  g of electrophoresis grade agarose {Invitrogen,  UK) was added to 
100 ml  lx TAE.)  This was microwaved until the agarose had completely dissolved.  The 
mixture was left for a minute before ethidium bromide {Sigma Aldrich,  UK) was added to 
give a final concentration of 0.5 pg/ml.  This is an intercalating dye that binds between 
base pairs so that  DNA  bands can  be visualised  under ultra violet  light.  The agarose- 
TAE mixture was poured into a plastic gel tray sealed securely at the sides with autoclave 
tape and plastic combs were placed at the appropriate slots.  The gel was left to set for an 
hour at room temperature.
After the  restriction enzyme digest had  been  incubated  at 37 °C,  2  pi  lOx  gel  loading 
buffer was added to each sample.  The buffer was made from 0.25 % (w/v) bromophenol 
blue, 0.25  % (v/v) xylene cyanol  FF,  30 % glycerol  {all supplied from Sigma Aldrich, 
UK).  The samples were mixed thoroughly and 20 pi was loaded into its designated well 
along with a standard DNA molecular weight marker VII {Roche Labs,  UK) as this was 
used to determine the size of the DNA fragments.  The gel was set to run at 100 V for an 
hour before it was viewed under the ultra-violet (UV) light at 312 nm wavelength  in a 
UVP  dual  intensity  transilluminator  connected  to  a  camera,  monitor  and  printer. 
Photographs were printed and DNA fragments were sized according to the DNA standard 
marker.
572.1.3  Extraction and purification of fragments/plasmid DNA from agarose gels
The DNA fragments separated by agarose gel electrophoresis was extracted and purified 
using a commercially available  kit  from  Qiagen (QiaEx II agarose gel extraction kit). 
Silica  gel  particles  bind  DNA  fragments  under  high  salt  conditions  and  contaminants 
were removed by a series of washes before the purified DNA was eluted with distilled 
water.  The DNA fragment of interest was excised with a clean scalpel from the gel and 
weighed in an eppendorf tube to which three volumes of buffer QX1   was added to one 
volume of DNA fragment 100 bp-4 kb.  This was resuspended in Qiagen II by vortexing 
for 30 seconds and for 2 pg DNA, 10 pi QiaEx II or for 2-10 pg DNA 30 pi QiaEx II was 
required to dissolve the gel.  The DNA fragment was incubated at 50 °C for 10 minutes to 
solubilise the agarose and bind the DNA.  The mixture was vortexed every two minutes 
to keep QIAEX  II  in suspension before the sample was centrifuged  for 30 seconds and 
supernatant discarded.  The pellet was washed with 500 pi of buffer QX1  before it was 
centrifuged  for 30 seconds and  it was washed twice with 500 pi wash buffer PE.  This 
was followed by centrifugation for 30 seconds; the pellet was air-dried for 10-15 minutes. 
The sample was centrifuged with 20 pi of distilled water and the eluted DNA collected 
into a clean tube.  This step was repeated so that approximately 40 pi was collected in 
total,  this  second  elution  step  should  in  theory  increase  the  yield  by  10-15  %.  The 
purified plasmid DNA/DNA fragment would be used in subsequent ligation reactions.
2.1.4  Ligation of DNA fragments
DNA  fragments can be inserted into a vector in a ligation reaction.  Whether a specific 
DNA fragment can be spliced into a vector is dependent on the termini produced by the 
restriction  enzyme  digest.  The  DNA  fragment  and  vector  are  usually  digested  with 
restriction enzymes that have compatible cohesive ends.  The enzyme DNA ligase is used 
during the  ligation  reaction  to  form  new  phosphodiester bonds between the phosphate 
residues located at the 5’ terminus and hydroxyl group at the 3’ terminus.  Calf intestinal 
phosphatase (CIP) (New England Labs,  UK) was used to remove the 5’phosphate group 
of the  vector  because  the  restriction  enzymes  producing  identical  cohesive  ends  may
58re ligate especially if once partially digested by one of the enzymes.  Ten units of CIP was 
added to the digested product and incubated at 37 °C for 1   hour.  The reaction was set up 
and incubated at  16 °C overnight.  The ligated DNA was then introduced into competent 
E.coli by transformation.  The ligation reaction was set up as follows:
5 pi CIP-treated digested vector 
12 pi digested DNA fragment 
2 pi  lOx ligation buffer
1   pi T4 DNA ligase (1  unit) {Roche Diagnostics,  UK)  Total volume 20 pi
2.1.5  Procedure for making competent E.Coli for transformation
Transformation  is the process of introducing foreign DNA into bacteria.  When bacteria 
are treated they are made  ‘competent’, meaning they can readily take up foreign  DNA. 
Foreign  DNA  can  be  introduced  into  bacteria  by  two  main  methods;  the  First  is  by 
electroporation  and  the  second  is  by  chemical  transformation.  In  the  case  of 
electroporation, an electrical pulse permeabilises the cell membrane allowing DNA to be 
introduced into the cell.  For chemical transformation, the bacteria were made competent 
by treating them in a variety of ice-cold buffers containing mostly CaCL or RbCl.  In this 
study,  chemical  transformation  was  used  as  it was efficient and  reliable method.  The 
Top 10  strain of E.Coli was  used  for transformations as this particular strain  is able to 
replicate steadily.  The original Top 10 stock was obtained from Invitrogen {Groningen, 
Netherlands).  The Top 10 E.coli competent cell stocks were replenished regularly.  Using 
a sterile inoculating loop, cells from a glycerol  stock were streaked onto Luria-Bertani 
(LB broth) agar plates.  This was left to incubate at 37 °C overnight and stored at 4 °C for 
1   week.  LB broth {Sigma Aldrich,  UK) is used as a growth medium for E.  Coli (1  litre: 
10 g Tryptone, 5 g yeast extract and 5 g NaCl).  The agar plates were made using  1.5 g 
agar {Sigma, Aldrich,  UK) for  100 ml LB broth.  The agar was heated in the microwave 
until it had completely dissolved and cooled down before they were poured into 90 mm 
Petri dishes {VWR,  Merck house,  UK).  Plates were left to set at room temperature and 
stored at 4°C until required.
59One or two individual colonies were picked using a sterile pipette tip and placed into a 
falcon tube containing 3 ml of LB broth and left on a shaking incubator (225 rpm) at 37 
°C for 7-9 hours.  A sterile 2-litre flask containing 200 ml LB broth was inoculated with 
1   ml of the starter culture and grown at 37 °C until the ODssonm was between 0.450 and 
0.550 nm.  The cells were transferred into sterile centrifuge bottles and allowed to cool 
on ice for 30 minutes before centrifuging cells at 2500 rpm for 15 minutes.  After this, the 
supernatant was discarded and the pellet was resuspended  with  25  ml of ice-cold  RF1 
buffer  (100  mM  RbCl,  50  mM  MnCl2.4H20,  30  mM  potassium  acetate,  10  mM 
CaCl2-2H20,  15  % (w/v) glycerol,  pH  adjusted  to 5.8  with 0.2  M acetic acid and  filter 
sterilised).  Cells were incubated on ice for 15 minutes before centrifugation at 2500 rpm 
for 9 minutes.  The supernatant was poured off and the pelleted cells were resuspended 
with 4.2 ml of ice-cold RF2 buffer (10 mM RbCl,  10 mM MOPS, 75 mM CaCl2.2H20, 
15 % glycerol, pH adjusted to 6.8 with 0.2 M NaOH- Filter sterilised) before they were 
kept on ice for 15 minutes.  The competent bacteria were aliquoted into sterile eppendorf 
tubes and flash frozen using liquid nitrogen before they were stored in the -80 °C freezer. 
They were left in the freezer for at least 24 hours before use.
2.1.6  Transformation of plasmid DNA
Top 10  E.Coli cells  were  slowly  thawed  out  on  ice before  use.  About  100  pi  E.Coli 
Top 10 cells were used for each transformation and mixed with 1   pi DNA in an eppendorf 
tube.  They were left on ice for 30 minutes before they were heat shocked at 42 °C for 90 
seconds  to  introduce  the  DNA  into  the  bacteria.  The  tubes  were  cooled  on  ice  for  2 
minutes before 800  pi  prewarmed  LB  broth  was added to each sample.  This gave the 
cells  time  to  express  the  antibiotic  resistance  gene  encoded  by  the  plasmid  DNA. 
Approximately  100 pi of the mixture was added to LB agar plates containing antibiotic; 
this was either with carbenicillin (100 pg/ml) or kanamycin (25 pg/ml) which was evenly 
distributed using a sterile spreader. (Frozen stocks of the antibiotics were added to the LB 
agar mixture when  the temperature was  less than  50 °C).  The  plates were  left  in  the 
incubator overnight at 37 °C to allow the formation of discrete colonies.
602.1.7  Procedure for plasmid DNA purification (Midi preparation)
Plasmids are used extensively in DNA cloning.  They are small double stranded circular 
DNA molecules that replicate independently of the host genome.  However, plasmids do 
require  the  transcription  and  translation  machinery  of the  host  cell  to  replicate.  The 
plasmid DNA with the correct sequence was identified before it could be retransformed 
and  produced  in  larger  quantities.  Qiagen  supplied  the  DNA  purification  kit  and  the 
method  was  followed  according  to  manufacturer’s  instructions.  The  kit  purifies  the 
plasmids  on  a  DEAE  anion  exchange  column  and  plasmid  DNA  were  produced 
according to how much DNA was needed for experiments.  The DNA could be purified 
using either the midi or maxi preparation depending on the DNA yield that was required. 
The midi preparation was employed because 20-100 pg of DNA was generally required 
for subsequent experiments.
2.1.8  Subcloning K a t p  subunits into specific vectors
The  K a tp  channel cDNA constructs were previously generated in the laboratory but it is 
important to understand how these constructs were made and the methods employed (Cui 
et al.  2001).  The  majority  of the  colocalisation  work  investigated  the  distribution  of 
Kir6.1  using a cDNA construct called  Kir6.1-GFP where the C terminus of Kir6.1  was 
fused to GFP (eGFP-Nl  vector) (Rizzuto et al.  1995).  In chapter 3.1, I will describe how 
this was made because elucidating the distribution of Kir6.1  with this fluorescent marker 
was a major focus of this thesis.  The cDNA of Kir6.1  was originally  identified  in  rat 
pancreatic  islet  cells  (Inagaki  et  al.  1995c),  Kir6.2  was  also  discovered  by  the  same 
group, this was expressed in rat pancreatic islets and glucose-responsive insulin-secreting 
cell lines (Inagaki et al.  1995a).  SUR1  was cloned from hamster cDNA (Aguilar-Bryan 
et al.  1995) and SUR2B was identified from mouse heart cDNA library (Isomoto et al. 
1996).  All the K a tp  channel subunits were expressed in pcDNA3 family of vectors.  The 
dominant  negatives  for  Kir6.1  (DNKir6.1),  SUR1  and  SUR2B  were  expressed  in 
pcDNA3 and Kir6.1, Kir6.2 in pcDNA3.1/Zeo (both vectors were from lnvitrogen,  UK). 
The endoplasmic  reticulum  marker,  DsRed2-ER  was bought commercially (Clonetech,
61UK).  Figure  2 . 1   shows the restriction  maps for the vectors used to subclone our  K A t p  
channel subunits.  Please refer to table  3 . 1   in the results section for the complete list of 
plasmid cDNAs used throughout this thesis.
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Figure 2.1.  The maps for the vectors used to subclone specific KA T P  channel units.  A is 
eGFP-Nl, B  is DsRed2-ER and in C, pcDNA3.!/Zeo vector was used to subclone original 
cDNAs.  The properties of the pcDNA vector will be discussed later on in the chapter.
622.2  Cell culture
HEK293, HepG2 and C2C12 cell line
Three  cell  lines  used  throughout  this  study  were  mostly  immortalised  eukaryotic  cell 
lines.  The  HEK293  cell  line  (< obtained from  Dr L  Y Jan,  UCSF)  is  an  immortalised 
human cell  line derived from primary embryonic kidney cells transformed with sheared 
adenovirus type 5 DNA. The HepG2 cell line (Obtainedfrom Dr. G Bellingham,  UCL) is 
a permanent cell  line from a human  liver cell line derived from hepatoma.  The C2C12 
cell line is derived from mouse skeletal muscle {Obtainedfrom ATCC).  These can grow 
indefinitely  in  culture  as  undifferentiated  myoblasts  but  can  form  morphologically 
distinct myotubes once they are grown to confluence upon serum deprivation.
2.2.1  General cell culture
The cells were grown and cultured  in  Eagle’s Minimal  Essential  Medium (MEM) with 
Earle’s  salts  and  L-Glutamine  (composition)  in  mM:  117  NaCI,  26  NaHCC>3,  158 
NaH2PC> 4, 5.3 KC1,  1.8 CaCh, 0.8 MgSC>4, 5.5 d-glucose and 0.02 phenol red {Invitrogen, 
UK).  This  was  supplemented  with  10  %  foetal  bovine  serum  and  1   %  pen ici 1 1  in- 
streptomycin  from  a  stock  of 5,000  units/ml  penicillin  {Invitrogen,  UK).  Cells  were 
grown in a T75 tissue culture flask {VWR, Merck house UK) in an incubator at 37°C with 
atmosphere  of 95  %  air  and  5  %  CO2.  Cells  were  usually  passaged  when  80-90  % 
confluent.  All  solutions were warmed at 37  °C  before use.  The growth  medium  was 
discarded  and  cells  were  washed  twice  in  Dulbeccos’  phosphate  buffered  saline,  PBS 
{Invitrogen,  UK).  Cells were removed from the surface of the flask by adding  1   ml of 
0.25 % Trypsin (2.5 % (w/v) stock {Invitrogen,  UK) made up in PBS for 2-3 minutes at 
37 °C.  Growth medium was added to inhibit the trypsin activity and the cell suspension 
was  collected  in  15  ml  falcon  tubes  (Sarstedt,  UK) and  centrifuged  at  800  rpm  for 5 
minutes.  The medium  was discarded and pelleted cells were resuspended in  10 ml of 
fresh medium.  One ml of resuspended HEK293 cells was used to seed a new T75 flask.
63For  HepG2  and  C2C12  cell  lines,  0.5  ml  was  used  to  seed  a T75  flask.  Cells  were 
cultured twice weekly and the growth medium was changed every 2-3 days.
2.2.2  Production and revival of frozen stocks
In  order  to  obtain  frozen  stocks  of cells,  they  were  only  passaged  when  80-100  % 
confluent.  After centrifugation, the cell pellet was resuspended in 5 ml growth medium 
and  5  ml  10  %  dimethyl  sulfoxide  DMSO  (Sigma  Aldrich,  UK)  before  they  were 
aliquoted (1  ml) into cryogenic vials (VWR, Merck house, UK).  These were frozen down 
using  a  Nalgene  freezing jar  containing  room  temperature  isopropanol  (VWR,  Merck 
house,  UK).  The  jar  with  the  cryovials  were  placed  into  the  -80  °C  freezer  for 
approximately 6-12 hours before the vials were transferred to a liquid nitrogen container 
for long-term storage.  The cells were revived by placing the vial in the waterbath set at 
37 °C  for 2-3 minutes.  The whole aliquot was added to a flask containing pre-warmed 
growth  medium.  The  cells  were  left  to  adhere  to  the  flask  under  normal  growth 
conditions.  After  6-18  hours  the  culture  medium  containing  DMSO  was  removed  as 
DMSO becomes toxic to the cells.  This was replaced with fresh growth medium.
2.2.3  Selection and maintenance of stably transfected cell lines
The stable cell  lines HEK  Kir6.1/SUR2B and  Kir6.2/SUR2B which  I  have used  in this 
thesis  were  originally  generated  in  the  lab.  Although  I  did  not  generate  these,  it  is 
important to fully understand and appreciate the process.  This section will explain how 
the stable cells expressing the K a tp  channel subunits were isolated.  When plasmid DNA 
enters the cell,  it  is trafficked  to the  nucleus where the  DNA encoded  proteins can  be 
expressed.  In transient transfections, most plasmids will replicate using the host DNA 
replication  machinery  but  this  process  cannot  continue  indefinitely  as  the  plasmid  is 
eventually lost.  With a stable transfection, the plasmid can either replicate independently 
of host cell and pass  its DNA on to daughter cells during division or alternatively, the 
plasmid can  be  randomly  integrated  into the  host cell,  replicate and pass on  from one 
generation  to the  next.  The  plasmid  usually contains a gene when  expressed  confers
64resistance to a specific antibiotic.  The stably transfected cells were selected in this way. 
The K a tp  channel subunits of interest intended for the generation of stable cell lines were 
subcloned into one of two mammalian vectors; pcDNA3 and pcDNA3.1/zeo (Invitrogen, 
UK).  These  vectors  have  been  genetically  manipulated  to  make  them  efficient  in 
introducing  the  genes  of  interest  into  my  cell  lines.  The  K At p   subunits  were  co­
transfected  simultaneously  and cells co-expressing both  constructs were selected  using 
media  containing  727  pg/ml  Geneticin  and  344  pg/ml  Zeocin  (Tranfections  will  be 
discussed  in the next section).  The pcDNA3  and pcDNA3.1/zeo vectors contain genes 
encoding for resistance to Neomycin (Geneticin) and Zeocin respectively.
Cells  containing  pcDNA3  vector  were  selected  using  Geneticin,  a  glycoside  which 
inhibits  protein  synthesis and  causes cell  death  by  affecting  ribosome  function.  Cells 
expressing  the  Neomycin  resistance  gene,  encodes  for  proteins  with  aminoglycoside 
phosphotransferase activity, which makes cells resistant to Geneticin.  Cells containing 
the pcDNA3.1 vector were selected with Zeocin, this causes cell death by DNA cleavage. 
Cells  expressing  the  Zeocin  resistance  gene  encode  a  protein  which  binds  to  Zeocin 
directly  preventing  DNA  cleavage.  All  pcDNA  vectors  also  contain  an  ampiciliin 
resistance  gene  that  permits  selection  of transformed  bacteria.  The  structure  of the 
vectors  is  shown  in  figure  2.2  with  notes  on  its  important  features.  Therefore  cells 
expressing these plasmids were selected using their relevant antibiotics.
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Figure 2.2.  PcDNA3 vector restriction map.
A  is the  multiples cloning site (MCS), this is a synthetic  DNA  sequence  which  encodes a 
variety of unique restriction endonuclease recognition sites.  This permits the insertion of the 
gene of interest and facilitates cloning.
B  is  known  as  the  promoter sequence,  this contains  a viral  human  CMV  immediate-early 
promoter (from Cytomegalovirus) for high level of expression in mammalian cells.  The T7 
promoter contains a binding site for RNA polymerase II  which also binds with transcription 
factors.  Expression  is  driven  by  the  CMV  immediate early  promoter,  the  powerful  CMV 
promoter (and SV40 polyadenylation site contains a sequence that provides signals required for 
termination of mammalian transcription and translation).
C encodes for specific genes that encode for drug resistance.  This allows cells to synthesise an 
essential component  in deficient media.  What makes the pcDNA3  vectors so useful  is that 
there are selectable markers for prokaryotic (amplicillin) and eukaryotic systems (Neomycin 
and Zeocin).  E.g. the neomycin resistance gene is used for the selection of stable cell lines.
2.2.4  General cell culture for K a t p channel stable cell lines
The stable cell  lines HEK  Kir6.1/SUR2B and Kir6.2/SUR2A were cultured  in the same 
way as described with the other cell  lines.  These cell  lines grew more slowly than wild 
type HEK293 so were only cultured every 7-10 days but the media was changed twice a 
week.  MEM was supplemented with FBS, 344 pg/ml Zeocin {Invitrogen,  UK) and 727 
pg/ml Geneticin orG418 {Life Technologies,  UK).
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The HL-l  cell line is derived from AT-1  cardiac myocytes, they are atrial cardiac muscle 
cells where expression  of the  SV40  large T antigen  was controlled by  atrial  natiuretic 
factor (ANF) promoter {these were obtainedfrom Prof. Claycomb,  USA).
2.2.5  Preparation of growth medium for HL-l cardiomyocytes
HL-l  cell  line were grown  in supplemented Claycomb medium, which contained  10 %, 
FBS {JRH Biosciences,  UK), 1  % penicillin/streptomycin, 0.1 mM norepinephrine {Sigma 
Aldrich,  UK) and 2 mM L-glutamine {Life technologies,  UK).  The medium was wrapped 
in foil as it was light sensitive and was replaced after two weeks because L-glutamine had 
to  be  replenished.  Norepinephrine  was  made  up  in  30  mM  L-ascorbic  acid  {Sigma 
Aldrich,  UK) and filter sterilised using a 0.2 pm syringe filter {VWR, Merck house,  UK) 
and stored at -20 °C for a month.  L-glutamine (lOOx) solution was also stored at -20 °C. 
Soybean trypsin  inhibitor (12.5  mg) was dissolved  in  50 ml of PBS {both supplied by 
Invitrogen,  UK).  This  was  filter  sterilised  and  stored  at  4  °C  for  a  week.  HL-l 
cardiomyocytes  were  cultured  on  a  gelatine  (0.02  %  [wt/vol])/fibronectin  (10  pg/ml) 
matrix.  Tissue culture flasks were coated with this the day before cells were passaged. 
To obtain stocks, 0.1  g gelatin {BD Biosciences,  UK) was added to 500 ml of distilled 
water (0.02 % gelatin) and this was autoclaved and  1   ml of fibronectin {Sigma Aldrich, 
UK) was diluted in  199 ml of 0.02 % gelatin.  This was mixed and aliquoted before they 
were frozen at -20 °C.
2.2.6  Maintaining and culturing HL-l cell line
HL-l  cardiomyocytes were grown  in  supplemented Claycomb medium every weekday 
and were passaged only at full  confluence.  A T75  flask was rinsed with 5  ml 0.05  % 
trypsin/EDTA  and  aspirated.  Another  5  ml  of trypsin/EDTA  was  added  and  left  to 
incubate at 37°C for 2 minutes.  This was removed and replaced with fresh trypsin/EDTA 
and incubated for an additional  5-8 minutes.  Five ml of soybean trypsin inhibitor was
67used to inhibit trypsin activity before cells were collected  in a falcon tube.  Five ml of 
Claycomb wash media (without FBS) was added to the flask to collect remaining cells 
and these were centrifuged at 800 rpm  for 5  minutes.  The gelatin/Fibronectin solution 
was removed from flasks and replaced with 10 ml of supplemented Claycomb media. The 
pelleted cells were gently resuspended in 4-5 ml of fresh Claycomb medium.  One ml of 
the cells was used to seed the new flask.
2.2.7  Production/revival HL-l cell line frozen stocks
In order to obtain stocks of HL-l  cell line, cells from a confluent T75 flask were frozen 
into one cryovial.  The cells were trypsinised and collected as before but were centrifuged 
at  1000  rpm  for  5  minutes.  Each  cell  pellet  was  resuspended  in  1.5  ml  of freezing 
medium  (95  %  FBS  and  5  %  DMSO).  Cryovials  were  frozen  down  using  the  same 
method as described for the other cell  lines.  Before reviving the cells, a T75  flask was 
coated  with  gelatin/fibronectin  the  day  before  and  frozen  stocks  were  thawed  for 2-3 
minutes  at  37  °C  before  centrifugation  at  1000  rpm  for  5  minutes.  The  pellet  was 
resuspended in 5 ml of supplemented Claycomb medium and transferred to a T75  flask 
already containing prewarmed Claycomb media.  The medium was replaced with fresh 
medium after 4 hours when the cells had attached.
2.2.8  Counting viable cells using Trypan Blue exclusion assay
The majority of cells cultured throughout this study were healthy but a minority of cells 
did not grow as expected,  in order to determine if a new aliquot of cells (frozen) were 
required,  counting  the  number  of  viable  cells  in  existing  tissue  culture  stocks  was 
necessary.  Trypan Blue (Sigma Aldrich,  UK) is a dye that is used routinely to determine 
the viability of cell lines.  Living cells exclude the dye, whereas dead cells will take up 
the blue dye.  This is because the plasma membrane is damaged therefore facilitates the 
uptake of the dye to which the cell  is normally  impermeable.  The blue  stain  is easily 
visible,  and  cells  can  be  placed  into  a  haemocytometer  and  counted  using  a  light 
microscope.  A 200 pi aliquot of cell suspension was mixed with equal volume of 0.4 %
68(w/v) Trypan  Blue staining solution.  A coverslip was placed on top of the grid on the 
haemocytometer (Neubauer 0.100 mm depth) (.Invitrogen,  UK).  A small drop of the cell 
suspension was applied at the edge of the coverslip because the two chambers filled by 
capillary  action).  The  number of viable  cells  in  each  1   mm  square  was counted  and 
results were averaged.  The number of cells per ml was calculated using the expression: 
No. of cells/ml = Mean count/mm2 x 10,000 x 2.  The volume of the  1   mm square is 0.1 
mm  (as the depth is 0.1  mm) and volume conversion factor for 1   mm  .  The calculated 
value was multiplied by two to take into account the dilution factor of the cell suspension 
in Trypan Blue solution.
23  T ransfection
Transfection  is the process of introducing foreign  DNA  into a eukaryotic cell.  Once in 
the cytoplasm,  DNA  is transported to the nucleus whereby the proteins encoded by the 
DNA  is expressed  by  using the  host cell’s transcriptional  and translational  machinery. 
Transfected DNA is maintained transiently in many cells but only stably integrated in a 
few.  There are many  known  methods  for introducing plasmid  DNA  into a eukaryotic 
cell.  There are numerous non-viral transfection techniques, the DEAE-dextran method 
was  discovered  by  Pagano  and  McCutchan  in  1969  and  calcium  phosphate  co­
precipitation by Graham and Van der Eb in  1972 (Graham &  Van der Eb 1973; Pagano 
& McCutchan 1969).  Liposome mediated gene transfer was pioneered in the late  1980’s 
by  Itani  et  al,  this  was  a  useful  method  because  it  provided  high  efficiency  of gene 
transfer and  DNA  could  be  integrated  transiently  or  stably  integrated  into  a cell  line. 
There  are  other  methods  for  introducing  DNA  into  a  cell  without  forming  a  DNA- 
mediator  complex;  these  include  electroporation  and  direct  microinjection.  The  best 
method  of transfection  would  allow  high  transfer of DNA  into the  cell  with  minimal 
interference to the cell’s physiology,  low toxicity, reproducibility and ease of use.  For 
the transfection experiments in this study, the liposome based transfection was employed.
692-3.1  Liposome based transfection
Cells were passaged the day before transfection into 6 well tissue culture dishes (Triple 
Red,  UK) so that they reached 60-70 % confluency the next day.  Cells were transfected 
with no more than 2 pg DNA because overloading the cells with DNA would cause cell 
death.  For each transfection,  5  pi of 2 mg/ml  Lipofectamine was diluted  in  100 pi of 
Opti-MEM reduced serum medium (both obtained  from Invitrogen,  UK).  Opti-MEM is a 
modification of Eagle’s Minimal Essential Medium (MEM) buffered which contains L- 
glutamine,  2400  mg/L  sodium  bicarbonate,  HEPES,  sodium  pyruvate,  hypoxanthine, 
thymidine, trace elements, growth factors and  1.1  mg/L Phenol Red.  A 100 pi aliquot of 
Opti-MEM was added to eppendorf tubes containing 0.8-2  pg DNA (depending on the 
amount of DNA used).
The  mixtures  were  incubated  for  15  minutes  before  100  pi  of lipofectamine-optimem 
mixture  was  added  to  DNA  and  left  to  incubate  for  30  minutes  to  allow  DNA-lipid 
complexes to form.  After this, 800 pi of optimem was added and mixed (final volume of 
1ml).  Cells were washed briefly with optimem before the ml of transfection mixture was 
added to appropriate wells.  The cells were incubated with the transfection mixture under 
normal growth conditions for 10-15 hours before it was removed and replaced with fresh 
medium. This allowed transfected cells to recover and to express the DNA.  With the cell 
lines used, cells were transfected up to  15 hours because it produced higher transfection 
efficiencies.  This gave cells sufficient time to take up the DNA, any longer than 15 hours 
would result in cell death.
2.3.2  Transfecting siRNA using liposome based transfection method
Lipofectamine 2000 reagent (Invitrogen,  UK) facilitates high transfection efficiency of 
small interfering RNA (siRNA) to mammalian cells with effective knockdown of a gene 
(see 2.4).  Some factors can affect the degree of gene expression and this can be reduced, 
for example when siRNA are used.  The factors to consider are transfection efficiency, 
the transcription rate of the gene of interest, protein stability (and its degradation) and the
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cultured the day before transfection into 6 well tissue culture dishes. After centrifugation, 
the pelleted cells were resuspended and plated in MEM media containing only 10 % FBS 
but with no P/S as it would affect the transfection efficiency and was reported to cause 
cell death.  The cells were incubated overnight under normal growth conditions so that 
they  would  be  30-50  %  confluent the  next day,  in  order to  minimise  the  loss of cell 
viability  due  to  cell  overgrowth.  The  procedure  for transfecting  siRNA  is  the  same 
method  used  in  2.3.1.  The  only  differences  are  that  the  first  incubation  period  with 
lipofectamine 2000 and the DNA with Opti-MEM is 5 minutes.  The DNA-lipofectamine 
complexes are allowed to form in 20 minutes and the mixture is added directly to cells 
still  in  growth  media.  The  plates were  mixed  gently  by  rocking them  back and  forth 
before they were incubated at 37 °C for 24-72 hours until cells were ready to be analysed 
for gene  knockdown  or used  in  subsequent experiments.  The  growth  media could  be 
removed after 4-6 hours without loss in transfection activity.
2.4  Small interfering RNA (siRNA)
2.4.1  2-for- Silencing siRNA Duplexes
Small  interfering  RNAs  are  a  useful  new tool  in molecular biology  as  they  have  the
ability  to  suppress  gene  expression.  The  siRNA  kit  used  throughout  this  study  was
custom made by Qiagen.  The first siRNA kit previously used in the first year of my PhD 
was a kit provided by Imgenex which was based on the short hairpin approach.  However 
the siRNA did not show any positive results in gene knockdown so it was not possible to 
move onto functional work.  Recently, Qiagen provided a service to design and make the 
siRNA  duplexes  and  2-for silencing  siRNA  duplexes were guaranteed to have  100 % 
effect in gene silencing.  The entire mRNA coding sequence for the gene of interest was 
scanned  for all  possible  21  base  pair primers  of this  gene  and  analysed  for  potential 
siRNA  activity  using  the  highly  accurate  Hiperformance  design  algorithm.  Stringent 
homology  analysis  was  used  and  high-scoring  candidates  were  ranked  by  their 
uniqueness using a sensitive alignment tool and a non-redundant sequence database.
71Two siRNA that combine optimal potential activity and high specificity were chosen and 
used as the duplexes.  Two high performance purity (HPP) grade siRNAs (20 nmol) for 
Kir6.1   were custom designed by Qiagen.  The siRNA were synthesised so that they were 
specific to rat, mouse and human Kir6.1.  The HPP process yielded > 90 % purity with 
the  quality  checked  by  ion-exchange  high  performance  liquid  chromatography  (IE- 
HPLC)  analysis.  The  sequence  and  identity  of  each  siRNA  was  confirmed  using 
MALDI-TOF spectrometry analysis.  The target sequences used for siRNA duplexes for 
the specific species are as follows.
61 siRNA Duplex 1  (Rat and Mouse)  61 siRNA Duplex 2 (Rat and Mouse)
5’ CAC CAC CTT GGT AGA CCT GAA 3’  5’ CAG GAA GAG CAT CAT CCC GGA 3’
61 siRNA Duplex 1  (Human onlvl
5’ GAG GTG GTT CCT ATT CAC CAA 3’
The siRNA was prepared in RNAse free environment.  A ml of siRNA suspension buffer 
was added to the lyophilised siRNA to obtain a 20 pM solution.  The tubes (Duplex 1  and 
2) were heated  for  1   minute at 95 °C before they were incubated at 37 °C for an hour. 
The duplexes were stored at -20 °C until required.  The method for transfecting siRNA 
into eukaryotic cells is described in section 2.3.  The transfection efficiency was observed 
under a fluorescent microscope (after co-transfection with eGFP) and images were taken 
in the eGFP field and brightfield.  However, the rat and human DNA sequence had 89 % 
homology  therefore  the  presence  of  mismatched  pairs  in  the  siRNA  would  not  be 
effective  (see  chapter  3.1).  Therefore,  separate  human  siRNA  was  acquired  for  the 
functional studies.  These siRNA in conjunction with the dominant negatives are vital in 
this project for determining the possible functions of Kir6.1  in  immortalised cell  lines. 
This will be discussed in chapter 3.1.
722.5  Confocal microscopy
The confocal microscope is an advanced and powerful tool compared to the conventional 
fluorescent microscope.  In contrast, the limitations of the fluorescent microscope are the 
resolution, depth of focus (magnification) and contrast.  The image produced  from the 
fluorescent microscope is obtained by illuminating the sample with a light source.  The 
fluorescent light source is usually either from a Xenon lamp, mercury bulb or a laser.  A 
monochromator  or  filter  transmits  a  selectable  narrow  band  of wavelengths  of  light 
filtered from the light source.  The directed light is then passed through a condenser lens 
and imaged with an objective lens before the image is viewed through the eyepiece.  The 
resolution of the image is predominantly dependent on the objective lens.
2.5.1  The basic principles of fluorescence
Fluorescence microscopy analyses fluorescence from a sample by using a beam of light, 
often  UV  light  to  excite the  electrons  in  the  sample  to  emit  light  of a  lower  energy, 
usually  in  the  visible  range.  The  compound  being  examined  will  have  a  ground 
electronic  state  or  low  energy  state  and  an  excited  electronic  state  of higher  energy. 
Photons  of high  frequency  have  a  greater  energy  than  those  of low  frequency.  The 
compound absorbs a photon of light from its ground state to various vibrational states in 
the excited electronic state.  The excited compound reaches the lowest vibrational state 
thus emitting a photon with energy equivalent to the difference of these states.
2.5.2  The basic principles of confocal microscopy
In  confocal  microscopy  the  light  source  is  provided  by  a  laser.  The  principle  of the 
confocal  microscope  is  to  direct  the  laser  beam  to  a  focal  point as  it scans  over the 
specimen.  A detector collects the light emitted from the point of focus while out of focus 
light is excluded.  Confocal microscopy removes out of focus light by passing the light 
through one or more small apertures (pinhole), leaving only a thin, highly focused plane. 
The thickness of the focal plane depends on the pinhole aperture and is placed in front of
73the detector to eliminate out-of-focus information.  Only the light within the focal plane 
can be detected, so the image quality is better and gives a higher resolution image than 
that  of wide-field  images.  Scanning  mirrors  then  use  the  focused  laser  light  to  scan 
different parts of the specimen until an entire field is obtained.
The light emitted from the specimen  is detected by photomultiplier tubes (PMT) which 
generates a current that is proportional to the light intensity.  PMTs are constructed from 
a glass vacuum tube which houses a photocathode, several dynodes to amplify the signal 
and an anode.  The light (photons) excites electrons in the tube wall and the electrons are 
accelerated  by  the  electric  field  towards  the  first  dynode.  The  high  energy  electrons 
strike  the  first  dynode  and  emit  low  energy  electrons  which  in  turn  are  accelerated 
towards the second dynode.  This cascade increases the number of electrons produced at 
each stage before it reaches the anode where the accumulation of charge results in a sharp 
current that generates a voltage across a resistor.  The signal is converted  into a digital 
mode by an A-D convertor which can be displayed on a computer as an image, see figure 
2.3.  For  the  study  of the  distribution  of  Kir6.1,  the  Bio-Rad  Radiance  2000  laser 
scanning confocal microscope (Bio-Rad, Hemel Hampstead,  UK) was used to investigate 
the localisation of Kir6.1 whereas the Zeiss laser scanning LSM 510 confocal microscope 
(Zeiss,  UK) was used to study the changes in mitochondrial redox state and mitochondrial 
membrane potential in cultured and primary cell lines.
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Figure 2.3.  A diagram to show the main components of a confocal microscope.
Table 2.1.  The excitation and emission wavelengths of K.ir6.1-GFP and DsRed2-ER are shown 
with other fluorescent probes used throughout this study.  * TMRM was used to measure changes 
in mitochondrial membrane potential using the Zeiss laser scanning LSM 510 confocal system.
Fluorophores Excitation 
wavelength 
used (nm)
Emission
filter
used (nm)
Maximum excitation and 
emission wavelength (nm)
Kir6.1-GFP 488 510-530 Ex: 488  Em: 509
DsRed2-ER 543 LP>560 Ex: 563  Em: 582
tetramethy  1  rhodam i ne, 
ethyl  ester,  perchlorate 
(TMRE)
543 LP>560 Ex: 549  Em: 573
tetramethy 1  rhodam i ne, 
methyl  ester,  perchlorate 
(TMRM)*
543 LP>560 Ex: 549  EM: 573
MitoTracker Red 543 LP>560 Ex: 579  EM: 599
Mito-Ds Red 543 LP>560 Ex: 563  Em: 582
Concanavalin A-FITC 488 510-530 Ex: 506  Em: 529
Rhodamine conjugated goat 
a rabbit antibody
543 LP>560 Ex: 560  Em: 584
For colocalisation studies,  live cells were transfected with fluorescently  labelled probes 
such as Kir6.1-GFP and DsRed2-ER and cells that were stained using specific antibodies 
and  markers  were  imaged  using  the  Bio  Rad  radiance  2000 confocal  microscope.  In 
some  cases,  cells  were  first  transfected  before they  were  loaded  with  a  mitochondrial
75membrane  potential  specific  probe.  The  imaging  conditions  for  the  excitation  and 
emission  wavelengths  of  flurophores  such  as  Kir6.1-GFP  and  other  probes  used 
throughout this thesis are shown in table 2.1.  The excitation and emission wavelengths 
used  fluorophores  were  optimised  for our confocal  system,  the optimal  excitation  and 
emission wavelengths for the fluorophores used are highlighted in the last column.
2.5.3  Colocalisation studies (Bio Rad Radiance 2000 Confocal Microscope)
Green  fluorescent protein  (GFP) was  first  identified  in the jellyfish Aequorea victoria. 
Advances  in  molecular  biology,  in  particular  subcloning  techniques  have  enabled 
scientists to tag GFP to a protein of interest.  The localisation of these fusion proteins can 
be studied using fluorescent or confocal microscopy.  There are also spectral variants of 
GFP such as YFP (yellow) and CFP (cyan).  The aim of the project was to investigate the 
distribution of Kir6.1  in the different cell  lines.  Cells were transfected with  Kir6.1  (in 
eEGP-Nl  vector) where the C terminus of Kir6.1  was tagged to GFP called Kir6.1-GFP 
and the endoplasmic reticulum marker called DsRed2-ER (in pDsRed2-ER vector).  Cells 
were also transfected with the sulphonylurea receptor, SUR1  (in pcDNA3 vector).  The 
cells transfected with Kir6.1-GFP, DsRed2-ER and or SUR1  were left for approximately 
24-48 hours before they were analysed and used in subsequent experiments.  Transfected 
cells  were  removed  using  500  pi  trypsin  and  cells  were  collected  by  adding  500  pi 
growth medium.  The dislodged cells were evenly distributed into a 6 well plate already 
prepared with 25 mm coverslips (VWR, Merck house,  UK).  These were left to grow at 37 
°C for 24-48 hours before they were imaged on the confocal microscope.  In some cases, 
cells were transfected directly on the coverslips.
The 543 nm and 488 nm argon laser, fluorescent lamp and Bio Rad TE300 Software were 
switched on first before the cells were handled.  The confocal microscope was also fixed 
to a brightfield light source and a mercury bulb.  The image resolution was set to 1024 x 
1024 pixels and the 25 mm coverslips containing the cells were removed carefully using 
fine forceps and placed  in an imaging dish {Harvard apparatus,  USA).  The cells were 
washed briefly with Opti-MEM without phenol red (This contains a HEPES buffer, 2,400
76mg/L sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace 
elements, and growth factors, but no phenol red) (Invitrogen,  UK) before it was replaced 
with  1ml  of the same  solution.  This was placed  on  the microscope  stage and  viewed 
using  an  x60  oil  objective.  The  cells  were  positioned  carefully  using  the  brightfield 
before they were checked  for red (DsRed2-ER) fluorescence then the field of cells was 
positioned and zoomed in accordingly in the green channel.  Scanning was then set to the 
Kalman configuration taking three scans in total so that the final colocalised image taken 
would be an average.  The Kir6.1-GFP signal was excited by the 488 nm argon laser with 
a 500-530 nm emission  filter.  The laser gain was set to 50 % and  laser power ranged 
from  20-40  %  depending  on  the  intensity  of the  green  fluorescence.  This  laser  was 
switched  off before  the  DsRed2-ER  was  excited  with  543  nm  laser with  560-630  nm 
emission filter; the signal was much weaker in comparison to GFP because the 543 nm 
laser is a weaker laser than the 488 nm argon laser.  Good signals were obtained which 
did  not  saturate  before  the  final  images  (Kir6.1-GFP  and  DsRed2-ER)  were  taken 
sequentially producing a composite image that is a superimposition of the two.
MitoTracker  Red  compounds  and  Tetramethylrhodamine,  ethyl  ester,  perchlorate 
(TMRE) (.Invitrogen,  UK) are red-fluorescent dyes that stain mitochondria in  live cells 
and their accumulation is dependent upon the mitochondrial membrane potential (Aijsm ). 
Mitotracker dyes can diffuse passively across the plasma membrane and concentrate in 
respiring mitochondria.  The probe contains a mildly thiol-reactive choromethyl moiety 
that  is oxidised  in  mitochondria and  this will  react with thiols on  proteins to  form  an 
aldehyde  fixable  conjugate.  The  probe  was  supplied  in  a  vial  containing  50  pg  of 
lyophilised  solid  for  reconstitution  in  high  quality  DMSO  to  a  make  a  1   mM  stock 
solution.  TMRE was also supplied as a powder and a 1  mM stock solution was prepared 
in  HEPES-buffered  salt  solution  (physiological  solution)  composed of (in  mM):  156 
NaCl,  3  KC1, 2  MgS04,  1.25  KH2P04, 2 CaCl2,  10 glucose, and  10 HEPES,  pH 7.35. 
The mitochondrial dyes were prepared  from  stocks stored at -20°C.  The  1   mM  stock 
solution of MitoTracker Red was diluted  in OptiMEM-1 (without phenol red) to a final 
concentration of 150 nM whereas 1  mM TMRE was diluted to a final concentration of 20 
nM in OptiMEM-1.  Cells on 25 mm coverslips were first transfected with Kir6.1-GFP
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media and cells were  left for 24-36 hours before  loading with  MitoTracker Red  for 30 
minutes at 37 °C.  The Kir6.1-GFP fluorophore was excited with 488 nm  laser and the 
emitted light was collected between 510-530 nm whereas MitoTracker Red was excited 
using  the  543  nm  laser  and  emitted  light  was  detected  using  long  pass  filter  for 
fluorescence above 560 nm.  Please refer to table 2.1.
2.5.4  Analysing colocalisation and statistical analyses
The  images were  analysed  individually  using the  Laserpix  program.  This was able to 
examine the red, green and merged  images separately, cells could be sized  individually 
and  thresholds  for  the  red  and  green  pixels  were  set  accordingly.  The  proportion  of 
colocalisation  was  measured  in  each  cell  and  the  numbers  were  given  as  percentages. 
The software measured e.g. the total number of existing green pixels (Kir6.1-GFP) which 
also contained red pixels (DsRed2-ER) and vice versa, see figure 2.4.
Number of green pixels that are also red
Total green pixels a + b
Number of red pixels that are also green
Total red pixels b + c
Figure 2.4.  A  Venn diagram to show how colocalisation is analysed.  These pixels represent 
Kir6.1-GFP (a) and the  pixels  that represent  DsRed2-ER  (c) and  (b)  is the total  number of 
pixels which colocalise.
Approximately  15 good images with at least two to three cells in each field were used in 
analysing the proportion of colocalisation between Kir6.1-GFP and DsRed2-ER signals. 
The  results  (in  percentages)  were  put  into  a  table  and  analysed  using  the  statistical 
package  Prism  4.0.  The  Mann  Whitney  test  (rank  scoring)  was  used  to  compare the 
proportion  of  colocalisation  between  Kir6.1-GFP  and  DsRed2-ER  signals  against  a 
theoretical  value  of zero.  The  null  hypothesis  (Flo)  where  ‘There  is no colocalisation
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compared to a significance level and if it was smaller, the null hypothesis was rejected. 
For example,  the  null  hypothesis  was  rejected  at the  5  %  significance  level,  this  was 
reported as "p < 0.05”.  The results are presented as medians and interquartile ranges.
2.5.5  Investigating changes in mitochondrial  redox state and mitochondrial membrane 
potential (Zeiss LSM 510 Confocal Microscope)
Mitochondrial  redox  state  was  monitored  by  measuring NADH  (nicotinamide  adenine 
dinucleotide)  and  FAD2+  (flavin  adenine  dinucleotide)  autofluorescence.  These  two 
variables  were  measured  nearly  simultaneously  on  the  Zeiss  510  CLSM  confocal 
microscope switching between excitation at 364 nm measuring fluorescence at 435-485 
nm for NADH, to excitation at 458 nm  measuring fluorescence at >505 nm  for FAD2+. 
See figure 2.5.  This is a good system as it minimises photo bleaching and produces good 
image with minimal background noise by using a high numeric aperture objective.  The 
pinhole was kept relatively wide open (confocal slice 4 pm) to optimise light collection 
but enough to keep spatial resolution to resolve mitochondrial structures.
NADH + 2H+ -> N AD+ + 2H+  complex i
Oxidised
FADH2  FAD + 2H+  Complex II 
Reduced
Diagram  2.5.  A  diagram  to  show  the  oxidised  and  reduced  forms  of redox  agents  in  the 
mitochondria.  The reduced form of NAD, NADH is fluorescent whereas the oxidised form of 
FAD2 +  is the fluorescent form.
792.5.6  Preparation of cells and physiological solution
The immortalised skeletal muscle cell line C2C12s were cultured for 1-2 days before they 
used  for  taking  mitochondrial  redox  state  and  mitochondrial  membrane  potential 
measurements.  After the centrifugation step, the cells were evenly distributed evenly into 
a 6 well plate already prepared with 22 mm coverslips (VWR,  UK).  The cells were left to 
grow  at  37°C  for  24-48  hours  before  they  were  used.  The  rat  primary  ventricular 
myocytes were grown on laminin coverslips in Ml99 medium.  These cells were used a 
few hours after isolation or the day after (These were generously provided by Dr. Sean 
Davidson,  Hatter institute,  UCL).  The cells were studied using physiological  HEPES- 
buffered salt (HBSS) solution composed of (in mM):  156 NaCl, 3  KC1, 2 MgSC>4,  1.25 
KH2PO4, 2 CaCl2, 10 glucose, and 10 HEPES, pH 7.35.
2.5.7  Procedure for imaging cells
The 22 mm coverslips containing the cells were removed carefully using fine forceps and 
placed in an imaging dish (Harvard apparatus,  USA) and filled with 500 pi of recording 
media (physiological solution).  This was placed into a specific dish holder before it was 
placed and secured tightly on the microscope stage.  The image quality was set to at least 
512  x  512  pixels  and  cells  were  viewed  using  an  x40  oil  objective.  The  cells  were 
positioned  carefully  using the  brightfield  channel  before they  were  checked  for green 
(FAD2+) fluorescence and the field of cells were positioned and zoomed  in accordingly 
by using the fast XY scanning method in the green channel (only the 458 nm laser was 
on).  The image settings were set to ensure that there was no background noise and the 
signals were not saturated.  Scanning was then  switched over to  364  nm  UV  laser to 
measure NAD fluorescence in the blue channel.  Both lasers were turned on before the 
experiment was started on the time series mode.  The images were taken every 5 seconds 
with the final image being an average of two images because this would produce a high 
quality image with little background noise.  Each drug such as diazoxide was applied and
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Zeiss software.  To ensure that the cells were viable, the ‘resting levels’ of fluorescence 
in  each  population  were  calibrated  to  the  maximally oxidised  and  maximally  reduced 
states as an index of the resting redox state.  A fully reduced state is induced by sodium 
cyanide (NaCN).  After washing off NaCN a fully oxidised state by Carbonyl cyanide 4- 
(trifluoromethoxy)  phenylhydrazone  (FCCP).  Both  NaCN  and  FCCP  were  purchased 
from Sigma Aldrich,  UK.  It is the reduced NADH that is the fluorescent form, observed 
as blue autofluorescence whereas oxidised FAD is observed as green autofluorescence.
To  measure  the  changes  in  mitochondrial  membrane  potential  (Avj/m ),  there  are  many 
types of commercial mitochondrial dyes available that will label live mitochondria.  The 
commonly used compounds are Tetramethylrhodamine methyl ester perchlorate (TMRM) 
and Tetramethylrhodamine ethyl ester perchlorate (TMRE).  These dyes are use for the 
quantitative measurements of the mitochondrial membrane potential (A\j/m ) based on the 
Nemst equation. The advantage with these dyes is that they do not form aggregates in cell 
membranes  and  interact  with  membrane  proteins  minimally.  The  transmembrane 
distribution of the dyes is directly related to the membrane potential via Nemst equation. 
The C2C12 cell line was loaded with 20 nM TMRM (made up in physiological solution) 
for  30  minutes  at  37  °C  before  imaging.  In  the  case  of the  rat  primary  ventricular 
myocytes, these were loaded with 20 nM TMRM for approximately  1   hour to allow full 
equilibration of the dye before confocal analysis.  The 543 nm laser was used to excite 
TMRM and images were taken every second in order to observe the changes in Avj/m .
2.5.8  Analysing the changes in mitochondrial redox state and Ai%
The  images were saved  as  LSM  image files.  For each experiment,  regions of interest 
(ROI) were selected from each cell in the field and the measurements for the changes in 
NADH and FAD2+ or TMRM fluorescence were saved as text files.  These text files were 
imported  into  Origin  6.0  for  further analysis  where the data were  normalised  using a 
macro.  The data were averaged and presented as means + SEM (arbitrary units) so that 
any changes in signal observed would be observed as a percentage change (increase or
81decrease  when  compared  to  the  basal  level).  The  data  for  changes  in  TMRM 
fluorescence were presented as individual traces so that changes such as mitochondrial 
depolarisation  in  response  to  the  drugs  could  be  observed.  One-way  ANOVA  with 
Dunnett’s  post  test  was  carried  out  on  NADH,  FAD2+  or  TMRM  measurements  to 
compare the control value with the values taken in response to each drug application.
2.6  Procedure for SDS polyacrylamide gel electrophoresis (PAGE)
The methods listed in 2.6 were taken from protocols for SDS PAGE and Western blotting 
The  apparatus  for  pouring  the  gels  were  set  up  as  described  in  the  BioRad  manual 
(Bio  Rad Laboratories,  Hemel Hempstead,  UK).  All gels were prepared with a thickness 
of 1.5 mm.  The resolving gel was prepared and polymerisation was initiated with  100 pi 
10% Ammonium persulfate (APS) and 20 pi N, N, N \ N’-Tetramethylethlyenediamine 
(TEMED) (Sigma Aldrich,  UK).  APS was made up in  1ml distilled water and stored at 4 
°C.  The gel mixture was mixed gently by inverting the tube before it was poured between 
two glass plates.  A small volume of distilled water or room temperature isopropanol was 
added to the top of the gel to prevent it from being exposed to the air.  This was left for 
an  hour  to  polymerise  and  the  water/isopropanol  was  removed  carefully  using  filter 
paper.  The stacking gel was prepared and mixed carefully before it was poured on top of 
the resolving gel.  A  10  well  plastic comb was  inserted  in  between the plates to form 
wells where samples would be loaded.  The stacking gel was left for 30 minutes for it to 
set.  The components for the resolving and stacking gel are listed in table 2.2.
Table 2.2.  A table to show the materials required to make the resolving and stacking gels.
Materials Required 10 % Resolving Gel' 4 % Stacking Gel
30 % solution of 29:1 
acrylamide: Bisacrylamide
6.6 ml 1.3 ml
0.5 M TrisHCl, pH 6.8 - 2.5 ml
1.5 M TrisHCl, pH 8.8 5 ml -
10 % SDS (w/v) 0.1 ml 0.1 ml
10 % APS 100 u .1 50 nl
TEMED 20 H i 13 jxl
dH2 0 8 ml 6.1 ml
Final volnme 20 ml 10 ml
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The cells required were grown  in T25  flasks until they were 80-90 % confluent before 
they were washed twice with PBS.  One ml of PBS was used, along with a cell scraper 
(VWR,  Merck house,  UK) to dislodge the cells from the flask and they were collected in 
eppendorf tubes.  The  samples  were  centrifuged  at  14,000  rpm  for  5  minutes.  The 
supernatant was removed and the cell pellet was resuspended in 300 pi of PBS and 300 
pi of 6x gel loading buffer containing 200 mM dithiothreitol (DTT) (Sigma Aldrich,  UK). 
The samples were heated at 95 °C for 5 minutes and sonicated for about 5 seconds using 
a  Soniprep  150  probe  sonicator  (MSE).  The  denatured  samples  were  kept  on  ice  or 
stored at -20 °C until required.  The gel plates were fixed onto the SDS PAGE apparatus 
as per instructions and placed into a tank filled with fresh running buffer (this was made 
from 25 mM Tris, 250 mM glycine, 0.1 % SDS, pH 8.3).
Prior to loading, the combs were removed and each well was washed with running buffer 
using a 5  ml syringe and needle.  Five pi of pre-stained broad range molecular weight 
marker (BioRad Laboratories, Hemel Hempstead,  UK) was loaded in the first lane of the 
gel, followed by 25  pi of each samples.  The maximum volume for each well  is 40 pi. 
The  gel  tank  lid  was  assembled  and  voltage  was  supplied  using  a  power  pack  at  a 
constant voltage of 40 V for 20 minutes through the stacking gel.  It was increased to 120 
V for 1.5 hours until the dye from the marker had reached the bottom of the glass plate.
2.6.2  Transferring proteins onto nitrocellulose and immunoblotting
In  order  to  transfer  protein  onto  nitrocellulose  for  western  blotting,  a  cassette  was 
prepared and the gel was cut and placed in transfer buffer.  The cassette had a layer of 
sponge, 2x  filter paper, SDS gel,  followed by nitrocellulose (Hybond ECL, Amersham- 
Pharmcia Biotech,  UK) cut to size and then another layer of 2x filter followed by another 
sponge.  This  was  assembled  tightly,  removing  any  air  bubbles  and  secured  into  the 
cassette.  The  cassette  was  placed  into  its  holder  and  placed  into  a  tank  containing 
transfer buffer (48 mM tris, 39 mM glycine, 0.03 % (w/v) SDS, 20 % (w/v) methanol, pH
838.3).  The tank was connected to the power supply and the transfer was carried out at 250 
mA for 2 hours at 4°C to prevent the apparatus from overheating because it could cause 
air bubbles to form and disrupt the transfer of proteins from gel to nitrocellulose.  After 
the  transfer,  the  nitrocellulose  membranes  were  removed  from  the  cassettes  (the 
appearance of the prestained marker indicated a successful transfer).  These were cut to 
size and placed into appropriate chambers with labels.
Membranes were first incubated in blocking solution containing 5 % (w/v) Non-fat milk 
{Marvel, Premier brands,  UK) in PBS + 0.1  % Tween-20 {Sigma Aldrich,  UK) (PBST) 
on  a shaker for  1   hour at room  temperature.  The primary antibody was added to the 
membranes at typical  dilution  of 1:500 and  1:2000  in  blocking solution  and  left on a 
shaker at 4 °C overnight.  After incubation with the primary antibody, the membranes 
were washed three times  in PBST for  15  minutes followed by two quick washes.  The 
secondary antibody used was Horseradish peroxidase linked anti-rabbit IgG (supplied in 
ECL kit) used at a dilution of 1:5000 and this was applied to membranes for  1   hour at 
room  temperature  (on  shaker).  After  incubation  with  horse  radish  peroxidase  (HRP) 
antibody, the membranes were washed five times in PBST for 15 minutes then followed 
by  four  quick  washes  before  they  were  visualised  using  ECL  reagents  and  film 
(Hyperfilm  ECL) {Amersham-Pharmcia Biotech,  UK).  Both  short and  long exposures 
were obtained.
2.7  Production of polyclonal antibodies
Polyclonal  antibodies  were  synthesised  to  aid  the  study  of  K Atp   sensitive  potassium 
channels.  The polyclonal antibodies to Kir6.1  were raised using two methods; one using 
a rat  peptide  sequence to  generate  antibodies against  Kir6.1C  (78A), this was already 
purified and characterised by our group. The second method chosen employed a maltose 
binding protein (MBP) fusion protein to generate Kir6.1  antibodies.  My contribution to 
this  part of the  study  was  to  purify  and  characterise  a  MBP  Kir6.1C  fusion  antibody 
called  MBP-Kir6.1C  (93A).  For this antibody, the first step was to express the MBP- 
Kir6.1C protein in E.coli competent cells followed by the purification of the expressed
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MBP-Kir6.1C  antibodies.  The  rabbit  would  produce  antibodies  to  both  MBP  and 
Kir6.1C therefore when the animal was culled the serum collected at the end of the study 
was affinity purified to obtain Kir6.1C antibodies.
2.7.1  The expression and purification of MBP Kir6.1C fusion protein
The plasmid  DNA,  pMALc2x +  Kir61C  terminus (a/a  179-424) was transformed  into 
E.Coli  BL21  (DE3)  competent  cells  and  plated  on  LB  agar  plates  containing 
carbenicillin.  A single colony was picked and placed into 10 ml of rich broth media (RB) 
and carbenicillin (RB composed of 10 g tryptone, 5  g yeast extract,  5  g NaCl and 2 g 
glucose  (all from  Sigma  Aldrich,  UK)  dissolved  in  1   litre  of  distilled  water  and 
autoclaved).  This  starter  culture  was  placed  in  a  shaking  incubator  for  12-16  hours 
before 5 ml was used to inoculate 2x 500 ml flasks containing RB media with  100 pg/ml 
carbenicillin.  The cells were grown for a further 2-3 hours until the OD at 600 nm had 
reached  0.6  to  0.8  absorbance  units.  A  1ml  sample  was  taken  for  analysis  and  the 
resulting cell pellet was resuspended in SDS loading buffer and stored at -20 °C.  Once 
the cells had reached  0.6 to 0.8 nm, the fusion  protein was induced with 0.3  mM  iso- 
propylthiogalactosidase 1PTG (Promega,  UK) and the cells were grown for a further 12- 
16 hours, shaking at 25 °C.  Before centrifugation,  1   ml supernatant was centrifuged and 
processed as before.  The contents of the  flasks were centrifuged at 6,000 rpm  for 30 
minutes at 4 °C.  After centrifugation, the supernatant was discarded and the pellet was 
resuspended in 25 ml of PBS + 5 mM EDTA +  1   mM DTT and subsequently stored at - 
20 °C.  The pellet was thawed in a waterbath for  10 minutes then sonicated for 5 x 60 
seconds.  The pellet was centrifuged at  12,000 rpm at 4 °C  for 30 minutes before the 
supernatant was removed and  kept on  ice.  The pellet was resuspended  in  8  ml  MBP 
column buffer (PBS + 5 mM EDTA +  1   mM DTT) and was centrifuged and sonicated 
again to ensure all of the protein was collected.  The supernatant from both samples were 
pooled and stored on ice and a sample was taken for analysis.
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was supplied as a slurry in ethanol (New England Labs,  UK), it was mixed gently before 
10ml  was applied to a  Poly-Prep chromatography column  (BioRad Laboratories,  UK). 
The slurry was left to settle in the column before it was equilibrated using 8-10 column 
volumes (CV) of MBP column buffer.  The supernatant containing MBP-Kir6.1C protein 
was diluted in the buffer 1:4 before loading onto the column.  It was washed with 12 CVs 
of MBP column buffer.  The packed amylose-protein mixture was resuspended with PBS 
+  5  mM  EDTA  in a  1:1  ratio and a sample was taken  for analysis.  The column was 
stored at 4°C  until  it was required.  The coupling efficiency was checked by taking a 
small  sample (20 pi) before and after the protein was coupled to the amylose resin by 
using the Bradford assay and SDS PAGE.  The samples collected were subjected to SDS 
PAGE analysis to determine whether the fusion  protein had been produced efficiently. 
Finally,  the  MBP-Kir6.1C  protein  was  eluted  by  washing  the  column  with  10  mM 
maltose in PBS buffer.  A sample of this MBP-Kir6.1C protein was sent to Eurogentec, 
Belgium where it was used to invoke an immune response of a susceptible animal.  The 
pre-immune  serum  was  taken  before  the  MBP  Kir6.1C  protein  was  injected  into  the 
rabbit.  The serum was collected at the peak of antibody production at  17 weeks where 
the rabbit was culled and the terminal bleed stored at -80 °C.
2.7.2  Coupling MBP to amvlose resin: Depleting MBP antibodies
The MBP-Kir6.1C fusion protein would evoke the rabbit to produce antibodies to MBP 
and  Kir6.1C  therefore  the  contaminating  antibodies to  MBP  were  first  removed  by 
affinity chromatography.  The terminal bleed (serum) was thawed out on ice before it was 
applied to the column.  The terminal bleed (~150 ml) was centrifuged at 2,000 G at 4 °C 
for  15 minutes.  This step was essential because it removed red blood cells and general 
cell debris.  A MBP affinity resin was prepared by coupling purified MBP (5 mg/ml) to 
the amylose resin, as described by the manufacturer {Bio-Rad Laboratories,  UK).  The 
serum  was  then  applied  to  the  equilibrated  amylose  column  and  the  flowthrough 
containing the Kir6.1C antibodies were collected and stored on ice.  The MBP antibodies 
will bind to the MBP-amylose resin, and therefore is not present in the flowthrough.
862.7.3  Affinity purification of Kir6.1  antiserum on affi-gel/protein  column
Affi-Gel  10 is an N-hydroxysuccinimide ester of agarose gel beads supplied in  1:1  slurry 
in  isopropanol.  The  total  concentration  of MBP-Kir6.1C  fusion  protein  used  in  the 
coupling reaction was 1.5mg/ml which was prepared in a solution of lOOmM HEPES pH
7.4  (Sigma Aldrich,  UK).  One ml of Affi-Gel  10 was transferred into a Buchner funnel, 
washed twice with cold distilled water before the protein was placed into the funnel.  The 
affi-gel/protein mixture was transferred to eppendorf tubes and placed on a rotating wheel 
for 1   hour at room temperature before it was left rotating overnight at 4 °C.  The mixture 
was then centrifuged at  16,000 g for  1   minute at 4 °C.  The gel was resuspended in an 
equal  volume of Tris  Buffered  Saline,  TBS  (50  mM  Tris base,  150  mM NaCl,  5  mM 
KCL, pH  7.4)  which  contained 0.01  % (w/v  %)  sodium  azide {All supplied by Sigma 
Aldrich,  UK).  This  affi-gel/protein  mixture  was  transferred  to  a  new  column  and 
prepared with a series of washes: Five CVs of NaCHCC>3, two CVs of Na2CC> 3, two CV 
of distilled water, two CV of 0.3 M Glycine HCL at pH2 and three CVs of TBS.
The flowthrough was placed into the column and collected before it was applied straight 
into  the  affi-gel/protein  resin  for  a  second  time  to  ensure  the  maximum  yield  of the 
antibody was collected.  This was followed by a series of washes in the following order: 
5 CV of TBS, 10 CV of TBS + 0.2 % Triton-X-100 followed by another five CV of TBS. 
The antibody acid  fractions were eluted  using 5  ml acidic buffer (0.2  M NaCl,  0.2 M 
Glycine HCI, pH 2.5) and collected in 1   ml fractions in tubes already containing 100 pi 2 
M Tris HCL, pH 8.5.  The absorbance of these fractions were measured at 280 nm using 
a  spectrophotometer  and  fractions  with  an  absorbance  between  0.04  to  0.1  nm  were 
pooled  together.  In  most cases, three to  four acid  fractions were pooled together and 
stored  on  ice.  The  column  was  washed  with  ten  CV  of TBS  before  the  antibody 
containing fractions were eluted by collection of 1  ml aliquots with 5 ml Guanidine HCL, 
0.1  M TrisCl pH 8.  The antibody was located in the acid fraction but guanidine fractions 
were  kept  in  case acid  fractions  were  low, the  guanidine  fractions could  be  used  less 
sparingly.  The column was washed with TBS and stored in TBS + 0.01  % NaN3.  The 
pooled acid and guanidine fractions were dialysed with 500 ml TBS + 0.01  % sodium
87azide in a beaker with a stirring bar overnight at 4 °C.  The samples were then placed into 
centrifuge tubes and spun at  100,00 g at 4 °C to remove excess aggregated substances. 
The purified antibody was aliquoted and stored at -80 °C until required.  See figure 2.6.
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Figure 2.6.  A schematic diagram  to show the various steps during the production of our MBP- 
Kir6.1C antibody.
2.8  Immunofluorescent staining
2.8.1  Procedure for immunofluorescent staining
Cells were co stained with  K Atp channel subunits Kir6.1  specific antibodies and reagents 
that specifically stain the endoplasmic reticulum.  The endoplasmic reticulum was stained 
using a  fluorescein conjugate of Concanavalin  A  (Molecular Probes,  USA).  The cells 
were  grown  in  6 well  dishes with  five  13  mm coverslips (VWR,  Merck house,  UK)  in 
each  well.  The cells were at  least 60-70 % confluent before staining.  The cells were 
washed twice with phosphate buffered saline, PBS, before they were fixed for 20 minutes 
at 4 °C with 4 % (vol/vol) paraformaldehyde (PFA).  The cells were washed twice for 10 
minutes with PBS before they were incubated for 20 minutes with PBS + 0.2 % Triton X- 
100  (Sigma Aldrich,  UK)  to  permeabilise  the  cells.  After this  step,  the  solution  was 
aspirated and cells were washed twice with PBS before they were incubated at 4 °C for 1
88hour with blocking solution containing 2 % BSA, 5 % goat serum, and 0.1  % triton X- 
100 in PBS.  During the blocking step, the appropriate primary antibodies were prepared 
in blocking solution and stored'on ice.  The affinity purified primary antibody, for Kir6.1 
was diluted 1/500 or 1/300 in blocking solution as determined by western blotting.
After  the  blocking  step,  coverslips  were  transferred  to  labelled  humidified  chambers 
before  100  pi  of the primary  antibody was added to each coverslip.  This was  left to 
incubate for 1   hour at room temperature.  The unbound primary antibody was washed off 
with  four  PBS  washes.  The  same  volume  of rhodamine  conjugated  goat  anti-rabbit 
antibody  (1/300  dilution)  {Molecular  Probes,  USA)  was  added  to  the  coverslips  and 
incubated  in the dark for  1   hour.  The coverslips were given another four PBS washes 
before  100  pi  of  100  pg/ml  solution  of Concanavalin  A  (fluorescein  conjugate)  was 
added.  After staining with Concanavalin A, the coverslips were washed with four PBS 
washes  followed  by  a brief wash  with distilled water before they were air dried  for 2 
hours or overnight and kept in the dark.  When the coverslips were completely dried, they 
were individually mounted onto slides (BDH',  UK) using a small drop of Vectashield, a 
non-fluorescent anti-fade specialised mounting medium {Vector Laboratories,  USA) and 
fixed into position with clear nail varnish.  The slides were stored at 4 °C before analysis.
The slides were analysed using a BioRad Confocal imaging system.  Controls were also 
used to ensure that the fluorescent signals visualised were from the purified antibody for 
Kir6.1  and  the  antibody  was  not  bound  to  any  endogenous  protein  in  the  cell.  The 
controls used were the pre immune serum samples before rabbits were immunised with 
the antigen and a fusion protein bound onto the antibody of interest. The fusion protein 
was used at 1  mg/ml for immunoflourescence and depending on the protein concentration, 
the correct volume of the fusion protein (1  mg/ml) was taken and spun at 14,000 rpm at 4 
°C  for 5  minutes.  The supernatant was removed and  1   ml blocking solution +  10 mM 
Maltose was added to the pellet, this was spun again for 15 minutes.  The supernatant was 
discarded and the antibody at the correct dilution (1:500) was added to the sample and 
put onto a rotating wheel for 1  hour before it was used.  In some experiments, we stained
89for  mitochondria  using  cytochrome  C  oxidase  antibody therefore  I  used  two  different 
fluorescently tagged (Rhodamine or FITC) secondary antibodies to identify the proteins.
2.8.2  Analysing fluorescently labelled cells
The cells were visualised using 60x water objective and the image quality was set to 1024 
x  1024 pixels.  The Kalman scan was set to three so that the final image taken would be 
an average.  The Kir6.1  antibody (using a rhodamine conjugated secondary) was excited 
by  the  543  nm  laser,  the  laser  powers  used  were  similar  to  DsRed2-ER  analysis. 
Concanavalin  A  staining  was  excited  by  the  argon  488  nm  laser,  the  staining  of the 
endoplasmic reticulum  was high so very  low laser power was required to see where it 
localised.  The  degree  of  colocalisation  between  the  antibody  for  Kir6.1  and 
Concanavalin A was measured using Laserpix as described in section 2.4.
2.9  FL1PR experiments- Investigating the changes in ROS production
The  FLIPR  Flurometric  imaging  plate  reader  system  {Bucher Biotech,  Switzerland)  is 
able to perform high throughput screening in kinetic cellular (adherent and non-adherent 
cells) assays in 96 well plate format.  The argon-ion laser excites a fluorescent indicator 
dye  and  the  CCD  camera  images  the  plate.  The  laser  illumination  and  cooled  CCD 
optical detection  is fast and sensitive with data points taken at each second  if required. 
Sensitivity  is further enhanced  by the proprietary cell-layer isolation optics that allows 
signal discrimination on a cell monolayer; this eliminates the extracellullar background 
fluorescence in the assay.  Cells were grown in T75 flasks and passaged 24 hours before 
the experiment.  The cells were counted using a haemocytometer so that approximately 
106 to  107 cells were plated into each of the appropriate wells using a black wall, clear 
bottom  96  well  plates  {Marathon  lab  supplies,  London).  Cells  were  placed  in  the 
incubator overnight at 37 °C to allow them to adhere to the plate surface.  The dyes used 
for measuring changes in ROS are susceptible to photo-oxidation therefore these black, 
wall,  clear bottom  plates were  used to minimise their exposure to  light.  By reducing 
scattered light of all wavelengths, this limits any background artefacts.
902.9.1  Preparation of cells, fluorescent indicator dve and drug plates
There  are  reactive  oxygen  species  (ROS)  detection  reagents  such  as  2'T 
dichlorofluorescein (DCF) which is a cell-permanent indicator.  The chemically reduced 
and acetylated forms of DCF are non fluorescent until the acetate groups are removed by 
esterases and oxidation in the cell.  The oxidation of DCF can be detected by measuring 
the increase in fluorescence using a microplate reader, fluorescent microscope, flurometer 
or other excitation sources with the appropriate filter for fluorescein (FITC).
DCF-DA  {Invitrogen,  UK)  is a light sensitive compound.  It was stored at -20 °C  and 
only dissolved immediately prior to use.  A 30 pM stock DCF-DA {Invitrogen,  UK) was 
prepared by weighing out 15 mg in an eppendorf tube which was dissolved immediately 
in  1   ml of 100 % ethanol.  The final concentration used for the assay was 15 pg/ml which 
was prepared in PBS.  The dye was loaded into each well and placed in the incubator at 
37 °C for 1   hour.  The cells were then washed twice with PBS and loaded with fresh PBS 
before the cells were imaged.  The drug plates were prepared and loaded in clear 96 well 
plates {VWR,  UK) after the cells were  loaded with dye.  Diazoxide and  glibenclamide 
were prepared as lOx stocks so that when the FLIPR machine transferred the drugs to the 
cell plate, the final concentrations were correct.  The agonist plate contained diazoxide 
(plate  1)  and  the  antagonist  plate  contained  glibenclamide  (plate  2).  The  final 
concentration  of DMSO  in  each  well  was 0.02  % (2.6  mM).  Equivalent experiments 
using DMSO in PBS omitting the pharmacological agents were used as controls.
2.9.2  ROS production assay
The plates were loaded onto the FLIPR system in the order as shown in figure 2.7.  The 
fluorescence was measured first to ensure that the signal was not saturated.  The laser 
power was lowered and adjusted accordingly so that there was room for an increase in 
fluorescence.  The FLIPR system includes an integrated state of the art 96 well pipettor. 
This was used to aspirate, dispense, and mix precise volumes of fluid from microplates 
containing the test compounds  and  the  microplate containing  cells.  The  fluorescence
91(arbitrary units) was measured and recorded every second with interventions applied at 1, 
2 and  3  minutes.  The cells were  illuminated  for a minute before 20  pi  of the agonist 
(diazoxide or PBS+ DMSO) was administered into the cell plate.  At 3 minutes, 20 pi of 
the antagonist (glibenclamide or PBS + DMSO) was applied into the same wells already 
containing the agonist or control buffer.  The conditions investigated were:
1.  Control (using control buffer consisting of DMSO and PBS 1:5)
2.  50 pM diazoxide and  10 pM glibenclamide
3.  100 pM diazoxide and 10 pM glibenclamide
DRUG PLATE 2
■ 4 —   PB S +  DM SO
—   lOO^M G libenclam ide  (10x)
+—   1 OOjiM  G libenclam ide  (10x)
CELL PLATE
DRUG PLATE  1
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Figure 2.7.  A figure to illustrate how the experiment was set up in the FLIPR system.
Drug  plate  l  contained  the  agonist,  diazoxide  and  drug  plate  2  contained  the  antagonist 
glibenclamide.
922.9.3  Using SiRNA to suppress the expression of Kir6.1
To investigate whether the K a tp channel subunit Kir6.1  was responsible for the potential 
changes in ROS production, siRNA for Kir6.1   was transfected into the cell lines and the 
experiment was repeated with the protocol.  The siRNA for Kir6.1  was transfected with 
some eGFP and the mixture was loaded equally  into the wells (approximately  100 pi), 
see section 2.3.  A parallel  plate was prepared with just siRNA as this plate would be 
used for the actual assay as eGFP would interfere with the fluorescence measurements. 
After transfection, the cells were placed in the incubator at 37 °C for at least 12-24 hours 
before they were used for subsequent FLIPR experiments.
2.9.4  Analysing ROS production
The data were exported as text files from the FLIPR software into Excel.  The aim of this 
experiment  was  to  examine  whether  50  pM  or  100  pM  diazoxide  and  10  pM 
glibenclamide  would  influence  the  rate of ROS  production  in  immortalised  cell  lines. 
The background fluorescence was first subtracted before the data were normalised.  The 
rate of ROS production was then calculated at the three specific time points (<1  minute, 
1-3 minutes and >3 minutes).  The rate of ROS production for each well was calculated 
from 0-<lmin (basal + control buffer),  1.5-2.5 minutes (Diazoxide or control buffer) and 
3-4.5 minutes (Glibenclamide or control buffer plus diazoxide or control buffer).  Thirty- 
second data points were omitted from the analysis after the addition of each drug because 
the fluorescence changed abruptly due to mixing of the solutions.  This was not included 
as it would not be a true representation of the data.  The data were analysed with Prism
4.0  and presented as a percentage (%) increase or decrease when compared to the control 
(mean absolute rate).  The t-test was used to test for statistical significances between the 
control  and  treated  groups  and  for  differences,  if any,  between  transfected  and  non 
transfected cells, see 2.9.4.  The data was significant when p<0.05 (*).  The data from 
each cell line and condition were obtained from at least three different preparations.
932.10  Measuring changes in intracellular calcium (Ca2+ )
2.10.1  The basic principles of Fura-2 AM
Fluorescent Ca2+ indicators such as Fura-2 AM are useful tools and provide insight into 
cell physiology since their manufacture by Roger Tsien in 1980 (Grynkiewicz et al.  1985, 
Tsien 1980).  Fura-2 AM is an acetoxymethyl ester that forms a high affinity, intracellular 
Ca2+  indicator  that  is  ratiometric  and  UV  light  excitable.  AM  esters  are  lipophilic 
molecules that freely pass through the lipid bilayer.  Inside the cell, the ester is cleaved by 
esterases to form the hydrophilic acid and the indicator becomes localised inside the cell. 
Two  wavelengths  were  used  to  excite  Fura-2,  340  and  380  nm  and  the  fluorescent 
emission  were monitored >515  nm.  On binding Ca2+, the emission spectrum shifts so 
that when  Fura-2  binds  Ca2+ as  it will  increase when excited  at 340 nm  and  decrease 
when  excited  at  380  nm.  The  ratio  of emission  at  340  and  380  nm  was  used  as  an 
indicator of intracellular Ca2+ concentration,  [Ca2+]j.  Using this ratiometric method for 
measuring  [Ca2*]i  has distinct advantages:  for example,  the absolute  magnitude of the 
signal  is not  affected  by  changes  such  as dye  leakage,  which  contributes to  increased 
efficiency at measuring changes in [Ca2+]j.  See figure 2.8.
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Figure 2.8.  Diagram to show the  fluorescence excitation (detected at 510 nm) and emission 
(excited at 340 nm) spectra of Ca2+ -saturated (A) and Ca2+ -free (B) Fura-2 in pH 7.2 buffer.  (The 
Information was obtained from the Invitrogen website)
942.10.2  Protocol for Ca2+ assay and analysing data
Cells were passaged and plated into 6 well plates containing 25 mm coverslips 24 to 48
+y  i
hours before the experiment.  For [Ca  ]c measurements, cells were loaded for 30 minutes 
at  room  temperature  with  5  pM  fura-2  AM  (Molecular  Probes,  UK)  and  0.005  % 
Pluronic {Sigma Aldrich,  UK) in a HEPES-buffered salt (HBSS) solution composed of (in 
mM):  156 NaCl, 3  KC1, 2 MgS04,  1.25 KH2P04, 2 CaCl2,  10 glucose, and  10 HEPES, 
pH 7 .35.  This medium was removed and replaced with the same solution without CaCl2  
and 0.5 mM EGTA.  The cells were left for 15 minutes to de-esterify.
Fluorescence  measurements  were  obtained  using  a  Nikon  epifluorescence  inverted 
microscope  with a 20x  fluorite objective {Tokyo,  Japan).  The  excitation  light  from  a 
Xenon arc lamp was selected using  10 nm bandpass filters centred at 340, 360, and 380 
nm housed in a computer-controlled filter wheel {Cairn Research, Faversham,  UK).  The 
emitted light passed through a long-pass filter to a cooled charged-coupled device (CCD) 
camera {Orca ER;  Hamamatsu,  Welwyn  Garden  City,  UK).  The cells were protected 
from phototoxicity by interposing a shutter in the light path to limit exposure between the 
acquisitions of successive images.  All  imaging data were collected at intervals of 5-10 
seconds  before  they  were  digitised  and  analysed  using  Origin  7.0.  The  traces  were 
obtained using the cooled CCD imaging system and are presented as ratios of excitation at 
340 and 380 nm, both with emission at > 515 nm.  All presented data were obtained from 
at least five coverslips using two to three different cell preparations.
952.11  General statistical analysis
All data in this thesis are presented as mean + S.E.M (Standard mean of error).  The N 
value  indicates  the  number  of cells  where  the  measurements  were  taken  from  or the 
number of times an experiment was carried out.  The mean value (p) is the sum of all the 
values (x) divided by N, the size of the sample.
Y   _  Z  x
A   —  n  n
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The sample standard deviation S, is a measure of dispersion, that is to say, a measure of 
how  widely  the  values  in  a  distribution  are  spread.  The  standard  deviation  of  a 
probability distribution is defined as the square root of the variance S2.  The formula for 
standard deviation is given below:  _____________
I  I  (x -x / 
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The  standard  error of a sample of sample  size  N  is the  sample's  standard  deviation  is 
divided  by J  n -  1  .  It therefore estimates the standard deviation of the sample mean
based on the population mean.  The standard error of the mean is given by:
SEM=  ——   -
J  n - 1
The data obtained  throughout this thesis was analysed  using the statistical  methods  in 
GraphPad Prism (version 4.0 for Windows) (Graphpad Software, San Diego California, 
USA).  For example, the colocalisation experiments examined the distribution of Kir6.1 
in the ER.  The proportion of colocalisation was measured in each cell and the numbers 
were  given  as  percentages.  The  software  measured  e.g.  the total  number of existing 
green pixels (Kir6.1-GFP) which also contained  red pixels (DsRed2-ER) (Vice versa). 
The results were compared against a theoretical  value of zero and the  null  hypothesis 
where  ‘There  is  no  colocalisation  between  Kir6.1  and  ER  pixels’  was  rejected  when 
p<0.05.  From my observations, every cell had some colocalisation therefore I carried out
96a rank scoring test (Mann-Whitney) to show the degree of colocalisation was significant. 
The data were presented as medians with the 25 % and 75 % interquartile ranges.
The Student’s t-Test was carried out to assess for statistical differences between two sets 
of data and to determine if two sample means were equal.  For example, to test if a new 
treatment  is  significantly  different to the  previous (control) treatment.  In chapter 3.4, 
ROS  production  was  measured  in  the  presence  of diazoxide  and  glibenclamide.  The 
means of the control  and the treatment groups were compared and the null  hypothesis 
(H0) was rejected if the means were significantly different.  The formula for the t-Test is 
given by:  _  _
The probability value (p-value) of a statistical hypothesis test is the probability of getting 
a value of the test statistic as extreme as or more extreme from the parameter specified in 
the null hypothesis Ho.  The p-value was compared to a significance level and if it was 
smaller, the null hypothesis was rejected.  For example, if the null hypothesis were to be 
rejected at the 5% significance level, this would be reported as "p < 0.05".  The use of 
this test requires non random sampling and assumes that the two populations have the 
same variances.  Therefore the unpaired t test should not be used if there is a significant 
difference between the variances of the two samples.
The  one-way  ANOVA  (ANalysis  Of  VAriance)  with  a  Bonferonni  post-test  was 
employed to test for significant differences in data with three or more groups.  ANOVA 
allows us to compare several  groups of observations, all of which are independent but 
possibly with a different mean for each group.  The ANOVA method relies heavily on the 
assumption that the populations have equal variances,  independent errors and a normal 
distribution.  The Dunnett's test is a specialised multiple comparison test that compares a 
single control group to all other groups several dependent or independent statistical tests 
are being performed simultaneously.  Significant differences between data are indicated 
as follows: NS p > 0.05, significant * p < 0.05, ** p < 0.01 and *** p < 0.001.
973.0  RESULTS
3.1  Characterising  K atp  subunit DNA constructs. Kir6.1  antibodies and small 
interfering RNA (siRNA) for Kir6.1 for colocaiisation and functional studies
In this chapter I will discuss how molecular tools such as  K atp  channel subunit cDNA 
constructs, antibodies and siRNA for Kir6.1 were characterised.  It is important that these 
tools were characterised first because they were essential for investigating the distribution 
and function of Kir6.1 in subsequent colocalisation and functional studies.
3.1.1  Characterising Katp channel subunit cDNA constructs
The  first  aim  of this  project  was  to  investigate  the  distribution  of the  ATP  sensitive 
potassium channel subunit Kir6.1  in cardiac and skeletal muscle cell lines.  K Atp channel 
subunits were subcloned into the pcDNA family of vectors (see methods and materials). 
Although the K Atp channel cDNA constructs were previously generated in the laboratory 
(Cui et al. 2001).  The K Atp channel cDNA constructs were used in colocalisation studies 
whilst other cDNAs such as dominant negatives were used in  functional  studies which 
will be discussed in detail in the relevant chapters.
3.1.1.1  Katp channel cDNA constructs
The majority of the cDNA constructs were provided to our laboratory as gifts, whereas 
the DsRed-2 ER vector was purchased commercially from Clontech,  UK.  Rat Kir6.1  and 
mouse Kir6.2 cDNAs were kind gifts from Professor S. Seino (Chiba University, Japan). 
Hamster SUR1  cDNA was kindly donated by Dr. J. Bryan (Bayor College of Medicine, 
Houston,  USA) and mouse SUR2B cDNA was kindly provided by Professor Y. Kurachi 
{Osaka  University, Japan).  The  species the original  cDNA  K Atp  subunit clones were 
derived  from,  along  with  the Genbank  accession  number are  listed  in  table  3.1.  The 
majority of the colocalisation work in this chapter investigated the distribution of Kir6.1 
using a cDNA construct called Kir6.1  -GFP where the C terminus of Kir6.1   was fused to
98GFP (eGFP-Nl  vector, see 2.1.8).  The subcloning of Kir6.1  to the eGFP-Nl  vector was 
carried out in two parts,  firstly,  inserting part of Kir6.1  sequence into eGFP-Nl  vector 
before  amplifying the  rest of the  Kir6.1  sequence  by  PCR.  These different strategies 
were employed to reduce the possibility of introducing mutations into Kir6.1-GFP.  This 
is because mismatched pairs can occur during the amplification process which may result 
in the miscorporation of nucleotides during PCR.
Table 3.1.  A table to show vector and species details of cDNA constructs used throughout this 
thesis.
cDNA construct (species) Vector Gen bank accession number
Kir6.1  (Rat) pcDNA3.1/Zeo NM_017099
Kir6.2 (mouse) pcDNA3.1/Zeo NM_010602
SUR1 (Hamster) pcDNA3 L40623
SUR2B (Mouse) pcDNA3 D86038
The  tetrameric  nature  of  K At p  channels  is  significant  as  one  gene  product  can  co- 
assemble with others to form heteromultimeric channels.  It is this distinct characteristic 
of  K a t p  channels  which  allows  us  to  explore  protein  function  by  using  dominant 
negatives (DN) for Kir6.1 (Tinker et al.  1996).  A DN contains a genetic mutation where 
the  gene encodes  mutant  polypeptides that when  overexpressed  will  interfere  with the 
activity of the wild-type gene (Herskowirz  1987).  The DNs for Kir6.1  were generated 
using site directed mutagenesis and were previously used in earlier studies to examine the 
heteromultimerisation  of the  Kir6.0  family  (Cui  et  al.  2001).  The  mutations  were 
introduced  to  the  highly  conserved  pore  regions  of  Kir6.1.  The  DN  were  named 
Kir6.1DN G->S (GFG to SFG) and Kir6.1  DN G->A (GFG to AFA).  The K a t p channel 
cDNA constructs used throughout this study were used to either create stable cell lines or 
in transfection experiments.  At the start of my PhD, the original cDNAs were already 
available in the laboratory but these were re-transformed and plasmid DNA was purified 
by standard midi or maxi preparation.  Table 3.2 lists the vectors the cDNAs were cloned 
into  and  the  specific  restriction  enzymes  used  for diagnostic  digest to  excise  specific 
DNA fragments expected from their restriction maps.
99Table 3.2.  A table to show the cDNAs used throughout this thesis.
The  cDNAs  samples  were  digested  with  their  specific  enzymes  for  approximately  one  hour  at 
37°C.  Some  samples  were double  digests  e.g.  Kir6.1  with BamHI/Not /,  this  sample  was  first 
digested with A  pa I and incubated at 25°C for one hour before the second enzyme was added.
cDNA construct Vector Restriction digest DNA fragment/s
Kir6.1 pcDNA3.1/Zeo Bam Hi/Not 1 5 kb & 2 kb
Kir6.2 pcDNA3.1/Zeo Bam Hl/Xba I 5 kb & 1.6 kb
Kir6.1-GFP eGFP-Nl NotI 6.2 kb
Kir6.2-GFP eGFP-Nl Not I 5.6 kb
Kir6.1  D N G ->A pcDNA3 Bam HI/Apa I 5.4 kb & 2 kb
Kirf.l  D N G ->S pcDNA3 Bam HI/Apa I 5.4 kb & 2 kb
SUR1 pcDNA3 Not I 5.4 kb & 4.5 kb
SUR2B pcDNA3 Not I 5.4 kb & 5 kb
DsRed2-ER DsRed-2 ER Xhol 4.7 kb
Figure  3.1  shows  the  restriction  digests  of  the  cDNAs  (Maxi  preparations)  used 
throughout  this  thesis.  The  DNA  molecular weight  marker  VII  {Roche  Diagnostics, 
Germany) was used to determine the fragment size of the samples in all the restriction 
digests (lane  1).  The BamHI enzyme was used to digest both Kir6.1  and Kir6.2 cDNAs 
as this would completely  linearise the plasmids,  if this was a single digest, this would 
produce a characteristic 7.0 kb fragment.  For Kir6.1, Not / would cut that linear fragment 
giving the exact size of the Kir6.1  insert which is about 2.0 kb; there is also a larger 5.0 
kb fragment which  is the pcDNA3.1/Zeo vector as shown  in  lane 2.  The Kir6.2 insert 
was smaller in size compared to Kir6.1; therefore Xba I was used to cut the 7.0 kb DNA 
fragment, giving a  1.6 kb fragment in  lane 3 which migrated further down the agarose 
gel.  There is also a 5.0 kb fragment for the pcDNA3.1/Zeo vector as in the Kir6.1 digest. 
Both Kir6.1  and Kir6.2 were fused to GFP via their C terminus.  The original eGFP-Nl 
vector is 4.9 kb in size, together with the Kir6.1   insert (1.3 kb) the total size of Kir6.1  - 
GFP would be about 6.2 kb as shown in lane 4.  The digest for Kir6.1-GFP was cut once 
with Not I enzyme which linearised the plasmid producing a large fragment at the 6.0 kb 
mark.  A linear fragment in lane 5 was also achieved with Kir6.2-GFP and Not /, the only 
difference is that the size as the Kir6.2 insert is smaller than Kir6.1   so the total fragment 
size shown in the gel in lane 5 is approximately 5.6 kb.  A Bam HI/Apa I digest was set
100up  for both  Kir6.1  DN  samples  in  lanes 6 and  7.  These enzymes were  used to clone 
Kir6.1  into pcDNA3.0 therefore after restriction digest, two bands corresponding to the 
insert and the vector would be expected.  The pcDNA3  vector is slightly  larger in size 
(5.4 kb) compared to its family member pcDNA3.1/Zeo (5.0 kb) but the insert would be
2.0  kb in size, exactly the same as the original  Kir6.1  insert.  The gel shows that more 
DNA was digested in the Kir6.1G— >A sample.
Figure 3.1.  Restriction digests of cDNAs containing specific KA T p subunits, their fluorescently 
tagged equivalents, dominant negatives and DsRed2-ER vector on a 0.8% agarose gel.
Both  SUR1  and  SUR2B  samples  were  digested  with  Not  I enzyme  which  cuts  the 
plasmid DNA twice to produce two characteristic fragments.  Firstly in  lane 8 (SUR1), 
one fragment is 5.4 kb belonging to linearised pcDNA3 with another fragment at 4.5 kb 
which  is the size of the  SUR1  insert.  The SUR  protein  is much  larger in than  inward 
rectifying (Kjr) proteins; this is reflected in the size of the insert.  The SUR2B digest in 
lane 9 has what appears to be a large fragment of DNA at around the 5-5.0 kb mark.  This 
is probably the combination of the pcDNA3 vector and the SUR2B insert as they migrate 
to a similar position on the gel because they are so similar in size.  Finally, the DsRed2- 
ER vector which was bought commercially was digested with Xho I as this was sufficient 
to linearise the plasmid DNA producing a large fragment at 4.7 kb in lane 10.
1013.1.1  The  characterisation  of  Kir6.1  antibodies  usinz  cloned  subunits  in  stably 
transfected HEK293 cells
The production of Kir6.1   channel subunit antisera and its characterisation using cloned 
K atp channel subunits stably expressed in HEK293 cells will be discussed in this chapter. 
This is of importance because these antibodies will be used to investigate the endogenous 
distribution of the native K atp channel subunit in cardiac and skeletal muscle cell lines.
3.1.2.1  Antibody structure and function
Antibodies are glycoproteins composed of four polypeptide chains, two heavy and two 
light chains that form a Y-shaped structure.  The light and N terminus of the heavy chains 
are held together by disulphide linkages that form the arms of the Y and the stem of the 
antibody  is  composed  of the  C  terminus  of the  heavy  chain.  The  N  and  C  terminal 
portions of the heavy chains are stabilised by a flexible region which allows movement of 
the Fab region that allows the antibody to bind to antigens in different ways.  Monoclonal 
antiserum  contains antibodies which  recognise a particular epitope  whereas polyclonal 
antiserum contains a heterogeneous population of antibodies that recognise a variety of 
epitopes.  Polyclonal  antibodies  obtained  from  affinity  purification  will  recognise 
epitopes on the antigen used to illicit the immune response but they will not all recognise 
the same epitope on the antigen.
The  Kir6.1  antibodies  1   have  used  throughout  my  studies  were  affinity  purified  from 
polyclonal antiserum and protein-containing fractions were pooled and dialyzed against 
the  column  buffer  before  the  acid  fractions  were  stored  at  -80°C  (see  methods  and 
materials 2.7).  Two Kir6.1  antibodies were purified and characterised for this study, one 
was  raised  against  a  C  terminal  peptide  sequence of rat  Kir6.1  called  Kir6.1C  (78A) 
corresponding to amino acids  399 to 420,  a terminal  cysteine was added  for coupling 
purposes  (RRNNSSLMVPKVQFMTPEGNQC).  This  antibody  had  been  previously 
purified and characterised by our group (Cui et al. 2001).  My main contribution was the 
purification  of an  antibody  which  was  raised  against  a  fusion  protein  consisting  of
102maltose-binding protein with the C terminus of rat Kir6.1  (amino acids  179-424) called 
MBP-Kir6.1C (93A) (jQuinn et al 2003).
3.1.2.2  Antibody characterisation
I performed Western blotting to determine the specificity of the Kir6.1  antibodies before 
they were used to stain for endogenous Kir6.1  in immortalised cell lines.  The antibodies 
were  characterised  using  cell  lysates  from  HepG2,  HEK293  and  stable  lines 
Kir6.1/SUR2B and Kir6.2/SUR2B, see figure 3.2.  The anti-Kir6.1  antibodies (78A and 
93A) both detect a band of approximately 48 kDa in the Kir6.1/SUR2B stable cell line. 
In figure 3.2A, the Kir6.1C (78A) antibody used at  1:5000 detected a single band at 48 
kDa  in  the  Kir6.1/SUR2B  stable  cell  line.  I  tested  the  same  antibody  at  a  higher 
concentration (1:100) and detected the same band in my stable cell line but the antibody 
also recognised other proteins of higher molecular weight in the samples, see figure 3.2B. 
In figure 3.2C, I tested the MBP-Kir6.1C (93A) antibody at 1:1000 with my cell lysates. 
This  antibody  detected  a  strong  band  in  the  stable  cell  line  Kir6.1/SUR2B  with  a 
molecular  weight  of  48  kDa.  It  also  detected  other  proteins  in  stable  cell  line
Kir6.2/SUR2B,  this  may  be  due  to  the  fact that there  is  some overlap between the  C 
terminus sequence of Kir6.1  and  Kir6.2  so my antibody detected other proteins in the 
lysates.  HEK293  cells  were  used  as a control  because they do not appear to express 
native Kir6.1 (or Kir6.2) (Cui et al.2001).
Antibodies  that  are  sensitive  in  immunofluorescent  staining  may  not  necessary  be 
sensitive  in  immunoblot analysis.  The  cell  lysates  used were  stained  with  Coomassie 
blue for all proteins present in the sample as shown in D.  Our group had limited aliquots 
of  the  affinity  purified  Kir6.1C  antibody  (78A)  so  this  was  used  sparingly  for 
immunofluorescent staining.  This was very sensitive and only detected a specific band 
(48 kDa) corresponding to Kir6.1.  However, the results showed that the MBP-Kir6.1C 
(93A) antibody detected Kir6.1 as well as perhaps Kir6.2 and other non specific proteins.
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Figure 3.2. Characterisation of Kir6.1 antibody by SDS-PAGE and Western blotting.
A.  Kir6.1C (78A) antibody at 1:5000 detected a band at 48 kDa in HEK Kir6.1/SUR2B.
B.  Kir6.1C  (78A)  antibody  at  1:1000  detected  the  same  band  at  48  kDa  in  HEK
Kir6.1/SUR2B cell lysate.  Non specific proteins were also detected.
C.  MBP-Kir6.1  (93A)  antibody  at  1:1000  detected  Kir6.1  as  48  kDa  band  in
Kir6.1/SUR2B cell lysate but also detected other proteins in the other samples.
D.  Coomassie staining of cell lysates
1043.1.3  The characterisation of small interfering RNA (siRNA) for K atp subunit Kir6.1 in 
wild type HEK293 and cloned subunits stably transfected in HEK293 cells
The aim of this study was to examine the functional role of K a t p   channel subunit Kir6.1  
with respect to its distribution.  One way of investigating its functional role is by either 
overexpressing Kir6.1   or using Kir6.1   DNs to knockout the function of the protein.  The 
DNs  for  Kir6.1  were  previously  described  at  the  beginning  of this  chapter.  A  DN 
contains a mutation whose gene product will affect the normal, wild-type gene product 
and  block  some  aspect  of its  function.  These  DN  for  Kir6.1  will  knockout  Kir6.1 
however, it is not always specific and can affect Kir6.2 as the C terminus of both  K a t p  
channel  subunits can  have overlapping sequences (Cui et al.  2001).  Small  interfering 
RNA (siRNA) became widely available at the start of my PhD so it decided that siRNA 
would be used to examine the potential function of Kir6.1.  Qiagen custom designed the 
siRNA  for Kir6.1  but  it  is  important to  note the  factors  in  the design  and delivery of 
siRNA.  The  critical  factors  in  their  design  include  potency  because  potent  siRNA 
ensures  high  knockdown  levels  and  secondly,  specificity  as  specific  siRNA  that  will 
target the gene of interest if designed correctly and not affect other genes in the cell.
The siRNA has to be delivered to the cell by transfection therefore high transfection rates 
are essential for knockdown of the protein.  As with any transfection experiment, toxicity 
is a factor to consider because this is vital if sensitive cells or primary cell lines are used. 
Transfection  protocols  were  optimized  specifically  for  siRNA  (see  methods  and 
materials) where Lipofectamine 2000 was used as the transfection reagent which required 
small  amounts  of  siRNA  (pmol).  Suitable  assays  to  confirm  knockdown  include 
quantitative  real-time  RT-PCR  which  confirms  knockdown  and  confirmation  at  the 
mRNA  level and  Western blot analysis and other methods of protein expression which 
shows  knockdown  at  the  protein  level.  The  latter method  was  used  in  this  study  to 
analyse Kir6.1 protein knockdown.
1053.1.3.1  Synthesising siRNA for Kir6.1
The  whole  nucleotide  sequences  for  Kir6.1  for  rat,  mouse  and  human  species  with 
accession numbers were first located using Genbank nucleotide database,  see table 3.3. 
The siRNA target sequences were located in the mouse, rat and human genome,  using 
NCBI  BLAST  {Basic  Local  Alignment  Search  Tool)  which  finds  regions  of  local 
similarity between sequences.  The program compares nucleotide or protein sequences to 
sequence databases and calculates the  statistical  significance of matches.  BLAST can 
also be used to identify members of gene families or similar genes in different species.
Table 3.3.  The accession number and name of Kir6.1  gene in rat, mouse and human.
Soecies Accession Number Name
Rat NM  017099 Rattus norvegicus potassium inwardly-rectifying 
channel, subfamily J, member 8 (Kcnj8)
Mouse NM  008428 Mus muse  ulus potassium inwardly-rectifying channel, 
subfamily J, member 8 (Kcnj8),
Human NM_004982 Homo- sapiens potassium inwardly-rectifying channel, 
subfamily J, member 8 (KCNJ8)
Preliminary experiments characterising the silencing effects of siRNA  (duplex  1   and 2 
known  as  61 siRNA  duplex  1   or  2  )  for  Kir6.1  showed  that  duplex  2  was  far  more 
effective because it knocked down protein expression by 95 % (see results).  BLAST was 
used to find out where the target sequence was located in the gene in each species.  The 
61 siRNA duplex 2 target sequence was located in mouse and rat Kir6.1  DNA sequence 
with  100 % match but there were two mismatched base pairs in the human sequence so 
duplex 2 would not work in my human cell lines.  The target sequences were present both 
in mouse and rat because the two species have 95 % homology between them whereas 
there is 89 % homology between rat and human so there is more chance that mismatched 
pairs would occur.  However, the 61 siRNA duplex was only specific to rat and mouse 
Kir6.1  gene so could only be used to knockdown native Kir6.1.  For example, this was 
used in the C2C12 skeletal muscle cells as the original Kir6.1 gene which was subcloned
106into the eGFP-Nl  vector was derived  from  rat  DNA.  The table  3.4  shows  the  exact 
sequences in the siRNA duplexes.
Table  3.4.  A  table to  show  the  DNA  sequence  of the  siRNA  for  Kir6.1.  The  siRNA  are 
compatible in both rat and mouse.
61siRNA data Duplex 1 (Rat and Mouse) Duplex 2 (Rat and Mouse)
Target name 61 siRNA duplex 1 61 siRNA duplex 2
Target sequence 5’  CAC  CAC  CTT  GGT  AGA 
CCT GAA 3’
5’  CAG  GAA  GAG  CAT  CAT 
CCC GGA 3’
Sense r(CCA  CCU  UGG  UAG  ACC 
UGA A)dTdT
r(GGA  AGA  GCA  UCA  UCC 
CGG A)dTdT
Antisense r(UCC  AGG  UCU  ACC  AAG 
GUG G)dTdG
r(UCC  GGG  AUG  AUG  CUC 
UUC C)dTdG
nmol/T ube 20 nmol 20 nmol
To perform functional studies, separate siRNA for human Kir6.1 gene was synthesised to 
accommodate later functional studies using human HepG2 and HEK293 cell lines.  (The 
original siRNA  for Kir6.1   for rat and mouse were synthesised as HiPerformance 2-For- 
Silencing siRNA Duplexes so came at 20 nmol whereas the siRNA for human Kir6.1 was 
synthesised individually at 5 nmol).  See table 3.5 for the target sequence.
Table 3.5.  A table to show the DNA sequence of siRNA for Kir6.1.  This siRNA is specific for 
human Kir6.1  gene.
61siRNA data Duplex 1 (Human)
Target name 61 siRNA
Target sequence 5’ GAG GTG GTT CCT ATT CAC CAA 3’
Sense r(GGU GGU UCC UAU UCA CCA A)dTdT
Antisense r(UUG GUG AAU AGG AAC CAC C)dTdC
nmol/T  ube 5 nmol
From the nucleotide database, the human Kir6.1 gene is 2381 base pairs long.  Part of the 
human sequence is shown below with the target sequence in table 3.4 highlighted.  This 
is the target sequence for siRNA for human Kir6.1.
107Homo-sapiens potassium inwardly-rectifying channel (K.CNJ8) NM  004982
961  TCATGTTCCG  AGTGGGTGAC  CTGAGGAAAA  GCATGATCAT
TAGTGCCTCT  GTGCGCATCC
1021  AGGTGGTCAA  GAAAACAACT  ACACCTGAAG  GGGAGGTGGT 
TCCTATTCAC  C A A ctggaca
1081  TTCCTGTTGA  TAACCCAATC  GAGAGCAATA  ACATTTTTCT
GGTGGCCCCT  TTGATCATCT
3.1.3.2  How does siRNA target genes?
In  eukaryotes,  protein  coding  genes  are  transcribed  from  the  DNA  template  by  RNA 
polymerase II enzyme.  The pre-mRNAs are processed to form mature mRNAs which are 
transported  from the nucleus where the mRNA code is translated on the ribosome to a 
specific amino acid sequence encoding a protein.  RNA interference (RNAi) occurs in a 
wide variety of eukaryotic organisms and regulates endogenous gene expression.  It is a 
form of post-transcriptional gene silencing where double stranded RNA (dsRNA) causes 
the degradation  of endogenous  mRNA  transcripts resulting  in  the  reduction  or loss of 
gene activity.  RNA interference was initially discovered in the nematode Caenorhabditis 
elegans where long double stranded RNA sequences were injected into the worm’s gonad 
(a standard procedure used to introduce transgenes into worms) and these were found to 
inhibit  protein  translation  by  targeting  genes  partially  complementary  to  the  3’
untranslated  region  of the  mRNAs.  Gene  silencing  is  triggered  by  the  presence  of 
dsRNAs,  these  can  vary  in  length  and  origin  can  arise  in  the  cell  from  a  variety  of 
sources,  including  virus  replication  and  hybridization  of homologous  transcripts  from 
repetitive DNA sequences (transposons).  There are three main steps in the mechanism of 
gene silencing by double stranded  RNA:  The first step involves processing the double 
stranded RNA to form siRNA, followed by the formation of the RNA-induced silencing 
complex  (RISC).  Finally,  the  RISC  complex  prevents  protein  synthesis  because  it 
cleaves the target mRNA sequence.  This is outlined in figure 3.3.
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Figure 3.3.  A diagram to show the steps involved in the mechanism of gene silencing.
Small  double-stranded  RNAs  arise  in  the  cell  from  a  variety  of sources,  including  virus 
replication, hybridisation of homologous transcripts from repetitive DNA sequences such as 
transposons,  and  introduction  of synthetic  siRNA  into  the  cell  in  an  experiment.  Double 
stranded  RNAs  are  first processed to  form  siRNAs,  after processing the RISC  complex  is 
assembled.  This causes siRNA to unwind and binds to a single strand.  Finally this complex 
targets complementary mRNAs which are cleaved therefore preventing protein translation. 
(This information was obtained  from the Qiagen website).
The  first  step  of gene  silencing  is  the  processing  of longer  dsRNAs  into  siRNAs  of 
characteristic size and structure.  Long dsRNA is recognized and processed by a member 
of the RNase-III family of endonuleases called Dicer which contains catalytic RNAse III 
and dsRNA-binding proteins (dsRBDs).  Processing of dsRNAs  by  Dicer yields  RNA 
duplexes of approximately 21  nucleotides and 2-nucleotide 3-end overhangs (siRNAs). 
After  processing,  a  ribonucleoprotein  complex  called  RISC  (RNA-induced  silencing 
complex)  is assembled.  There are many components of the RNA  silencing machinery 
that have not been identified yet but there is an unidentified nuclease called ‘Slicer’ that 
is part of this protein complex.  During RISC assembly,  siRNAs unwind  and  a single
109strand of RNA (antisense strand) remains bound to the RISC.  The antisense strand of 
siRNA guides the RISC to target mRNA that has complementary sequences. The RISC 
cleaves the target mRNA  in the middle of the region of homology to the siRNA, ten 
nucleotides  upstream  of the  nucleotide  paired  with  the  5’  end  of the  siRNA  and  so 
translation is prevented.
3.1.3.3  Kir6.1 siRNA specifically suppresses Kir6.1 expression
Custom  made  siRNA  for  Kir6.1  were  also  characterised  for  this  thesis  because  in 
comparison to DNs, protein expression is suppressed and the effect is sustained, siRNA 
are also specific to their target gene.  The siRNA for Kir6.1  were first assessed for their 
silencing effects by examining the knockdown of Kir6.1 using Kir6.1-GFP and observing 
the intensity of the green fluorescence as an indicator of gene suppression.  Wild type 
HEK293 cells were transiently transfected with Kir6.1-GFP with SUR2B in the presence 
of siRNA for Kir6.1  duplex  1   or 2.  These cells were chosen because they contain very 
little or no Kir6.1  so that the effect of siRNA could be quantified.  Cells were imaged 
about  36  hours  after  transfection.  Separate  images  were  captured,  one  for  green 
fluorescence (Kir6.1-GFP) and one for brightfield.  Cells were healthy after transfection 
with cell populations at similar confluence.  This experiment was repeated at least three 
times.
The result for this experiment is displayed  in figure 3.4.  The control cells in A were 
transfected at high efficiency with Kir6.1-GFP and SUR2B.  In the second experiment 
cells were also co-transfected with siRNA for Kir6.1  (duplex 1), see figure 3.4B.  There 
is a substantial knockdown of Kir6.1  of 50 % in comparison to the control cells.  In the 
presence of 61 siRNA duplex 2, the expression of Kir6.1  was also suppressed, refer to 
figure 3.4C.  However, this is more significant then the first duplex as there is about 95 % 
knockdown of Kir6.1-GFP fluorescence.  The brightfield image show that the cells are 
clearly visible and healthy therefore the decrease in fluorescence is due to the presence of 
61 siRNA.
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Figure 3.4.  61 siRNA duplex 1   and 2 and gene silencing in HEK293 cells.
Images to show the silencing effect of siRNA for potassium channel subunit Kir6.1.  HEK293 
cells were cultured into 6 well plates with MEM containing only  10 % FBS and were 40-50 % 
confluent on  the  day  of transfection.  The  cells  were  transfected  using  Lipofectamine  2000 
with  Kir6.1-GFP,  sulfonylurea  subunit  SUR2B  and  siRNA  for  Kir6.1  (Duplex  1   or 2)  at  a 
concentration  of 20  pmol/pl.  The  cells  were  left  to  incubate  for  approximately  36  hours 
before they were imaged.
A.  The control cells were transfected with Kir6.1-GFP and SUR2B (without siRNA).
B.  Cells transfected with 61 siRNA duplex 1   show a decrease in Kir6.1-GFP expression.
C. Cells transfected with 61 siRNA duplex 2 had pronounced knockdown of Kir6.1-GFP (95 
%).  The brightfield  images  in all cases  show that cells are  healthy  and not affected  by the 
transfection process.
IllThis is convincing data where the 61 siRNA  duplex  is effective  in  suppressing  Kir6.1 
gene expression.  The next step was to establish whether the 61 siRNA was only specific 
to Kir6.1  and not just suppressing the expression of any K atp channel subunit protein in 
the cells, therefore, a parallel experiment using Kir6.2-GFP was set up and repeated using 
the same protocol and conditions.  In  figure 3.5, HEK293  cells were transfected with 
Kir6.2-GFP  instead of Kir6.1-GFP.  The control cells in A were transfected with just 
Kir6.2-GFP and  SUR2B; these cells have bright green  fluorescence similar to control 
cells transfected with Kir6.1-GFP, shown in A.
When HEK293 cells were co-transfected with either 61 siRNA duplex  1   or 2, there was 
no significant decrease in the expression of Kir6.2-GFP, refer to figure3.5 B and C.  The 
images were not different to the control cells; the brightfield images also show that the 
cells under the three different conditions were all viable and healthy after transfection. 
From these experiments, I report that my custom made 61 siRNAs are specific to Kir6.1 
subunit and does not affect Kir6.2 protein expression.  In particular, 61 siRNA duplex 2 is 
an effective tool in elucidating the potential function of Kir6.1  and this will be used in 
later functional  studies  in  my cardiac and smooth muscle cell  lines.  For example,  in 
chapter 3.4, I will use this tool to examine the role of Kir6.1  in ROS production because 
m ito K ATP  channel  opening  has  been  proposed  to  facilitate  ROS  production  in  IPC. 
Finally  in  chapter  3.6,  I  will  examine  the  significance  of Kir6.1  in  the  ER  in  Ca2+ 
handling.
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Figure 3.5.  61 siRNA duplex 1  and 2 and gene silencing in HEK293 cells.
Images to show the effect of siRNA for potassium channel subunit Kir6.1.  HEK293  cells 
were cultured as described in Figure 5.2.  This is to show that the siRNA for Kir6.1 was only 
specific to the Kir6.1  subunit and not Kir6.2.
A.  The control cells transfected with Kir6.2-GFP and SUR2B (without 61 siRNA).
B.  Cells  transfected  were  with  61 siRNA  duplex  1   show  green  fluorescence  (therefore 
expression of Kir6.2).  The number of transfected cells is the same as in a.).
C.  Cells  transfected  with  61 siRNA  duplex  2.  Again,  the  siRNA  had  no  effect  on  the 
expression of Kir6.2.
1133.1.3.4  Kir6.1  protein  expression  is  knocked  down  with  61 siRNA  in  HEK293  cells 
transiently transfected with potassium channel subunits
I  report  that  the  expression  of  transiently  transfected  Kir6.1-GFP  is  significantly 
suppressed  in  the  presence  of siRNA  for  Kir6.1.  The  next  step  was  to  quantify the 
proportion of Kir6.1  protein knockdown using our 61 siRNA by Western blot analysis. 
Wild type HEK293 cells were transfected with Kir6.1 or Kir6.2 subunit, SUR2B receptor 
and  either  61 siRNA  duplex  1   or 2.  No  more  than  2  pg  DNA  was  transfected  into 
HEK293 cells.  Figure 3.6 shows the results of Western  immunoblot with cell  lysates 
from HEK293 cells transfected with either Kir6.1  or Kir6.2 and SUR2B in the presence 
of our 61 siRNA (duplex 1  and 2).  Cells were also transfected with 50 ng GFP to ensure 
that the K atp subunits had been transfected efficiently before they were harvested.  The 
Western blot analysis was performed with these samples and the presence of Kir6.1   was 
detected using Kir6.1C antibody (78A) which was already characterised.  A 48 kDa band 
was detected in control cells transfected with just Kir6.1 and SUR2B.  No (or very little) 
Kir6.1 protein was detected in the samples co-transfected with 61 siRNA.
On closer inspection, HEK293 cells transfected with 61 siRNA duplex 1  (lane 2) contain a 
very faint band for Kir6.1, indicating that there is reduced expression of Kir6.1  in that 
sample when compared to the control in lane 1.  Those cells co-transfected with 61 siRNA 
duplex 2 show that there is no Kir6.1 in that sample (lane 3).  The blot is consistent with 
the results in figure 3.4 and 3.5.  Cells transfected with Kir6.2 and SUR2B with 61 siRNA 
duplex 2 do not contain  any Kir6.1  protein at all  so  no bands were detected  in these 
samples  (lanes  4-6).  As  shown  in  figure  3.4,  61 siRNA  does  not  affect  theKir6.2 
expression because it is specific to Kir6.1, therefore my Kir6.1  antibody did not detect 
any bands in these samples.
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Figure 3.6.  The effect of 
61 siRNA duplex 1  and 2 on 
Kir6.1  protein expression.
Western  blot  of  HEK293 
lysates,  these  were  transiently 
transfected  with  Kir6.1/Kir6.2 
with  SUR2B  and  61 siRNA 
(Duplex 1  or 2).  The molecular 
weight of the marker is shown 
on the left (kDa).  The Kir6.1C 
antibody  (78A)  was  used  to 
detect Kir6.1   (1:1000).  A band 
at 48 kDa is detected in samples 
transfected  with  Kir6.1   and 
SUR2B
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Figure 3.7.  The effect of 
62siRNA duplex 1  and 2 on 
Kir6.1  protein expression.
Western  blot  of  HEK293 
lysates,  these  were  transiently 
transfected  with  Kir6.1/Kir6.2 
with  SUR2B  and  62siRNA 
(Duplex 1  or 2).  The molecular 
weight of the marker is shown 
on the left (kDa).  The Kir6.1C 
antibody  (93A)  was  used  to 
detect  Kir6.1   (1:1000).  The 
antibody detected a band at 48 
kDas  which  is  consistent  for 
Kir6.1.
115In  figure 3.7,  HEK293  cells were transfected with the same  K a tp   channel  subunits but 
this time, they were co-transfected with  siRNA  for Kir6.2 (62siRNA).  The siRNA  for 
Kir6.2 was ordered at a later date so I decided to carry out a parallel experiment to prove 
that Kir6.1  protein expression was not affected by silencing Kir6.2 gene.  As mentioned 
previously,  the  Kir6.1C  antibody  (78A)  was  in  short  supply  at  this  time  so  for  this 
particular immunoblot, the MBP-Kir6.1C  antibody (93A) was used to detect a band of 
approximately  48  kDa  corresponding  to  Kir6.1  protein.  According  to  the  blot,  the 
antibody detected a 48  kDa band  in  HEK293  cells transfected with  Kir6.1  (lanes 4-6). 
The presence of 62siRNA did not affect the expression of Kir6.1.
This  MBP-fusion  antibody  93A  is  not as  selective as the  78A  because  it detected  the 
presence  of  other  proteins  in  the  sample  when  used  at  higher  concentrations. 
Furthermore, the immunofluorescent staining data showed that this antibody was reliable 
as appropriate controls were used and  it did detect endogenous Kir6.1  in my cell  lines 
(see  3.3).  There  were  no  visible  bands  in  HEK293  cells  transfected  with  the  Kir6.2 
subunit,  see  lanes  1-3.  These  samples  were  not  contaminated  and  transfections  were 
efficient because no proteins were detected by our MBP-Kir6.1C antibody (93A) and it is 
clear that 62SiRNA does not affect the expression of Kir6.1.  To summarise, 61 SiRNA is 
a  very  effective  tool  in  investigating  the  potential  role  of Kir6.1  by  knocking  out  its 
expression.  From my results, 61 siRNA duplex 2 will be used for functional assays.
Kir6.1  protein expression is suppressed  in the presence of 61 siRNA but to confirm that 
there was reduced  K a t p   channel activity, whole-cell patch clamp recordings were taken 
from  HEK293 cells stably transfected  with  K a t p   channel  subunits (control).  The cells 
were  transfected  with  61 siRNA  36  hours  before  recordings  were taken.  The  patching 
experiments  in  our  stable  cell  lines  were  kindly  carried  out  by  Dr.  Kathryn  Quinn 
{Clinical Pharmacology,  UCL,  London).  The data for Kir6.1/SUR2B currents in stably 
transfected HEK293 cells is displayed in figure 3.8.  Whole cell currents were taken and 
61 siRNA  significantly  reduced  Kir6.1/SUR2B  currents  (n=  8),  see  figure  3.8A  and 
figure3.8B but not in Kir6.2/SUR2B currents (n= 7) (figure 3.8C and figure 3.8D).
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Figure 3.8.  Whole cell patch recordings of single-channel currents from HEK293 cells stably 
transfected  with  KA TP channel  subunits.  The  Kir6.1   siRNA  was  transiently  transfected  into 
these stable cell lines along with eGFPNl  to allow transiently transfected cells to be identified 
using epifluorescence.  Control recordings were made from cells which had gone through the 
transfection  process  but which  had  not taken  up the GFP cDNA  (and thus assumed  had  not 
been  co-transfected  with  Kir6.1  siRNA).  Patch  pipette  solutions  were  supplemented  with 
nucleotide  phosphates  and  diphosphates  and  recordings  were  made  in  a  symmetrical  K' 
gradient (140  mM).  Under these conditions,  the  Kir6.1/SUR2B  and  Kir6.2/SUR2A  currents 
were  activated  without  use  of levcromakalim  or similar  KCO  but  gradually  reached  steady 
state  around  5  minutes  after  breaking  through  to  whole-cell.  At  this  point,  steady-state 
currents  were recorded  by  applying 250  ms  voltage steps  from  a holding potential  of 0 mV 
between  -100  mV  and  +100  mV.  Glibenclamide  (10  pM)  was  applied  at  the  end  of the 
experiment  to  ensure  that  the  current  was  abolished.  Kir6.1/SUR2B  channel  activity  is 
significantly  reduced  in the  presence of 61 siRNA  when  p<0.03  (A  and  B).  Kir6.2/SUR2A 
currents were not affected by the presence of 61 siRNA p>0.05 (C and D).
The basal current density at -50 mV was < 25 pA/pF in untransfected HEK293 cells (Giblin et 
al  1999).  Application of 10 pM  glibenclamide in the Kir6.1\SUR2B  stable line reduces the 
current  density  to  <20  pA\pF  (Quinn  et  al  2003).  Therefore  the  effect  of the  siRNA  are 
significant  but  not  complete  i.e  subtracting  the  background  current  would  go  from  ~175 
pA\pF (control) to -40 pA\pF (+ siRNA to Kir6.1) -  80 % reduction.
The characterisation of siRNA is an important step in determining the function of K Atp  
channel subunit, Kir6.1  in cardiac and skeletal muscle cell lines.  61 siRNA duplex 2 will 
be  used  in  functional  studies  so  that  the  importance  of  Kir6.1  (channel)  in  ROS 
production, mitochondrial function and Ca2+ handling could be determined.
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^99923.2  Investigating the distribution of Katp subunit Kir6.1 in immortalised
cell lines:
Kir6.1  has been proposed to be a major component of the mitoKATP channel.  The focus 
of this chapter is to establish whether Kir6.1  localises to mitochondria.  Previous data 
showed that Kir6.1  existed in other intracellular organelles such as the ER.  The cDNA 
constructs of K Atp channel subunits which were cloned and purified as described in the 
previous section were used to investigate the subcellular distribution of Kir6.1   in cardiac 
and skeletal muscle cell lines.  HEK293 cells were also used because they were useful for 
the expression of recombinant proteins such as Kir6.1-GFP.  HepG2s are a liver cell line, 
which are rich in mitochondria from which the mitoKA xp channel was originally isolated 
as described  by  Inoue in the early  1990’s (Inoue et al.  1991).  The C2C12 cell  line  is 
derived from mouse skeletal muscle.
3.2.1  Kir6.1  primarily localises to the ER
The subcellular distribution of Kir6.1  was investigated using transient transfections and 
cells were cultured so that they were 50-70 % confluent, ready for transfection 24 hours 
later.  HEK293, C2C12 and HepG2 cells lines were transiently transfected with Kir6.1- 
GFP and with a specific ER marker called DsRed2-ER.  The cells were analysed using 
laser scanning  confocal  microscopy  (Bio-Rad  system)  before  they  were  first observed 
under a fluorescent microscope to assess the transfection efficiency.  In HEK293 cells, it 
was approximately 50-80 % compared to 40-60 % in C2C12 cells however,  in  HepG2 
cells it was only  10-15 %.  Therefore, it was decided that the HepG2 cell line would be 
omitted  from  this  part  of the  study.  The  data  from  this  chapter  is  from  C2C12  and 
HEK293 cell lines and experiments were repeated on separate occasions so that at least 
30 transfected cells could be used to analyse colocalisation between the two fluorescent 
markers.  (Please refer to chapter 2.5.3 in methods and materials).
118Kir6.1-GFP  DsRed2-ER  Merged
C2C12  Kir6.1-GFP and DsRed2-ER
Figure 3.9.  Kir6.1 and ER colocalisation in C2C12 cells transfected with Kir6.1-GFP and 
DsRed2-ER.
Images  to  show  colocalisation  between  Kir6.1-GFP  and  DsRed2-ER  in  C2C12  cells. 
These were transfected with Kir6.1-GFP and DsRed2-ER.  The cells were transfected for 
15 hours at 37°C before the transfection mixture was removed and replaced with MEM 
supplemented with 10 % FCS and 1  % P/S.  The cells were used for confocal analysis 36- 
48 hours later.
Kir6.1-GFP was excited using the 488 nm laser with a 510-530 nm emission filter whereas 
DsRed2-ER was excited with the 543  nm  laser with 560-630 nm emission  filter.  The 
fluorophores were images sequentially.  The merged image (right) shows the colocalisation 
between the Kir6.1-GFP and DsRed2-ER.  A high proportion of Kir6.1 channel subunit is 
located in the endoplasmic reticulum.
3.2.1  Kir6.1  is predominantly distributed in the endoplasmic reticulum
In  figure  3.9,  C2C12  cells  were  transfected  with  Kir6.1-GFP  and  DsRed2-ER.  The 
images  show  that  there  was  a  high  proportion  of Kir6.1  located  in  the  ER  and  the 
majority  of the  yellow  pixels  (where  there  is  colocalisation)  were  located  around  the
119nucleus and ER.  However, the signals did not overlap at the plasma membrane.  C2C12 
cells were also co-transfected with SUR1  but Kir6.1  in the presence of the sulphonylurea 
receptor was  still  retained  in  the  ER and  not trafficked  to  the  plasma  membrane,  see 
figure  3.10.  The rationale  for transfecting  SUR1  and not SUR2A  or SUR2B  in these 
experiments is because there  is strong evidence to suggest that the SUR subunit of the 
native m i t o K A T P  channel could be SURl.  Pharmacological studies carried out by Liu et 
al  concluded  that  native  m i t o K A T P  channels  they  isolated  closely  resembled  the 
Kir6.1/SUR1 channel expressed in HEK293 cells {Liu et al. 2001).
Kir6.1-GFP  DsRed2-ER  Merged
C2C12  Kir6.1-GFP, DsRed2-ER and SURl
Figure 3.10.  Kir6.1  and ER colocalisation in C2C12 cells transfected with Kir6.1-GFP, 
DsRed2-ER and SURl.
Images to show the colocalisation between Kir6.1-GFP and DsRed2-ER in C2C12 cells. 
Cells were transfected with Kir6.1-GFP, DsRed2-ER and SURl.  The cells were prepared 
as described in figure 3.9.  The degree of colocalisation is the same as cells transfected 
with just  Kir6.1-GFP  and  DsRed2-ER  but  Kir6.1  is  still  retained  in  the  endoplasmic 
reticulum in the presence of SURl.
The proportion of colocalisation between the two signals was calculated using a program 
called Laserpix and the results were compared against a theoretical value of zero using a
120rank scoring test known as the Mann  Whitney test.  Results were significant if p<0.05 
(*).  The  results  for  C2C12  cells  transfected  with  Kir6.1-GFP  and  DsRed2-ER  and 
Kir6.1-GFP,  DsRed2-ER  and  SURl  are  displayed  as  medians  with  25  %  and  75  % 
interquartile ranges in figure 3.11.  The graph shows the proportion of Kir6.1-GFP pixels 
which colocalise with DsRed2-ER pixels and vice versa.  The first column (b) represent 
the data for cells transfected with Kir6.1  -GFP and DsRed2-ER where the total number of 
green  pixels (a) which  also contain  red  pixels (c)  please refer to the  Venn  diagram  in 
chapter 2.5.3.  The second column shows the total number of red pixels that colocalise 
with the green.  The third and fourth columns show the proportion of colocalisation  in 
cells co-transfected with SURl.
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Figure 3.11.  The proportion of Kir6.1   and ER colocalisation in C2C12 cells.
A  graph  to  show  the  proportion  of  Kir6.1  (Kir6.1-GFP)  that  colocalises  with  endoplasmic 
reticulum  (DsRed2-ER) n= 48  and  Kir-6.1  GFP with  DsRed2-ER  in  C2C12  cells  co-transfected 
with  SURl  n=  32.  The  first  and third  column corresponds to  the total  number of Kir6.1-GFP 
pixels  that  colocalise  with  the  red.  Statistical  analysis  showed  that  the  data  were  highly 
significant when p<0.001  (***).  The percentage of colocalisation between the two experiments is 
almost  identical  for  cells  transfected  with  and  without  SURl.  SURl  does  not  significantly 
influence the trafficking of Kir6.1  to the plasma membrane.
The  first column  indicates that 28  % (median  value) of Kir6.1  was  ER  retained and  a 
similar  value  was  observed  in  cells  co-transfected  with  SURl  (column  three).  The 
second  and  fourth  columns  confirm  that  45  %  and  55  %  (SURl)  of the  DsRed2-ER
121marker colocalises with  Kir6.1-GFP.  Although a significant  proportion of Kir6.1  was 
located in the ER, there is still a large proportion of Kir6.1 that is unaccounted for.  This 
may  be  located  in  other  specialised  compartments  throughout  the  cell  such  as 
mitochondria.  The  results  for  C2C12  cells  co-transfected  with  SURl  show  that  the 
sulphonylurea  receptor  did  not  significantly  influence  the  transport  of Kir6.1  to  the 
plasma membrane because the similar median values were obtained.  The null hypothesis 
(Ho) where ‘ There is no colocalisation between Kir6.1-GFP and DsRed2-ER signals' was 
rejected p<0.001 (***).
Kir6.1-GFP  DsRed2-ER  Merged
HEK293  Kir6.1-GFP and DsRed2-ER
Figure 3.12.  Kir6.1 and ER colocalisation in HEK293 cells transfected with Kir6.1-GFP, 
and DsRed2-ER.
Images to show the colocalisation of Kir6.1-GFP and DsRed2-ER in HEK293 cell  line. 
Cells were transfected with Kir6.1-GFP and DsRed2-ER.  The cells were imaged in the 
same manner as described in figure 3.2.  The images show that a high percentage of Kir6.1  
is located in the ER.  The ER appears to be more reticular than in C2C12 cells.
122The HEK293 cell line was also used to investigate the distribution of Kir6.1.  HEK293 
cells do not contain endogenous Kir6.1  so transfecting Kir6.1-GFP would be useful  in 
determining where the  Kir6.1  protein  may  be distributed  in the cell  (Cui et al.  2001). 
Figure  3.12  shows  the  images  for  HEK293  cells  transfected  with  Kir6.1-GFP  and 
DsRed2-ER.  A  higher percentage of Kir6.1-GFP pixels overlap with the DsRed2-ER 
pixels.  The merged images show that there was a significant proportion of Kir6.1  in the 
ER,  most  of Kir6.1  appeared  to  be  cytoplasmic  and  ER  retained  with  some  strong 
colocalisation on the nuclear envelope.
Kir6.1-GFP  DsRed2-ER  Merged
HEK293  Kir6.1-GFP, DsRed2-ER  and SUR1
Figure 3.13.  Kir6.1  and ER colocalisation in HEK293 cells transfected with Kir6.1- 
GFP, DsRed2-ER and SURl.
Images to show the colocalisation of Kir6.1-GFP and DsRed2-ER in HEK293 cells.  Cells 
were transfected with Kir6.1-GFP, DsRed2-ER and SURl.  The cells were imaged in the 
same  manner  as  described  in  figure  3.2.1.  Kir6.1  is  predominantly  located  in  the 
endoplasmic reticulum and nuclear envelope, even in the presence of the sulphonylurea 
receptor, SURl.
123In figure 3.13, the proportion of Kir6.1 that was trafficked to the plasma membrane in the 
presence  of SURl  was  expected  to  be  significantly  higher  but  the  proportion  of ER 
colocalisation  remained  the  same  in  the  cells  without  the  sulphonylurea  receptor,  see 
figure 3.12.  I would expect less Kir6.1 to be ER retained because Kir6.1  should form an 
octameric complex with SURl.  The ER retention motif (RKR) on both subunits would 
be masked promoting exit from the ER followed by translocation to the cell surface to 
form functional K a t p  channels (Zerangue et al. 1999).
HEK293
Kir6.1-GFP + DsRed2-ER  Kir6.1-GFP + DsRed2-ER +SUR1
Figure  3.14.  The proportion of Kir6.1 and ER colocalisation in HEK293 cells.
A  graph  to  show  the  proportion  of Kir6.1  (Kir6.1-GFP)  that  colocalises  with  endoplasmic 
reticulum (DsRed2-ER) n= 34 and Kir6.1-GFP with DsRed2-ER in the presence of SURl n= 48. 
The first and third column corresponds to the total number of Kir6.1-GFP pixels that colocalise 
with DsRed2-ER pixels.  Statistical analyses showed that both sets of data were highly significant 
when p<0.001  (***).  The colocalisation between the two signals was almost identical for cells 
transfected with and without the sulphonylurea receptor.
HEK293 cells contained a greater proportion of transfected Kir6.1  in the ER compared to 
the  C2C12  cell  line,  see  figure  3.14.  In  cells  transfected  with just  Kir6.1-GFP  and 
DsRed2-ER,  the  median  value  showed  that  50  %  of  Kir6.1  was  ER  retained  (first 
column).  The other 50 % of Kir6.1   as discussed previously could  be  located  in  other 
intracellular compartments such as the mitochondria.  The results for cells co-transfected 
with SURl  are the same because SURl  does not influence the trafficking of Kir6.1 to the 
plasma membrane.  The proportion of colocalisation between Kir6.1-GFP and DsRed2- 
ER is significant p<0.001 (***).
124From  this  colocalisation  study,  transfecting  SURl  did  not  significantly  affect  the 
distribution of Kir6.1.  However, SURl  will form functional  K A t p   channels with Kir6.2 
as found in pancreatic p-cells {Ashcroft & Gribble 1998).  Liu’s study demonstrated that 
Kir6.1/SUR1  formed distinct membrane  currents similar for native  mitoKATP channels. 
One  can  argue  that  as  the  SURl  cDNA  used  was  not  fluorescently  tagged  it  would 
difficult to establish whether it was transfected  successfully  into the  cell  lines  I  used. 
However,  previous  observations  in  our  laboratory  showed  that  our  SURl  cDNA  co­
transfected with Kir6.2 subunit showed distinct K a t p  channel activity in patching studies. 
Therefore, HEK293 cells were subsequently transfected with  Kir6.2-GFP and  SURl  to 
show that functional channels do form with the SURl  cDNA.  Transfected Kir6.2-GFP 
was intracellular and mainly distributed in the ER.  In the presence of SURl, Kir6.2-GFP 
was not ER retained because these subunits were expressed at the plasma membrane, as 
shown  in figure 3.15.  The data show that the distribution of Kir6.1  and  Kir6.2 (in the 
presence of SURl) are clearly distinct from one another.
Kir6.2-GFP Kir6.2-GFP + SURl
HEK293
Figure 3.15.  HEK293 cells transfected with Kir6.2 GFP and SURl.
On the right, the image show that Kir6.2-GFP alone is retained in the ER whereas co- 
transfection with SURl  (right) allows the two K At p subunits form a protein complex and 
exit the ER to localise to the plasma membrane.
1253.2.2  Kir6.1  mav be localised in mitochondria
This part of the colocalisation study has shown that Kir6.1 is predominantly distributed in 
the ER however,  it is not trafficked to the plasma membrane when co-transfected with 
SURl.  Although the data have shown that the Kir6.1  is mostly expressed  in the ER, 
there was  also  a significant proportion  of Kir6.1  that may be  located  elsewhere.  For 
example, Kir6.1  may exist in subcellular compartments such as the mitochondria.  The 
identity of the m ito K ATP channel is under debate but I decided to examine if Kir6.1  exists 
in  mitochondria  by  continuing  the  colocalisation  studies  using  mitochondrial  specific 
dyes  and  probes.  I  examined  the  distribution  of Kir6.1  in  mitochondria  using  three 
different approaches,  i).  Mito DsRed  ii). TMRE and iii).  MitoTracker Red.  See figure
3.16.
In figure 3.16A, the mito DsRed probe was transfected alone to label the mitochondria 
but  this  caused  problems  because  the  probe  produced  significant  green  background 
fluorescence in cells transfected with just MitoDs-Red.  This occurred regularly in cells 
which  were  transfected  for  less  than  36  hours  as  MitoDs-Red  existed  as  the  green 
fluorescent product which was the immature form of the protein.  Therefore, it was not 
possible  to  co-transfect  Mito  DsRed  with  Kir6.1-GFP  this  into  these  cells  for 
colocalisation experiments.  This overlap of the  signals complicated the  colocalisation 
analysis and was pursued  further with a mitochondrial  membrane potential  dye  called 
TMRE.  C2C12 and HEK293 cells were first loaded with TMRE to ensure that there was 
no crosstalk between the two fluorophores during imaging Kir6.1-GFP, see figure 3.16B. 
In figure 3.16C, C2C12 and HEK293 cells were then transfected with Kir6.1-GFP before 
they were  loaded  with  TMRE.  Cells were also transfected with  either Kir6.1-GFP  or 
Kir6.1-GFP and SURl.  C2C12 and HEK293 cells were packed with mitochondria after 
loading with 50 nM TMRE with mitochondria observed as thin structures.  TMRE is a 
membrane  potential  sensitive  dye  and  Kir6.1  overexpression  may  have  caused 
mitochondrial depolarisation decreasing TMRE fluorescence which in effect would be a 
problem when interpreting data.
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Figure 3.16.  Investigating the distribution of Kir6.1 in mitochondria.
A.  C2C12 cells were also transfected with just Mito DsRed probe; this was not a stable 
probe to use as Mito Ds-Red also fluoresced in the green channel if it was imaged less than 
36 hours after transfection (left image).  The green product is the immature form of the 
protein.  The red product was visible between 36-48 hours (right image).
B.  HEK293 and C2C12 cells were loaded with 50 nM TMRE for 30 minutes at 37°C 
before confocal analysis.  The mitochondria appear as small distinct structures.
C.  C2C12  cells  were transfected  with  Kir6.1-GFP prior loading with  50  nM  TMRE. 
There is a small amount of colocalisation in mitochondria.  However, there is very little 
overlap of signals in HEK293 cells
Using  TMRE  was  technically  difficult  and  labelling  mitochondria  was  not  always 
successful because they appeared to depolarise, therefore the next approach was to use to
127another mitochondrial probe called MitoTracker Red to examine this further.  See figure
3.17.
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Figure 3.17.  Investigating the distribution of Kir6.1  using mitotracker red.
A.  HEK293 and C2C12 cells were loaded with 150 nM Mitotracker Red for 30 minutes at 
37°C before confocal analysis.  B.  C2C12 cells were transfected with Kir6.1-GFP prior to 
loading with Mitotracker Red.  The signals show little overlap and the same overlap of 
signals  is observed in cells transfected  with  SURl  in C.  where C2C12 cells were co­
transfected with SURl before they were loaded with Mitotracker Red.
128In figure 3.17A, the mitochondria in C2C12 and HEK293 cells were loaded with 150 nM.
The images in figure 3.17B show that there was some overlap between MitoTracker Red
and Kir6.1-GFP,  although not all cells were successfully transfected  and  labelled  with
both fluorescent probes but there is a higher proportion of resulting yellow pixels in the
merged images.  The proportion of colocalisation between Kir6.1-GFP and MitoTracker
Red  signals  in  cells  co-transfected  with  SURl  in  figure  3.17C  were  not  significantly
different to the cells in figure 3.17B.  Therefore, these results obtained using MitoTracker
Red were analysed.  In comparison, the proportion of colocalisation in mitochondria was
significantly lower in comparison to colocalisation experiments with DsRed2-ER marker.
Figure 3.18.  The proportion of 
Kir6.1  colocalisation in 
mitochondria in C2C12 cells.
A graph to show the proportion 
of Kir6.1  that colocalises with 
Mitotracker Red n= 36 and  in 
the  presence  of SURl  n=  17. 
The statistical analysis showed 
that  the  data  were  significant 
for  Kir6.1-GFP  and
Mitotracker  Red  and  when 
Kir6.1-GFP was co-transfected 
with  SURl  when  p<0.001 
(***)
The graph in  figure 3.18 shows that the median value for cells transfected with Kir6.1- 
GFP was 25 % (first column) and  14 % in the presence of SURl  (third column).  The 
presence of SURl  subunit did  not  promote the distribution  of Kir6.1  to  mitochondria. 
However, the proportion of colocalisation between Kir6.1-GFP and DsRed2-ER signals 
was significant p<0.001 (***), this result was unaffected by the presence of SURl.
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129The distribution of Kir6.1  was  investigated  using transient transfections  in  C2C12 and 
HEK293 cell  lines.  Kir6.1  was evenly distributed in both cell  lines but predominately 
expressed  in  the  ER.  About  28  %  of Kir6.1  was  retained  in  C2C12  cells  whilst  in 
HEK293 cells; it was higher at 50 %.  One explanation for this difference may be because 
HEK293 cells contain very little endogenous Kir6.1  so the transfected protein would be 
evenly distributed throughout the cell.  My data also indicate that Kir6.1 could be present 
in other subcellular compartments such  as mitochondria or perhaps nuclear membrane. 
In  the  presence  of SURl,  Kir6.1  was  perhaps  expected  to  translocate  to  the  plasma 
membrane.  However, both cell  lines showed no clear membrane staining.  Kir6.1  and 
SURl  may  associate  but not as efficiently  as  Kir6.2  and  SURl  because  Kir6.1/SUR1 
type channels do  form  as the plasma  membrane {Liu et al 2001).  In addition  to this, 
Kir6.2 and SURl  have been expressed together in one study to mask the RKR retention 
signal  on  both  subunits therefore promoting the trafficking of the  K a t p   channel  to the 
plasma membrane (Zerangue et al 1999).
The  K a t p   channel  will  only  migrate  to  the  plasma  membrane  when  the  ER  retention 
signal RKR motif is masked on both subunits.  This process is important because it acts 
like  a molecular chaperone to  ensure that  proteins  are correctly  folded  and  assembled 
before they reach  their target destination  (Klausner &  Sitia  1990).  My  colocalisation 
studies showed that co-transfection with  SURl  did not significantly change the results. 
However,  staining  for  natively  expressed  SURl  has  also  been  completed  in  our 
laboratory with this particular plasmid.  The HEK293 and C2C12 cell lines co-transfected 
with Kir6.1-GFP and SURl  showed that the same proportion of Kir6.1  is still retained in 
the ER.  Furthermore, our group were able to carry out some studies in  HEK293  cells 
expressing Kir6.2-GFP and SURl  and this was trafficked to the cell membrane and not 
ER retained with distinct membrane currents (Cui &  Tinker,  unpublished observations). 
See Figure 3.19.  This also showed that Kir6.1  fluorescently tagged to GFP did not affect 
the trafficking of mature K a t p  channel to the plasma membrane.
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Figure 3.19.  KA T p channel activity in HEK293 cells transfected with Kir6.1-GFPand SUR2B.
Cells were stimulated with 0.3  mM diazoxide and channel activity was  inhibited with  10 pM 
glibencl amide.  (The data was kindly provided by Professor Andrew Tinker).
The  investigation  was  taken  one  step  further  to  examine  if  Kir6.1  was  present  in 
mitochondria as suggested by several  investigators (Zhou et al 2005; Lacza et al 2003a, 
2003b;  Suzuki  et  al  1997).  After  preliminary  work,  MitoTracker  Red  was  used  for 
colocalisation studies because in my hands, using the Mito DsRed probe in our cell lines 
along with Kir6.1-GFP was problematic.  Transfecting cells with just mitoDs Red alone 
produced green fluorescence in control cells without Kir6.1-GFP.  With MitoTracker Red 
it  diffuses  readily  across  the  plasma  membrane  readily  and  accumulates  in  active 
respiring  mitochondria,  which  oxidises  the  dye  into  a  fluorescent  conjugate.  This 
produced  better images and was technically an easier probe to  use than  TMRE.  After 
statistical analysis,  my results showed that a small  but significant proportion of Kir6.1 
may exist in mitochondria.  Given these observations, the next step was to examine the 
distribution of natively expressed Kir6.1  in immortalised cell lines in chapter 3.3.
1313.3  Investigating the endogenous expression of Kir6.1:  Kir6.1  is predominantly 
expressed in the ER
To  investigate  whether  exogenous  GFP  labelled  protein  Kir6.1-GFP  influences  the 
distribution of Kir6.1, it was essential to determine the endogenous expression of Kir6.1. 
Immunofluorescent  staining  was  carried  out  in  conjunction  with  colocalisation 
experiments so that I could compare the distribution of endogenously expressed Kir6.1  in 
native  cells  and  in  cells transiently transfected  with  the  protein.  The  distribution  of 
Kir6.1  was examined in HepG2, C2C12, HL-1  and HEK293 cell lines with the Kir6.1 
MBP antibody, which was characterised in chapter 3.1.  I also investigated the expression 
of  Kir6.1  in  rat  ventricular  myocytes  and  these  cells  were  also  co-stained  with 
Concanavalin  A-FITC  (Con  A  FITC).  This  is  a  lectin  that  predominantly  binds  to 
glycosylated proteins in the ER.  The cells were first grown on coverslips, before they 
were  stained  and  fixed onto  slides  for confocal  analysis  with  an  upright  microscope. 
Please refer to chapter 2.8.
3.3.1  Kir6.1  is endogenously expressed in cardiac, liver and skeletal muscle cells
Control experiments were set up using wild type HEK293 cells and the stable line HEK 
Kir6.1/SUR2B to determine the sensitivity of MBP-Kir6.1C (93A) antibody.  Kir6.1 was 
detected  with  a  rhodamine conjugated  goat anti  rabbit secondary antibody,  see  figure 
3.20.  As expected, the stable cell  line Kir6.1/SUR2B  showed a significant amount of 
natively expressed Kir6.1.  From my observations, Concanavalin A staining appeared to 
be membrane associated in the stable cell lines.  As expected, the antibody did not detect 
endogenous Kir6.1  in wild type HEK293 cells.  HEK293 cells are an important cell line 
to use in this part of the study because in our hands (Tinker group), immunofluorescence 
studies showed that HEK293 cells do not express endogenous Kir6.1  (and Kir6.2) (Cui et 
al 2001).
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Figure 3.20.  The distribution of Kir6.1 in HEK293 and Kir6.1/SUR2B cells.
HEK293  and  HEK  Kir6.1/SUR2B  cell  lines  were  used to act as controls  for the  MBP 
Kir6.1C  antibody (93A).  The cells were analysed  using confocal  microscopy using the 
same settings for colocalisation experiments in chapter four.
Wild type  HEK293  cells  contain  very  little endogenous  Kir6.1.  The  stable  line HEK 
Kir6.1/SUR2B was processed at the same time as HEK293 cells and the antibody detected 
Kir6.1.  Endogenous  Kir6.1  was  detected  with a rhodamine  conjugated  antibody.  The 
staining for Concanavalin A FITC is the same for both cell lines.  Concanavalin A staining 
in  the  stable  cell  line  is  more  membrane  associated;  this  may  be  the  results  of stably 
tranfecting KA T P  channel subunits.
C2C12  cells  contain  an  abundant  amount  of endogenous  Kir6.1  and  this  was  evenly 
distributed throughout the cell,  see figure 3.21.  The pre-immune sample and the 93A 
antibody fused to the MBP fusion protein were used as controls where no endogenous 
Kir6.1 was detected in both control experiments.  The images also show that C2C12 cells 
stained well with Concanavalin A FITC.  The graph  in figure 3.22  suggests that 38 % 
(Median value) of Kir6.1 was located in the ER (second column).  However, there is still 
a significant amount of Kir6.1  that may be  located  in other intracellular compartments 
such as mitochondria; this was previously discussed in chapter 3.2.  The null hypothesis
133(H0)  where  ‘ There  is  no  colocalisation  between  Kir6.1  and  Concanavalin  A  FITC 
signals' was rejected if p<0.05 (*).
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Figure 3.21.  The distribution of Kir6.1 in C2C12 cells.
Images  to  show  the endogenous distribution of Kir6.1  in  C2C12  cell  line  using  MBP- 
Kir6.1C antibody (93A) and ER marker, Concanavalin A FITC.  The controls used were 
pre-immune sample and MBP-fusion protein bound to the antibody.
The images show that the C2C12 cells contain endogenous Kir6.1; Kir6.1  is predominately 
located in the ER.  The controls show no Kir6.1 staining with 93A pre-immune sample and 
93A + MBP-fusion protein, whereas staining with Concanavalin A FITC is consistent in all 
of the experiments.
134Figure 3.22.  The proportion 
of Kir6.1 and ER 
colocalisation in C2C12 
cells.
A  graph  to  show  the 
proportion  of  colocalisation 
between Kir6.1 using a MBP 
Kir6.1 C antibody (93A) and 
endoplasmic  reticulum 
marker  Con  A  FITC  in  n= 
25.  Statistical  analysis 
showed  that  the  data  were 
highly  significant  when
p<0.001 (***)
The images in figure 3.23 show that the HepG2 cell line contains higher levels of natively 
expressed Kir6.1, the staining for Concanavalin A FITC is similar to the C2C12 cell line. 
In the merged image, there is a significant proportion of colocalisation between the green 
(ConA FITC) and red pixels (The MBP-Kir6.1  C antibody).  The controls in figure 3.23 
also  confirm  that the  MBP-Kir6.1  C  antibody  is  sensitive  for Kir6.1  because the  pre- 
immune  93A  and  MBP-Kir6.1C  antibody  incubated  with  MBP-fusion  protein  did  not 
detect Kir6.1.  The graph in figure 3.24  indicates that 48 % of Kir6.1  was expressed in 
the ER (second column).  This result is highly significant p<0.001  (***) confirming that 
a large amount of Kir6.1 does exist in the ER in liver cells
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Figure 3.23.  The distribution of Kir6.1 in HepG2 cells.
Images  showing the  endogenous  distribution  of Kir6.1  in  HepG2  cell  line  using  MBP 
Kir6.1C antibody (93A) and endoplasmic reticulum marker Concanavalin A FITC.  The 
same controls were used here as in figure 3.21.
The HepG2 cell line contains high levels of endogenous Kir6.1 which colocalises with the 
ER marker in the merged image.  The controls show that no Kir6.1   was detected with the 
93A pre-immune sample and 93A + MBP-fusion protein. The staining with Concanavalin A 
FITC is consistent in all experiments.
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Figure 3.24.  The proportion 
of Kir6.1 and ER 
colocalisation in HepG2 
cells.
A  graph  to  show  the 
proportion  of colocalisation 
between  Kir6.1  using  a 
MBP-Kir6.1  C antibody 93 A 
and  endoplasmic  reticulum 
using  Con  A  FITC  n=  30. 
The  data  were  highly 
significant  when  p<0.001  
(***).
The initial aim was to stain H9C2 (derived from embryonic rat heart) in conjunction with 
C2C12  skeletal  muscle  cells  because  they  could  also  be  differentiated  into  a  more 
muscular phenotype with trans retinoic acid treatment {Menard et al.  1999).  However, 
H9C2 cells were difficult to transfect after a few months in culture; I then studied HL-1 
cardiomyocytes  because  these  cells  were  reported  to  be  good  cellular  models  for 
preconditioning and were able to spontaneously contract whilst maintaining their cardiac 
phenotype  {White  et al.  2004).  The  HL-1  cardiomyocytes  were  also  subjected  to the 
same protocol  to examine whether they contained  Kir6.1.  I  found that they expressed 
high levels of Kir6.1, which was evenly distributed throughout the cell, see figure 3.25. 
The merged  image shows that there was also a significant proportion of colocalisation 
between Kir6.1  and Concanavalin A FITC pixels.  The yellow pixels exist in the ER but 
as the images suggests, a small proportion of Kir6.1  may be located elsewhere, perhaps at 
the plasma membrane as well.  I  found that the pre-immune sample  for 93A  and  93A 
incubated  with  the  MBP  fusion  protein  did  not  detect  any  Kir6.1  in  HL-1 
cardiomyocytes.  The  graph  in  figure  3.26  suggests  that  the  degree  of colocalisation 
between the two signals is high p<0.001  (***).  This is reflected in the statistics because 
the median value showed that 46 % of the ER pixels colocalise with Kir6.1  pixels (see 
first column).
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Figure 3.25.  The distribution of Kir6.1 in HL-1 cardiomyocytes.
Images showing the endogenous distribution of Kir6.1 in HL-1 cardiomyocytes using Kir6.1 
antibody  (93A)  and  endoplasmic  reticulum  marker  Concanavalin  A  FITC.  The  same 
controls were used here as in figure 3.20
The images show that the HL-1 cardiomyocytes contain endogenous Kir6.1 as in the HepG2 
cell line and this channel subunit does colocalise with the endoplasmic reticulum marker. 
The controls show no Kir6.1   staining was observed with the 93A pre-immune sample and 
93A + MBP-fusion protein, staining with Concanavalin A FITC remains the same.
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Figure 3.26.  The proportion 
of Kir6.1 and ER 
colocalisation in HL-1 
cardiomyocytes.
A  graph  to  show  the 
proportion  of  colocalisation 
between Kir6.1 using a MBP 
Kir6.1  C  antibody  93A  and 
endoplasmic reticulum using 
Con  A  FITC  n=  28.  The 
data were  highly  significant 
when pO.OOl (***).
So far I have detected the endogenous distribution of Kir6.1   in three different cell lines 
(C2C12, HepG2 and HL-1  cardiomyocytes).  The majority of Kir6.1  was located in the 
ER  (using  MBP-Kir6.1C  antibody)  with  a  small  proportion  perhaps  existing  in  other 
cellular compartments, such as mitochondria.  At the beginning of my PhD, one antibody 
for Kir6.1  was already available for me to perform my colocalisation studies but my own 
contribution  was  the  purification  of the  MBP-Kir6.1C  antibody  (93A).  The  Kir6.1C 
(78A)  affinity  purified  antibody  was  previously  purified  in  our  group  but  I  also 
characterised this antibody as described  in  chapter 3.1.  However,  the affinity purified 
Kir6.1C antibody was used by others in our group hence the acid fractions were in very 
short  supply.  Therefore  the  MBP-Kir6.1C  antibody  (93A)  (which  was  purified  and 
characterised  by  me)  was  used  throughout  this  chapter  to  detect  native  Kir6.1  as  I 
managed to purify a significant amount of this antibody.
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Figure 3.27.  The distribution of Kir6.1 in HepG2 cells.
Images to show the endogenous distribution of Kir6.1  in HepG2 cell line using Kir6.1C 
(Affinity purified) antibody 78G and Concanavalin A FITC.  The 78G pre-immune sample 
was used as the control and slides were analysed as described in figure 3.20.  This second 
antibody confirms that there is endogenous Kir6.1 in the HepG2 cell line.
During the purification  process, the antibody  is usually  present  in  acidic  fractions but 
there is also a possibility it is present in the guanidine fractions (which was also stored). 
The concentration of this antibody would be lower in the guanidine fractions so a higher 
concentration of the Kir6.1C (78A) affinity purified antibody was used to detect natively 
expressed  Kir6.1.  This antibody was able to detect a  significant amount of Kir6.1  in 
HepG2 cells, see figure 3.27.  In addition to this, the control experiment show that Kir6.1 
was  not  detected  with  the  pre-immune  sample  (78PI).  The  statistics  in  figure  3.28 
indicates that there was significant colocalisation between Kir6.1  and ER pixels p<0.001 
(***).  About 50 % of Kir6.1 was expressed in the ER.
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Figure 3.28.  The proportion of 
Kir6.1  and ER colocalisation in 
HepG2 cells.
A graph to show the proportion 
of  colocalisation  between 
Kir6.1  and  the  endoplasmic 
reticulum  using  a  affinity 
purified  Kir6.1C  antibody
(78G)  and  endoplasmic
reticulum marker Concanavalin 
A FITC  n= 29.  The data were 
highly  significant  when
pO.OOl (***).
In  summary,  I  have  confirmed  that  cardiac  and  skeletal  muscle  cell  lines  contain  an 
abundant  amount  of natively  expressed  Kir6.1,  which  is  mostly  expressed  in  the  ER. 
Despite this observation, there is a small but rather significant proportion of Kir6.1 that is 
unaccounted  for which  may be  located  in other intracellular compartments such as the 
mitochondria.  I then decided to explore this further by using a marker for mitochondria 
called  as  cytochrome  C  oxidase  (complex  IV)  as  this  is a  component  of the  electron 
transport  chain  involved  in  oxidative  phosphorylation.  The  MBP-Kir6.1C  antibody 
(93A)  is  a  reliable  tool  as  I  had  previously  set  up  suitable  controls  to  detect  Kir6.1. 
However,  I  decided  for  this  particular  experiment  to  also  use  the  affinity  purified 
antibody Kir6.1C (78G) to stain for Kir6.1.  In my hands, this antibody was more specific 
than the MBP-Kir6.1C antibody because it only detected a 48 kDa band corresponding to 
the molecular weight of Kir6.1  (see chapter 3.1).  The endogenous expression of Kir6.1 
and cytochrome oxidase in skeletal muscle and liver cell lines is shown in figure 3.29.
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Figure 3.29.  The distribution of Kir6.1 in mitochondria.
Images to show the endogenous expression of Kir6.1 and cytochrome C oxidase in C2C12 
and HepG2 cell line.  I used Kir6.1C (78G) antibody and mouse monoclonal cytochrome C 
oxidase as the marker for mitochondria.  The secondary antibody used to identify Kir6.1 
was a rhodamine conjugated goat anti-rabbit antibody and a FITC conjugated donkey anti­
mouse antibody was used to detect cytochrome C oxidase.
The liver and skeletal muscle cell  lines stained for cytochrome C oxidase in particular, 
the protein in C2C12 cell line is evenly distributed throughout the cell whereas in HepG2 
cells,  the  signal  for cytochrome  C  oxidase  is  more  granular  and  randomly  distributed 
throughout the cytoplasm.  The proportion of colocalised yellow pixels in the C2C12 cell 
line is high as shown in the merged image.  HepG2 cells are active cells and contain lots 
of mitochondria  and  interestingly;  the  mitoKATP channel  was  originally  isolated  from 
mitochondria  in  this  cell  line  (lnoue  et  al  1991).  The  proportion  of colocalisation 
between  Kir6.1  (red) and cytochrome C oxidase pixels (green) was significant for both
142cell lines.  The results in figure 3.30 show that about 65 % (second column) of Kir6.1 was 
present in  mitochondria in C2C12 cells where the degree of colocalisation was highly 
significant p<0.001  (***).  The merged  image for the HepG2 cell  line  is displayed  in 
figure 3.28 and shows that a fraction of Kir6.1  does not colocalise in the mitochondria 
and remains cytoplasmic.  Despite this, about 30 % of Kir6.1  pixels exist in mitochondria 
as indicated by the second column in figure 3.31.  The colocalisation between Kir6.1 and 
mitochondria in HepG2 cells was also significant when pO.OOl  (***).
Figure 3.30.  The proportion of 
Kir6.1 colocalisation in 
mitochondria in C2C12 cells.
A graph to show the proportion 
of  colocalisation  between 
mitochondria and Kir6.1   using a 
affinity  purified  Kir6.1C 
antibody (93A) and cytochrome 
C oxidase antibody n= 17.  The 
data  were  significant  when 
pO.OOl (***).
Figure 3.31.  The proportion of 
Kir6.1  colocalisation in 
mitochondria in HepG2 cells.
C.  A  graph  to  show  the 
proportion  of  colocalisation 
between  mitochondria  and 
Kir6.1   using a affinity purified 
Kir6.1C  antibody  (93A)  and 
cytochrome  C  oxidase 
antibody n= 22.  The data were 
significant  when  pO.OOl 
(***).
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Figure 3.32.  The distribution of Kir6.1 in cardiac myocytes.
Images to  show the endogenous distribution of Kir6.1  using  MBP-Kir6.1C  (93A)  in  rat 
ventricular myocytes.  The cardiomyocytes do not contain Kir6.1.  However, these cells are 
rich  in  mitochondria  (using  cytochrome  C  oxidase  as  the  marker)  and  contain  ER 
(Concanavalin A FITC).  The affinity purified antibody was no longer available at this stage 
of the project so we were not able to repeat this experiment with this tool.
Finally, based on the notion that mitoKATP channel may be involved in cardioprotection 
and that Kir6.1  may be a possible component of this channel, I decided to examine the 
expression of Kir6.1   in freshly isolated rat ventricular myocytes.  These cells were also 
were a kind  gift from  Dr.  Sean Davidson  {Hatter institute,  UCL,  London).  See figure 
3.32.  The myocytes stained well for the ER and cytochrome C oxidase but I was unable 
to  detect  Kir6.1  using the  MBP-Kir6.1C  antibody  (93A) this  could  be  because  Kir6.1 
expression  may  be  below  detectable  levels.  Although  this  antibody  could  not  detect 
Kir6.1  in rat myocytes, earlier, I was able to detect Kir6.1  in rat HL-1 cardiomyocytes.
1443.4  Investigating reactive oxygen species production in immortalised cell lines
Kir6.1  is mainly expressed in intracellular membranes such as the ER and to  some 
extent in mitochondria.  Therefore, the next objective of this thesis was to examine the 
potential function of Kir6.1  in these membranes.  One possible role is the production 
of ROS as a consequence of mitoKATP channel opening during IPC.  The mechanisms 
conferring  protection  are  poorly  understood  but  the  general  consensus  is  that 
mitoKATP channel opening promotes mitochondrial matrix swelling, conserves ATP 
reserves  and  ROS  production.  It  is  therefore  essential  to  establish  whether  ROS 
production is linked to K atp channel activity in cells that express Kir6.1  (C2C12 and 
HepG2) and cells that do not (HEK293).  Using pharmacological compounds to assess 
the role of K atp channels, the ROS assay was set up to examine whether diazoxide 
could  increase  ROS  production  in  these  immortalised  cell  lines  and  whether 
glibenclamide could abolish this response.
3.4.1  Investigating the effect of diazoxide and glibenclamide on ROS production
Three experimental conditions were set up to measure ROS production.  In the control 
experiment,  a placebo  consisting of DMSO  and  PBS  was  administered  at  1   and  3 
minutes.  The control experiment was set up to demonstrate that the basal medium and 
drug solvents did not modulate the activity of K atp channels; therefore, there should 
be no significant changes in ROS production.  ROS production was then examined in 
the presence of 50 pM diazoxide and  10 pM glibenclamide.  I also investigated the 
effect of 100 pM diazoxide to assess whether ROS production was dose dependent. 
Each  experimental  condition  was  carried  out  at  least  three  times.  Please  refer to 
chapter 2.9 for methods.
The focus of this chapter was to establish whether ROS production is related to the 
expression of Kir6.1.  This was carried out by suppressing Kir6.1 protein expression 
to  probe  for  differences,  if any,  in  ROS  production  in  response  to  diazoxide  and 
glibenclamide with molecular tools such as DN and siRNA of Kir6.1.  In figure 3.33, 
a typical  trace  measuring the changes  in ROS  fluorescence  from each condition is 
shown for HepG2 cells.  The raw data for each cell line and different experimentalcondition were not displayed as means + SEM because if the whole data set for each 
condition were averaged, this would obscure the results with large error bars which 
would make it difficult to observe any trends in response to the drugs.
4 0 0 0 0
- •   50pM  Diazoxide +  10pM Glibenclamide 
A   100|jM Diazoxide *  10pM Glibenclamide
3 5 0 0 0   -
3 0 0 0 0   -
s
t
2 5 0 0 0   -
20000  -
1 5 0 0 0   -
10000  -
5 0 0 0   -
Diazoxide/DM SO + Buffer Glibenclamide/DlVISO +  Buffer
5 0 0 1 0 0 1 5 0
Tim e (S econds)
200 2 6 0 3 0 0
Figure 3.33.  A graph to show the raw data for HepG2 cells loaded with DCF-DA.
Three different conditions were set up and the cells were either treated with DMSO + buffer 
or diazoxide  (50  pM  or  100  pM)  followed  by  10  pM  glibenclamide.  The  fluorescence 
(arbitrary units) was measured every second.
To analyse the effect of interventions, the alteration of the rate was compared to the 
control value for each experiment using a paired t-test.  The p values that were <0.05 
were considered significant.  For graphical display, the control values are set to  100 
%, and changes are observed as percentage (%)  increase or decrease.  The data for 
ROS  production  is  displayed  in  figure  3.34.  Statistical  analyses  were  carried  out 
between the two concentrations of diazoxide as well  as differences between control 
cells and cells without Kir6.1.  Please refer to tables 3.6 and 3.7 (end of chapter).
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Figure 3.34.  Data for ROS production in HepG2 cells.
A.  A graph to show the rate of ROS production in HepG2 cells (n= 47).
B.  A graph to show the rate of ROS production in the presence of 50 pM diazoxide and 10 
pM glibenclamide in HepG2 cells (n= 48).
C.  A graph to show the rate of ROS production in the presence of 100 pM diazoxide and 10 
pM glibenclamide in HepG2 cells (n= 41).
147Figure 3.34 shows the rate of ROS production in control HepG2 cells.  The carriage 
medium consisting of DMSO + buffer was applied at 1   and 3 minutes.  It is important 
to  demonstrate  that  the  DMSO  used  to  reconstitute  diazoxide  and  glibenclamide 
would not affect ROS production.  This is true because the rate of ROS production in 
HepG2 cells was not affected by the addition of DMSO + buffer at both interventions 
p>0.05 (NS) (n= 47, figure 3.34A).  HepG2 cells treated with 50 pM diazoxide and 10 
pM  glibenclamide  showed  that  diazoxide  significantly  increased  ROS  production 
with glibenclamide abolishing this response, both are significant p<0.01  (***) (n= 48, 
figure 3.34B).  Treatment of HepG2 cells with the higher dose of diazoxide (lOOpM) 
showed the  same response where diazoxide significantly increased ROS production 
p<0.01  (**)  and  glibenclamide  blocked  it  p<0.001  (***)  (n=  41,  figure  3.34C). 
Interestingly, the decrease in ROS production was below the basal rate indicating that 
there was  some basal  K atp  dependent ROS production.  However, the rate of ROS 
production was similar between the two concentrations of diazoxide p>0.05 (f).  See 
table 3.6.
In  C2C12  cells,  similar  responses  were  observed  when  cells  were  exposed  to 
diazoxide and glibenclamide, see figure 3.35.  The cells were treated with DMSO + 
buffer  (n=  24,  figure  3.35A)  however,  the  rate  of  ROS  production  decreased 
significantly in the presence of the control buffer at each intervention, p<0.001  (***). 
C2C12 cells were then treated with 50  pM diazoxide and  lOpM glibenclamide (n= 
24, figure 3.35B).  There was a significant increase in ROS production after diazoxide 
application and this was reversed in response to  10 pM glibenclamide p<0.001  (***). 
At the higher dose of diazoxide (100 pM), ROS production also increased and 10 pM 
glibenclamide  abolished  this response  (n= 24,  figure  3.35C).  Both time points  are 
significant p<0.001  (***).  However, there was no significant difference between the 
two concentrations of diazoxide p>0.05  (€),  see table 3.6.  This may be because 50 
pM  is  sufficient to  activate  the  K atp  channels  in  question  as  this  concentration  of 
diazoxide reached the top of the dose response curve and increasing the concentration 
of diazoxide would therefore not have any further effect on ROS production.
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Figure 3.35.  Data for ROS production in C2C12 cells.
A.  A graph to show the rate of ROS production in C2C12 cells (n= 24).
B.  A graph to show the rate of ROS production in the presence of 50 pM diazoxide and 10 
pM glibenclamide in C2C12 cells  (n= 24).
C.  A graph to show the rate of ROS production in the presence of 100 pM diazoxide and 10 
pM glibenclamide in C2C12 cells  (n= 24).
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Figure 3.36.  Data for ROS production in HEK293 cells.
A.  A graph to show the rate of ROS production in HEK293 cells (n= 59).
B.  A graph to show the rate of ROS production in the presence of 50 pM diazoxide and  10 
pM glibenclamide in HEK293 cells (n= 53).
C.  A graph to show the rate of ROS production in the presence of when  100 pM diazoxide 
and 10 pM glibenclamide in HEK293 cells (n= 51).
150
999999999^The HEK293 cell line which does not express endogenous Kir6.1  was also used for 
this assay (Cui et al. 2001).  HEK293 cells recorded a steady rate of ROS production 
in the presence of DMSO + buffer at  1   and 3  minutes (n=  59,  figure  3.36A).  No 
significant changes were observed in the presence of DMSO + buffer p>0.05  (NS). 
HEK293 cells were then treated with 50 pM diazoxide and 10 pM glibenclamide (n= 
51,  figure  3.36B),  and with the higher dose of diazoxide  (100  pM)  (n=  53,  figure 
3.36C).  Both doses  of diazoxide  caused  a  significant  increase  in ROS  production 
p<0.001  (***)  and  these  effects  were  abolished by  10  pM  glibenclamide  p<0.001 
(***).  The  presence  of  glibenclamide  significantly  reduced  the  rate  of  ROS 
production in both experiments i.e. lower than the basal rate.  In table 3.6, the rate of 
ROS production was not affected by the concentration of diazoxide p>0.05 (J).
These experiments have demonstrated that both diazoxide and glibenclamide have a 
significant effect on ROS production in these cell lines.  Diazoxide increased  ROS 
production whereas glibenclamide reduced it.  However, the data also suggests that 
Kir6.1  may  not  play  a  role  in  ROS  production.  From  earlier  colocalisation  work 
(chapter  3.2  and  3.3),  C2C12  and  HepG2  cells  express  a  large  proportion  of 
endogenous Kir6.1  however; HEK293  cells do not contain endogenous Kir6.1  (and 
Kir6.2).  Therefore in theory, in HEK293  cells, there should not be any changes in 
ROS production in response to diazoxide and glibenclamide but the data show that 
HEK293  cells produced  a significant amount of ROS  in the presence of diazoxide 
with glibenclamide abolishing this response.  This result is the same as the other two 
cells lines that do express Kir6 . 1   indicating that perhaps diazoxide and glibenclamide 
may act on other intracellular targets to produce cellular ROS.
To determine the role of Kir6.1  in diazoxide induced ROS generation, I treated my 
cells with siRNA and DN for Kir6.1 to knockdown Kir6.1  protein expression.  These 
molecular tools were previously characterised in chapter 3.1.
151The  human  form of siRNA  for  Kir6.1  was transiently transfected  into  HepG2  and 
HEK293  cell  lines  whilst  61 siRNA  duplex  2  (from  rat)  was  transfected  into  the 
C2C12 cell line.  A parallel experiment was set up where cells were co-transfected 
with eGFP so that the transfection efficiencies could be assessed, see figure 3.37.  The 
transfected cells were visualised with a UV  microscope 24 hours after transfection. 
The transfection efficiency for HepG2 cells would be higher than 30 % after 48 hours, 
however, I did not want the cells to become too confluent as this would affect the cell 
density and may obscure the results.  The transfected cells were examined again after 
36  hours  before  the  plate  containing  cells  transfected  with just  61 siRNA  (without 
eGFP) were loaded with the ROS indicator, DCF-DA.  The logic for not using cells 
transfected with both 61 siRNA and eGFP is because the  fluorophore would also be 
excited by the 488 nm laser which is intended for the DCF-DA dye.
61 siRNA 
HEPG2
1.)  eGFP+ 61 SiRNA
eGFP
C2C12
2.)  eGFP+ 61 SiRNA
HEK293
3.)  eGFP+ 61 SiRNA
Brightfield
1
x20 m a g n ific a tio n
Figure 3.37.  Images to show the cells used for ROS assay were transfected efficiently with 
siRNA for potassium channel subunit Kir6 .1.
1.)  HepG2 cells were transfected with eGFP and 61 siRNA; these cells had a transfection 
efficiency  of about  30-40  %.  The  cells  were  healthy  and  alive  after transfection,  see 
brightfield image.  2.)  C2C12 cells had a transfection efficiency of 40 %.  3.)  HEK293 
cells were also transfected with eGFP and 61 SiRNA but had 90 % transfection efficiency.
152To  explore  the  possible  role  of  Kir6.1  in  ROS  production,  HepG2  cells  were 
transfected  with  the  human  form  of siRNA61,  see  figure  3.38.  These  cells  were 
treated with 50 pM or 100 pM diazoxide and 10 pM glibenclamide (both n= 24).  In 
figure 3.38A, there was an increase in ROS production from basal levels in response 
to  50  pM diazoxide p<0.05  (*) with glibenclamide blocking this response p<0.001 
(***).  In  figure  3.38B,  100  pM  diazoxide  also  increased  ROS  production  and 
glibenclamide  significantly  decreased  ROS  production  p<0.001  (***).  Statistical 
analysis  showed  that  there  was  no  significant  difference  between  the  two 
concentrations of diazoxide (tf), see table 3.6.
Basal (Control)  50  Diazoxide  10  Glibenclamide
Basal (Control)  100  Diazoxide  10  Glibenclamide
Figure 3.38.  Data for ROS production in HepG2 cells without Kir6 .1.
A.  A graph to show the rate of ROS production in HepG2 cells transfected with siRNA for 
Kir6.1 in the presence of 50 pM diazoxide and 10 pM glibenclamide (n= 24).
B.  A graph to show the rate of ROS production in HepG2 cells transfected with siRNA for 
Kir6.1 in the presence of 100 pM diazoxide and 10 pM glibenclamide (n= 24).
153The  effects  of diazoxide  and  glibenclamide  were  also  examined  in  C2C12  cells 
transfected with 61 siRNA duplex 2 (both n= 24, figure 3.39).  In figure 3.39A, 50 pM 
diazoxide significantly increased ROS production with glibenclamide abolishing this 
response  p<0.001  (***).  This  is  a  big  increase  compared  to  control  C2C12  cells 
which contain Kir6.1,  see  figure  3.35.  The higher dose  of diazoxide (100  pM)  in 
figure 3.39B also increased ROS production but this was similar to the lower dose of 
diazoxide  (50  pM)  (€€),  see  table  3.6.  In  figure  3.39B,  glibenclamide  reversed 
diazoxide induced ROS production p<0.001 (***).  The data suggest that the absence 
of Kir6.1 may increase the cells’ sensitivity to diazoxide but also questions the role of 
K atp  channels, particularly the mitoKATP channel.  These pharmacological compounds 
may modulate other mechanisms that contribute to cellular ROS production.
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Figure 3.39.  Data for ROS production in C2C12 cells without Kir6 .1.
A.  A graph to show the rate of ROS production in C2C12 cells transfected with siRNA for 
Kir6.1 in the presence of 50 pM diazoxide and 10 pM glibenclamide (n= 24).
B.  A graph to show the rate of ROS production in C2C12 cells transfected with siRNA for 
Kir6.1 in the presence of 100 pM diazoxide and 10 pM glibenclamide (n= 24).
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8282The previous data in HEK293 cells suggested that these pharmacological compounds 
have a significant effect on ROS production which is independent of K a tp  channels. 
HEK293 cells were also transfected with human 61 siRNA, see figure 3.40.  HEK293 
cells treated  with  50  pM  diazoxide significantly  increased  ROS  production and  10 
pM glibenclamide abolished this effect p<0.001  (***) (n=  24,  figure  3.40A).  The 
higher  dose  of diazoxide  showed  a  similar  response  (n=  24,  figure  3.40B).  The 
addition  10 pM glibenclamide significantly reduced ROS production p<0.001  (***). 
However, the rate of ROS production was not affected by the two concentrations of 
diazoxide ({J), see table 3.6.
Basal (Control)  50  Diazoxide  10  Glibenclamide
Basal (Control)  100  Diazoxide  10  Glibenclamide
Figure 3.40.  Data for ROS production in HEK293 cells without Kir6.1.
A.  A graph to show the rate of ROS production in HEK293 cells transfected with siRNA for 
Kir6.1 in the presence of 50 pM diazoxide and 10 pM glibenclamide (n=24).
B.  A graph to show the rate of ROS production in HEK293 cells transfected with siRNA for 
Kir6.1 in the presence of 100 pM diazoxide and 10 pM glibenclamide (n=24).
155The  data  show  that  diazoxide  promoted  ROS  production  whereas  glibenclamide 
inhibited this response.  HEK293 cells do not contain endogenous Kir6.1  but showed 
a response to diazoxide suggesting that Kir6.1  probably does not have a role in ROS 
production.  Moreover, the absence of Kir6.1  in cells transfected with 61 siRNA did 
not affect the rate of ROS production.  These results show that the responses observed 
in cells transfected with 61 siRNA were independent of Kir6.1  and diazoxide-induced 
ROS  production  may  involve  other  cellular  mechanisms.  To  confirm  this  finding, 
C2C12 cells were transfected with DN forms of Kir6.1, called 61DN G— >A or 61DN 
G-»S.  These were co-transfected with eGFP so that the transfection efficiency could 
be  quantified.  Figure  3.41  contains  examples  of these  transfections  with  the  DN 
forms of Kir6 .1.  It must be noted that these cells were not used in the assay because 
eGFP  would  interfere  with  ROS  measurements.  Therefore,  separate  plates  were 
prepared in parallel and these cells were transfected with 61DN G— >A or 61DN G— >S 
only.  These cells were used for the ROS assay.
C2C12
eGFP + 61DN G-»A
eGFP + 61 DN G— »S
x20  m a g n ific a tio n
Figure 3.41.  C2C12 cells transfected with dominant negatives for Kir6.1
Images  to  show  the  C2C12  cell  were  transfected  efficiently  with  dominant  negative  for 
potassium channel subunit Kir6.1.  The brightfield images show that the cells were healthy 
after transfection.  C2C12 cells transfected with eGFP and DN for Kir6.1  G— »A substitution 
and Kir6 .1  G— >S substitution.  The transfection efficiency was approximately 50%.
eGFP Brightfield
156In  figure  3.42,  C2C12  cells  were  transfected  with  61DNG— »A  before  they  were 
treated with 50 pM or 100 pM diazoxide and 10 pM glibenclamide.  The lower dose 
of diazoxide  (50  pM)  caused  a  significant  increase  in  ROS  production  (100  %) 
p<0.001  (***)  with  10  pM  glibenclamide abolishing this effect p<0.01  (*)  (n=  19, 
figure 3.42A).  C2C12 cells treated with the higher dose of diazoxide (100 pM) also 
showed the same response (n=  17, figure 3.42B).  The addition of both drugs were 
highly significant p<0.001  (***).  In table 3.6, the stimulatory effect of diazoxide was 
not  dose  dependent  (#)  but  both  experiments  show  that  the  inhibitory  effect  of 
glibenclamide reduced ROS production below basal levels.
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Figure 3.42.  Data for ROS production in C2C12 cells transfected with dominant negatives for 
Kir6 .1.
A.  A graph to show the rate of ROS production in C2C12 cells transfected with transfected 
with 61DNG->A in the presence of 50 pM diazoxide and 10 pM glibenclamide (n= 19).
B.  A graph to show the rate of ROS production in C2C12 cells transfected with transfected 
with 61DNG->A in the presence of 100 pM diazoxide and 10 pM glibenclamide (n= 17).
157In figure 3.43, C2C12 cells treated with 61DN G->S also showed the same response 
to diazoxide and glibenclamide.  Both concentrations of diazoxide (50  pM and  100 
pM)  significantly  increased the rate of ROS  production with  10  pM  glibenclamide 
inhibiting the stimulatory effects of diazoxide p<0.001 (***) (n= 16, figure 3.43 A and 
n=  17, figure 3.43B).  The concentration of diazoxide did not affect the rate of ROS 
production (f), see table 3.6.  These experiments show that Kir6.1  is not involved in 
mediated ROS production as suppressing Kir6.1  protein expression did not alter the 
cells’  response to these compounds.  The results  in this chapter are  summarised  in 
table 3.6.  Statistical analyses were carried out to test for significant differences in i) 
the rate of diazoxide induced ROS  production and ii) and ROS  production in cells 
with and without Kir6.1, see table 3.7.
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Figure 3.43.  Data for ROS production in C2C12 cells transfected with dominant negatives for 
Kir6 .1.
A.  A graph to show the rate of ROS production in C2C12 cells transfected with transfected 
with 61DNG->S in the presence of 50 pM diazoxide and 10 pM glibenclamide (n= 16).
B.  A graph to show the rate of ROS production in C2C12 cells transfected with transfected 
with 61DNG— >S in the presence of 100 pM diazoxide and 10 pM glibenclamide (n= 17).
158Table 3.6.
A table to summarise the average % increase or decrease in ROS production in the presence 
of 50 pM or 100 juM diazoxide and  lOpM glibenclamide in control and transfected C2C12, 
HepG2 and HEK293 cells.  The results are presented as means ± SEM.
Cell Type Average  %  increase  in  ROS 
production  in  the  presence  of 50 
pM or 100 pM diazoxide
Average  %  decrease  in  ROS 
production  in  the  presence  of  10 
pM glibenclamide
HepG2 (50 pM) + 25.0 ± 5.9  t . 44.0 ± 4.2
(100 pM) + 27.9 ±8.0 - 46.87 ± 4.6
C2C12 (50 pM) + 52.3 + 5.0  € -42.45 + 3.5
(100 pM) + 65.3+ 6.3 - 52.03 + 4.3
HEK293 (50 pM) + 79.4 ± 11.5  X - 37.44 ± 6.7
(100 pM) + 86.3 ± 10.1 -40.15 ±5.4
HepG2 + (50 pM) 120.6 ±7.9  ft -59.35 ±3.5
61 siRNA (100 pM) 135.5 ±3.7 - 53.27 ± 4.6
C2C12 + (50 pM)+ 121.2 ±4.1  €€ -  19.50 ±4.9
61 siRNA (100 pM )+129.7 ±7.8 -22.51 ±5.0
HEK293 + (50 pM) + 74.6 ± 8.2  X t -46.12 ±8.6
61 siRNA (100 pM) + 67.8 ±6.7 - 20.92 ± 8.6
C2C12 + (50 pM) + 98.7 ± 13.1  # - 54.14 ± 19.1
DNG-»A (100 pM)+ 101.6± 10.5 - 67.57 ± 6.0
C2C12 + (50 pM) + 90.1 ± 10.5 - 73.23 ± 3.0
DNG->S (100 pM) + 78.1 ± 13.3 -60.11 ±4.7
f HepG2 50 pM vs. 100 pM diazoxide, ns p>0.05.
X  HEK293 50 pM vs. 100 pM diazoxide, ns p>0.05. 
tf HepG2 + 61 siRNA 50 pM vs. 100 pM diazoxide, ns p>0.05. 
€€ C2C12 + 61 siRNA 50 pM vs. 100 pM diazoxide, ns p>0.05. 
f%  HEK293 + 61 siRNA 50 pM vs. 100 pM diazoxide, ns p>0.05 
# C2C12 + DNG-»A 50 pM vs. 100 pM diazoxide, ns p>0.05.
If C2C12 + DNG— >S 50 pM vs. 100 pM diazoxide, ns p>0.05.
Table 3.7.
A table to show the significant differences in ROS production in cells expressing Kir6 .1   and 
in cells without Kir6 .1.  If p<0.001, the data are highly significant (***).
Control vs. transfected cells SO pM Diazoxide 10 pM Glibenclamide
C2C12 vs. C2C12 +61siRNA ♦** ***
C2C12 vs. C2C12 DNG-»A *** NS
C2C12 vs. C2C12 DNG->S ***
HepG2 vs. HepG2 + 61 siRNA NS *
HEK293 vs. HEK293 + 61 siRNA NS NS
159To  summarise,  I  have  demonstrated  that  the  KCO  diazoxide  increased  ROS 
production and  inhibitor  glibenclamide  abolished this  effect  in  C2C12,  HepG2  and 
HEK293  cell  lines.  Diazoxide  increased  ROS  production  at  both  concentrations 
however;  there  were  no  significant  differences  between  the  two  concentrations  of 
diazoxide.  In C2C12 cells transfected with siRNA and DN for Kir6.1, the stimulatory 
effect of diazoxide and inhibitory effect of glibenclamide were pronounced compared 
to control C2C12 (apart from DNG— »A, where the response of both transfected and 
non transfected C2C12 cells to 10 pM glibenclamide were similar).  For HEK293 and 
HepG2 cells, the stimulating effect of diazoxide on ROS production was the same in 
cells expressing Kir6.1  and in cells without Kir6.1.  HepG2 cells lacking Kir6.1  were 
more sensitive to glibenclamide but the response was similar in HEK293 cells.
The  data  suggest  that  these  pharmacological  compounds  will  modulate  other 
mechanisms  that  may  lead  to  ROS  production.  The  mitoKATP  channel  has  been 
hypothesised  to  be  involved  in  preconditioning  by  generating  protective  levels  of 
intracellular  ROS,  which  act  as  messengers  that  trigger  other  pathways  leading  to 
protection.  My  results  show  that  Kir6.1  is  not  involved  in  ROS  production  in 
immortalised  cells  lines  suggesting  that  the  responses  were  independent  of Kir6.1. 
While Kir6.1  may not be accountable  for the changes  in ROS  levels,  my cell  lines 
may  contain  K atp  channels  composed  of Kir6.2.  However,  there  is  no  concrete 
evidence to  suggest that ROS production is linked to  sarcKATp channels and Kir6.2 
had  not  been  put  forward  as  a  component  of the  mitoKATP  channel.  The  likely 
explanation for these results is that both diazoxide and  glibenclamide possess  K atp 
channel independent effects that can modulate ROS production.
1603.5  Investigating the changes in mitochondrial redox state and mitochondrial
membrane potential (Animl in C2C12 cells and rat ventricular mvocvtes
The ATP-sensitive potassium subunit Kir6.1  is predominantly distributed in the ER in 
cardiac  and  skeletal  muscle  cell  lines  with  a  small  but  significant  proportion  in 
mitochondria.  In my hands, I was not able to detect endogenous Kir6.1 in rat isolated 
ventricular myocytes.  The  objective  of this chapter was to  examine the  effects  of 
KCOs  and  inhibitors  on  mitochondria  in  these  cells.  Using  confocal  analysis,  I 
examined  mitochondrial  function  by  measuring  the  changes  in  flavoprotein  and 
NADH autofluorescence and mitochondrial membrane potential (Av|/m ) in C2C12 cells 
and rat ventricular myocytes.  The myocytes were generously provided by Dr.  Sean 
Davidson {Hatter Institute,  UCL,  London).  These  primary cells were used for this 
study, as it would be interesting to compare differences in mitochondrial  function, if 
any, between acutely dissociated cells and immortalised cell lines.
Recently,  a  multiprotein  complex with  mitoKATP  channel  activity  was  identified  in 
mitochondrial fractions.  This consisted of SDH but Kir6.1  was reported to be absent 
from this complex {Ardehali et al.  2004).  This protein complex also exhibited K atp  
channel activity upon the addition of 100 pM diazoxide and was inhibited with 500 
pM 5-HD, 10 pM glibenclamide or 2 mM ATP.  Three-nitroproprionic acid (3-NPA), 
an  inhibitor  of  SDH,  activated  this  channel  with  5-HD  abolishing  this  response. 
Preliminary  experiments  in  our  group  showed that  primary  cardiomyocytes treated 
with  1   mM  3-NPA  and  30  pM  diazoxide  exhibited  an  increase  in  flavoprotein 
oxidation,  which  could  not  be  observed  with  3-NPA  or  diazoxide  alone  {Duehen, 
unpublished observations).  Therefore,  I decided to  test this phenomenon further to 
examine flavoprotein oxidation in the presence of 3-NPA and diazoxide and whether 
this response could be reversed by glibenclamide.
161For mitochondrial redox state measurements, cells were assessed fluorimetrically by 
measuring NADH  (blue  autofluorescence),  excited by the  364  nm laser and FAD2+ 
(green  autofluorescence)  which  was  excited  by  the  458  nm  laser  using  the  Zeiss 
LSM510  confocal  system.  A  fully  reduced  state  is  induced  by  NaCN,  and  fully 
oxidised state by FCCP.  The two variables will change reciprocally.  The cells were 
first  calibrated  with  NaCN  to  the  reduced  state,  indicated  by  an  increase  in  blue 
autofluorescence and a decrease  in green autofluorescence.  NaCN was washed out 
and  the  addition  of  FCCP  stimulated  respiration  producing  maximal  oxidation, 
indicated  by  an  increase  in  green  autofluorescence  and  decrease  in  blue 
autofluorescence.  Calibrations were carried out so that specific  redox  signals were 
measured.  The images presented in 3.5.1  with the two variables will be shown as a 
merged image.  The data from this chapter will not include results from HEK293 and 
HepG2  cells  because  in  preliminary  experiments,  the  signal  could  not  be  detected 
making it technically difficult to take measurements from these cells.
The Ai|/m  was examined  using a mitochondrial  dye called TMRM.  For each set of 
experiments,  a region of interest (ROI) was selected from each cell  in the field and 
data for NADH and FAD2+ (and TMRM) fluorescence were saved as text files before 
they  were  imported  into  Origin  6.0  for  further  analysis.  From  here,  the  data was 
normalised and averaged so any changes in the fluorescence would be expressed as a 
percentage and changes could be quantified from the basal level (arbitrary units).  The 
data for mitochondrial redox state and TMRM fluorescence are presented as means + 
SEM.  One-way ANOVA with Dunnetts post test was used to analyse the changes in
^  I
NADH, FAD  and TMRM where each drug application was compared to the basal 
value.  Examples of each experimental condition are displayed in 3.5.1  and 3.5.2 with 
the total number of experiments indicated in brackets.  The experiments were carried 
out at least three times using different cell preparations.
1623.5.1  Mitochondrial redox state
In figure 3.44 (n= 3, total cells = 10), myocytes were treated with 100 p,M diazoxide 
and 10 pM glibenclamide.  In figure 3.44A, NADH and flavoprotein autofluorescence 
did not change throughout the whole experiment (the time in minutes are shown in 
brackets).  These  observations  are  supported  by  the  graph  in  figure  3.44B.  The 
statistical  analysis  in  figure  3.44C  and  figure  3.44D  show  that  the  diazoxide  and 
glibenclamide did not significantly alter these variables p>0.05 (NS).  The conclusion 
is that diazoxide and glibenclamide have no apparent effect on mitochondrial function 
because there  were  no  changes in NADH  and  FAD2+  autofluorescence.  However, 
other groups reported an increase in flavoprotein autofluorescence in the presence of 
100  pM diazoxide  {Sato  et al 2000;  Liu  et al  1998).  It must be  noted that these 
groups did not study flavoprotein and NADH autofluorescence simultaneously.
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Figure 3.44.  The changes in mitochondrial redox state in rat myocytes treated with 100 pM 
diazoxide and 10 pM glibenclamide (n= 3).
A.  A set of images to show the redox state of the myocytes.  B. A graph to show the changes 
in NADH/FAD2+  autofluorescence (arbitrary units).  The data were normalised, averaged and 
presented  as  percentage  means  +  SEM.  C.  A  graph  to  show  the  changes  in  NADH 
autofluorescence.  Statistical analyses were carried out using One-way ANOVA.  D.  A graph 
to show the changes in FAD2+  autofluorescence.
163In my hands, Kir6.1  was not detected in rat myocytes.  Diazoxide and glibenclamide 
had  no  effects  on  these  cells;  therefore,  I  decided  to test the  same  compounds  on 
C2C12 cells, which do express native Kir6.1.  The data are summarised in figure 3.45 
(n= 4, total cells =11) where C2C12 cells were exposed to  100 pM diazoxide and 10 
pM glibenclamide.  Despite the presence of Kir6 .1  in this cell line, 100 pM diazoxide 
and  10  pM  glibenclamide  did not significantly alter mitochondrial  redox  state,  see 
figure 3.45A and figure 3.45B.  There were no significant changes in flavoprotein and 
NADH  autofluorescence  p  >0.05  (NS),  see  figure  3.45C  and  figure  3.45D.  The 
results obtained so far suggest that diazoxide and glibenclamide had no effects on the 
redox state, hence mitochondrial function in immortalised and primary cell lines.  The 
next step was to examine the maximal  oxidised and reduced state of the cells with 
FCCP and NaCN to ensure that signals could be calibrated to provide specific redox 
signals that could be measured.
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Figure 3.45.  An experiment to show the changes in mitochondrial redox state in C2C12 cells 
treated with 100 pM diazoxide and 10 pM glibenclamide (n= 4).
A.  A set of images to show the redox state of C2C12 cells.  B. A graph to show the changes 
in NADH/FAD2+  autofluorescence  (arbitrary  units).  C.  A  graph  to  show the  changes  in 
NADH autofluorescence.  D.  A graph to show the changes in FAD2 +  autofluorescence.
164In figure 3.46 (n= 4, total cells = 10), C2C12 cells were calibrated with 2 mM NaCN 
and  1   |iM FCCP.  Calibration with NaCN and FCCP is an important step because it 
gives  an  indication  of the  cell’s  resting  redox  state.  NaCN  was  used  to  inhibit 
complex  IV  of the respiratory chain as this  impairs  oxidative phosphorylation and 
NADH cannot be oxidised resulting in a build up of fluorescent NADH,  see figure 
3.46A.  This was observed as an increase in NADH autofluorescence and decrease in 
flavoprotein  autofluorescence,  see  figure  3.46B.  Interestingly,  NADPH  is  also 
fluorescent  because  it  has  similar  spectral  properties  to  NADH.  Both  forms  are 
present  in  mitochondrial  and  cytosolic  compartments,  I  assumed  the  NADH 
measurements were mitochondrial because it is more abundant than cytosolic NADH 
and only mitochondrial NADH will change with FCCP (Duchen et al  2003,  2001). 
The recording medium was replaced with fresh solution to allow cells to recover from 
NaCN application before  FCCP was  then applied.  This  stimulated respiration and 
increased flavoprotein autofluorescence.
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Figure 3.46.  A calibration experiment using 20 mM NaCN and  1   pM  FCCP to show the 
maximally reduced and oxidised state in C2C12 cell line.
A.  A set of images to show the redox state of C2C12 cells used in this experiment (n= 4). B. 
A graph to show the changes in NADH/FAD2+  autofluorescence (arbitrary units).  C. A graph 
to show the changes in NADH autofluorescence.  D.  A graph to show the changes in FAD2 +  
autofluorescence.
165In figure 3.46C, NaCN significantly increased the NADH autofluorescence by 50 % 
(100-150) p<0.01  (**)  but flavoprotein autofluorescence at this time point was not 
significant  p>0.05  (NS)  (figure  3.46D).  During  the  washout  period,  NADH  and 
flavoprotein  autofluorescence  returned  to  basal  levels.  FCCP  (1  pM)  was  then 
applied which caused a substantial reduction in NADH fluorescence by  100 % (150- 
50) p<0.01  (**), this was followed by an increase in flavoprotein autofluorescence by 
almost 80 % (100-180) p<0.001  (***).  The previous experiment showed that C2C12 
cells did not respond to diazoxide and glibenclamide, the signal in these cells could be 
calibrated with NaCN and FCCP.  Therefore, the next step was to test the combination 
of 3-NPA  and  diazoxide  and  observe  whether  respiration  would  be  stimulated  as 
demonstrated in the pilot experiments  (Duchen,  unpublished observations).  C2C12 
cells were treated with  1   mM 3-NPA,  100 pM diazoxide and  10 pM glibenclamide. 
The data for this experiment is displayed in figure 3.47 (n= 5, total cells = 13).
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Figure 3.47.  An experiment to show the changes in mitochondrial redox state in C2C12 cell 
treated with 1  mM 3-NPA, 100 pM diazoxide and 10 pM glibenclamide.
A.  A set of images to show the redox state of C2C12 cells used in this experiment (n= 5). B. 
A line graph to show the changes in NADH/FAD2 +  autofluorescence (arbitrary units).C.  A 
graph to show the changes in NADH autofluorescence.  D.  A graph to show the changes in 
FAD2 +  autofluorescence.
166On closer inspection, the graph in figure 3.47C shows that NADH autofluorescence 
decreased in the presence of 3-NPA p<0.05 (*), diazoxide and glibenclamide p<0.01 
(**).  Flavoprotein autofluorescence  decreased  after 3-NPA application p<0.05  (*) 
and continued to decrease in the presence of diazoxide and glibenclamide p<0.05 (*), 
see  figure  3.47D.  C2C12  cells  showed  small  but  significant  changes  in  NADH
autofluorescence  in the  presence  of 1  mM  3-NPA,  100  pM  diazoxide  and  10  pM 
glibenclamide.  However, the decrease in NADH autofluorescence was not followed 
by the reciprocal increase in flavoprotein autofluorescence.  These compounds were 
then  tested  on  rat  ventricular  myocytes  to  compare  responses.  In  figure  3.48, 
myocytes  were  treated  with  1  mM  3-NPA,  100  pM  diazoxide  and  10  pM 
glibenclamide, (n= 4, total cells = 12).
i  ;   :
5 0 m m |* j  ■   yr  n   A
I  r   I f
B 100 pm Diaz 
1 mM 3-NPA  ■ ■ ■
10 pM Glib
n=4 180 -
160-
o   140
120
100
60
40
20
Time (minutes)
to
x   a»
n= 4
D
■ S
w. 14* 
8 xs>
§ ®
I   a>
r « J  4 >
^   2)
O
n= 4
NS
NS
NS
EM  3NA  D roicte  Ctoila^fe
Figure  3.48.  An  experiment  to  show  the  changes  in  mitochondrial  redox  state  in  rat 
ventricular  myocytes  treated  with  1   mM  3-NPA,  100  pM  diazoxide  and  10  pM 
glibenclamide.
A.  A set of images to show the redox state of rat myocytes used in this experiment (n= 4).  B. 
A graph to show the changes in NADH/FAD2*  fluorescence (arbitrary units).  C.  A graph to 
show the changes in NADH autofluorescence.  D.  A graph to show the changes in FAD2 +  
autofluorescence.
167In figure  3.48A, the combination of 3-NPA, diazoxide and glibenclamide increased 
flavoprotein oxidation; this was similar to the response induced by uncoupler FCCP. 
These  changes  in  NADH  and  flavoprotein  autofluorescence  are  shown  in  figure 
3.48B.  It is important to note that individual cells in each field respond to the drugs at 
different  times,  some  cells  become  more  oxidised  than  others,  which  may  have 
influenced the statistical analysis.  NADH autofluorescence decreased upon diazoxide 
application and this response continued in the presence of glibenclamide p <0 . 0 1  (**), 
(figure  3.48C).  Flavoprotein  autofluorescence  was  not  affected  by  3-NPA  and 
diazoxide  p>0.05  (NS)  but  in  the  presence  of  glibenclamide,  respiration  was 
stimulated and flavoprotein autofluorescence increased significantly by 60 % p<0 . 0 1  
(**).  The next experiment was designed to confirm that flavoprotein oxidation was 
stimulated in response to 3-NPA and diazoxide and not glibenclamide.  The data is 
displayed in figure 3.49 (n= 3, total cells = 14).
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Figure  3.49.  An  experiment  to  show  the  changes  in  mitochondrial  redox  state  in  rat 
ventricular  myocytes  treated  with  1   mM  3-NPA,  100  ]llM   diazoxide  and  10  fiM 
glibenclamide.
A.  A set of images to show the redox state of cardiomyocytes used in this experiment (n= 3).
B. A graph to show the changes in NADH/FAD2+  autofluorescence (arbitrary units).  C.  A 
graph to show the changes in NADH autofluorescence.  D.  A graph to show the changes in 
FAD2 +  autofluorescence.
168This  time,  the  drugs  were  administered  in  the  same  order  but  with  longer  time 
intervals  in  between  each  application  to  show  the  effect  of  each  compound  on 
mitochondrial  redox  state.  Myocytes  are  quite  robust  cells  so  it  was  possible  to 
extend the duration of this experiment to prove this point.  In figure 3.49A and figure 
3.49B,  the  myocytes  were  unaffected  by  3-NPA  and  flavoprotein  autofluorescence 
only started to increase after diazoxide application.  There was also a 10-minute gap 
before  diazoxide  was  administered  to  show that  3-NPA  alone  did not affect  redox 
state.  After glibenclamide application, the increase in flavoprotein autofluorescence 
and decrease in NADH autofluorescence continued.  The statistical analysis in figure 
3.49C and figure 3.49D reflects these changes and shows that 3-NPA itself did not 
have  any  effects  on  redox  state  p>0.05  (NS).  Diazoxide  decreased  NADH 
autofluorescence p<0.05  (*)  but it did not increase  flavoprotein autofluorescence  at 
this  point  p>0.05  (NS).  In  figure  3.49C,  NADH  autofluorescence  decreased  and 
continued to decrease after glibenclamide application p<0.05 (*).  Glibenclamide also 
significantly increased flavoprotein oxidation p<0.01 (**), see figure 3.49D.
The data suggests that the rate of NADH and flavoprotein oxidation vary in response 
to the test compounds and the changes are not always reciprocal.  However, I have 
found that the  combination of 3-NPA  and  diazoxide  are  both required to  stimulate 
flavoprotein oxidation.  This phenomenon is reproducible but this does not agree with 
results  from  other  groups  who  reported  significant  changes  in  flavoprotein 
autofluorescence in the presence of diazoxide alone (Sato et al 2000; Liu et al 1998). 
In my hands,  the oxidising properties of diazoxide (in the presence of 3-NPA)  was 
reproducible and mimicked the stimulatory effects of FCCP.  Therefore,  in the final 
experiment, 3-NPA and diazoxide were administered first to demonstrate flavoprotein 
oxidation  but  instead  of  applying  glibenclamide  at  the  end,  in  figure  3.50,  the 
myocytes were calibrated with 2 mM NaCN and  1  pM FCCP to give the maximally 
oxidised and reduced states (n= 2, total cells = 9).
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Figure  3.50.  An  experiment  to  show  the  changes  in  mitochondrial  redox  state  in  rat 
ventricular myocytes treated with 1  mM 3-NPA, 100 pM diazoxide, 20 mM NaCN and 1  pM 
FCCP.
A.  A set of images to show the redox state of cardiomyocytes used in this experiment (n= 2).
B. A graph to show the changes in NADH/FAD2+  autofluorescence (arbitrary units).  C.  A 
graph to show the changes in NADH autofluorescence.  D.  A graph to show the changes in 
FAD2 +  autofluorescence.
Figure  3.50A  and  figure  3.50B  show that the  application  of 3-NPA  and diazoxide 
caused  an  increase  in  flavoprotein  autofluorescence  and  a  decrease  in  NADH 
autofluorescence.  Mitochondrial  redox  state  did  not  change  immediately  but  only 
after  a  time  delay  of 5-10  minutes.  Diazoxide,  in  the  presence  of  3-NPA  can 
somehow induce cells to their fully oxidised state; the degree of oxidation is similar to 
FCCP and was very significant p<0.001 (***).  There was an increase in flavoprotein 
autofluorescence  and decrease  in NADH  fluorescence,  see  figure  3.50C  and  figure 
3.50D.  NaCN addition to these myocytes show that diazoxide stimulated respiration 
could be reversed, this response took about  1 0  minutes but is a reversible effect and 
must  be  due  to  some  non-specific  target  in  mitochondria.  Inhibiting  respiration 
restored NADH and flavoprotein autofluorescence to near basal levels.  Flavoprotein
170autofluorescence at this time point was similar to basal levels p>0.05 (NS).  However, 
NADH autofluorescence had not recovered fully from NaCN application p<0.01 (**). 
NaCN  would  normally  inhibit  respiration  immediately  but  it  is  possible  that  the 
presence of the other drugs in the solution may have slowed down the cell’s response 
to NaCN.  A washout period followed before cells were exposed to FCCP, this caused 
an  immediate  increase  in  flavoprotein  autofluorescence,  producing  the  maximal 
oxidised  state  p<0.001  (***),  indicated  by  the  increase  in  flavoprotein
autofluorescence and decrease in NADH autofluorescence.
3.5.2  Mitochondrial membrane potential (A\|/m )
The  mitochondrial  membrane  potential  (Ai|/m )  is  an  important  variable  to  measure 
because it provides further insight on mitochondrial function.  I have established that 
diazoxide stimulated respiration in the presence of 3-NPA and this was observed as an 
increase  in  flavoprotein  fluorescence  and  decrease  in  NADH  autofluorescence. 
Glibenclamide  did  not  inhibit this response.  According to  the  literature,  diazoxide 
will activate the mitoKATP channel and cause mitochondrial depolarisation promoting 
respiration  and the  oxidation of flavoproteins  and NADH.  This  in turn allows the 
influx of K+ ions into the matrix, which will be driven by an equal rate of H+ ejection 
by  the  electron transport  chain.  The  increase  in  H+  current  would  lower the  Avpm  
(Garlid 2000).  If K+ influx capacity is large, part of the H+ gradient that is used to 
export K+  ions via  K+/H+  exchanger will  prevent mitochondrial  swelling  and  lysis. 
Closing  the  mitoKATP  channel  with  glibenclamide  would  cause  repolarisation  and 
recovery of the Ai|/m .
The  A\|/m   was  measured  with  Tetramethyl  rhodamine  methyl  ester  (TMRM)  (see 
materials and methods 2.5.4).  C2C12 cells were loaded with 20 nM TMRM for 30 
minutes at 37 °C whereas myocytes were loaded for one hour, as this was required for 
these  cells  to  equilibrate  and  reach  a  steady  state.  The  dye  distributes  in  the 
compartments  according  to  the  Nemst  equation.  When  mitochondria  become 
depolarised,  the  dye  redistributes  and  moves  from  mitochondria  to  cytosol. 
Therefore,  mitochondrial  TMRM  fluorescence  decreases  whereas  cytosolic  TMRM 
fluorescence  increases  (Voronina  et al.  2004,  Duchen  et al.  2003).  In  preliminary
171experiments, I observed diazoxide induced flavoprotein and NADH oxidation (in the 
presence of 3-NPA) in myocytes but not in C2C12 skeletal muscle cells therefore, it 
would  be  relevant  to  examine  if the  responses  in  Av|/m   are  different  in  these  two 
cellular models.
In figure 3.51  (n = 3, total cells =11).  C2C12 cells were loaded with 20 nM TMRM 
and treated with  100  pM diazoxide,  10 pM glibenclamide and  1   pM FCCP.  Three 
ROIs were selected from each cell and are shown as different coloured traces in figure 
3.5IB.  Diazoxide caused a small decrease in TMRM fluorescence.  The application 
of glibenclamide caused a slight spike in the data but this was due to the addition of 
the drug, see figure 3.51 A.
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Figure 3.51.  An experiment to show the changes in A vjjm  in C2C12 cells loaded with 20 nM 
TMRM.  The cells were treated with  100  pM diazoxide,  10  pM  glibenclamide and  1   pM 
FCCP.
A.  A  set  of  images  to  show  the  changes  in  overall  TMRM  fluorescence  during  the 
experiment (n=3  ROIs =  9).  B.  A  graph  to  show the  changes  in  mitochondrial  TMRM 
fluorescence (arbitrary units).  The results were normalised before they were averaged and are 
presented as percentage means + SEM.  C. An  image to show the three ROIs which were 
taken for cytosolic TMRM fluorescence measurements.  D.  A graph to show the changes in 
cytosolic TMRM fluorescence in the ROIs highlighted in C.  Statistical analyses were carried 
out using One-way ANOVA, the time points were taken at the end of each drug application.
172When FCCP was administered, the mitochondria depolarised  immediately allowing 
the  dye  to  exit  the  mitochondria  and  enter  the  cytosol,  see  figure  3.51C.  This 
observation  was  confirmed  by  measuring  the  increase  in  cytosolic  TMRM 
fluorescence.  In figure 3.5ID, diazoxide caused mitochondrial depolarisation p<0.05 
(*), there were no  significant changes  in Avj/m  in response to  glibenclamide but the 
collapse  of the  A\j/m   in  response  to  FCCP  was  observed  as  a  significant  drop  in 
TMRM fluorescence by almost 80 % (100-20) p<0.001  (***).  The next step was to 
explore the effects of 1   mM 3-NPA,  100 pM diazoxide and 10 pM glibenclamide on 
Av|/m  in rat myocytes because the combination of 3-NPA and diazoxide significantly 
increased flavoprotein autofluorescence.  See figure 3.52 (n= 3, total cells = 10).
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Figure 3.52.  An experiment to show the changes in A vj/m  in C2C12 cells loaded with 20 nM 
TMRM.  The cells were treated with 1  mM 3-NPA, 100 pM diazoxide, 10 pM glibenclamide 
and 1  pM FCCP.
A.  A  set  of  images  to  show  the  changes  in  overall  TMRM  fluorescence  during  the 
experiment (n= 3).  B. A graph to show the changes in mitochondrial TMRM fluorescence.
C.  A graph to show the changes in cytosolic TMRM fluorescence in the ROIs highlighted in 
A.  D.  A graph to compare the changes in A vjjm  in response to the different compounds.
173Two  ROIs  were  selected  for each  cell  and the traces  are  displayed  as  six  coloured 
traces  in  figure  3.52B.  The  data  show  that  mitochondria  did  not  depolarise  in 
response  to  diazoxide  (and  3-NPA)  and  mitochondrial  depolarisation occurred  after 
glibenclamide  application.  The  rate  of depolarisation  increased  when  FCCP  was 
administered  as  this  resulted  in  an  immediate  decrease  in  mitochondrial  TMRM 
fluorescence  and increase  in cytosolic TMRM fluorescence.  In figure  3.52A, three 
ROIs were selected for cytosolic TMRM fluorescence measurements in figure 3.52C. 
The addition of FCCP caused a prominent ‘spike’ at 14 minutes where the dye moved 
from  mitochondria to  the  cytosol.  Statistical  analysis  in  figure  3.52D  showed that 
mitochondrial  TMRM  fluorescence  was  not  influenced  by  3-NPA  and  diazoxide 
p>0.05  (NS).  However,  the  addition  of  glibenclamide  and  FCCP  were  highly 
significant p<0.01  (**).  In my hands, I have demonstrated that 3-NPA and diazoxide 
had no significant effect on mitochondrial redox state and these same compounds did 
not have major effects on A\|/m  in C2C12 cells either.
The  next  step  was  to  examine  changes  in  Avj/m   with  the  dequench  mode  which 
requires high concentrations of TMRM.  When the mitochondria become depolarised, 
this results in an overall increase in cell fluorescence because the densely packed dye 
is released immediately into the cytosol where it is diluted and  so the quenching is 
reduced.  The dequench mode  is more  sensitive and is more effective for detecting 
small but substantial changes in Avj/m  (Voronina et al 2004).  This not only applies to 
TMRM but other A\j/m  dyes such as TMRE and Rhodamine 123 (Duchen et al 2001). 
In  figure  3.53,  C2C12  cells  were  loaded  with  400  nM  TMRM  before  they  were 
treated with 1 mM 3-NPA, 100 pM diazoxide,  10 pM glibenclamide and 1  pM FCCP 
(n= 5, total cells =  14).  Whole cell measurements were taken for the ROIs because 
mitochondrial depolarisation in these cells loaded with this concentration of dye could 
be observed as an increase in overall cell fluorescence.
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Figure 3.53.  An experiment to show the changes in Av|/m  in C2C12 ceils loaded with 400 nM 
TMRM.  The cells were treated with 1  mM 3-NPA, 100 pM diazoxide, 10 pM glibenclamide 
and 1  pM FCCP.
A.  A  set  of  images  to  show  the  changes  in  overall  TMRM  fluorescence  during  the 
experiment (n=5).  B.  A graph to  show the changes  in  mitochondrial TMRM  fluorescence 
(arbitraiy units).  C. A graph to show changes in A vj/m  fluorescence during the experiment.
The images in figure 3.53A suggest that were no changes in TMRM fluorescence in 
response  to  3-NPA  and  diazoxide.  However,  glibenclamide  and  FCCP  induced 
mitochondrial  depolarisation, contributing to the  increase  in cell  fluorescence.  The 
changes in mitochondrial  TMRM  fluorescence are displayed  in figure 3.53B  where 
five  separate  traces  are  shown  for  each  cell  in  the  field.  The  results  show  that 
mitochondria did not respond to 3-NPA or diazoxide p>0.05 (NS) but in figure 3.53 
C, mitochondria started to depolarise in the presence of glibenclamide p<0.01  (**). 
The application of FCCP continued to  dissipate the Av|/m  p<0.05  (**).  This is an 
interesting  result  because  previously  I  was  not  able  to  measure  any  changes  in 
mitochondrial redox state with the same compounds in this cell line.  This suggests 
that  the  changes  in  redox  state  and  A\|/m   are  not  necessarily  associated  with  the 
changes in mitochondrial redox state.
175The experiments with myocytes have not been included in this chapter because these 
experiments  were technically  difficult to  perform within the  timescale  available.  I 
also  found  that  mitochondria  depolarised  rapidly  because  the  laser  used  had 
phototoxic  properties.  The  dye  would  ‘leak’  from the  cells,  an  indication that the 
myocytes  were  not  capable  of  maintaining  their  A\j/m ,  which  in  turn  caused  the 
myocytes to shorten with no relaxation.  On the other hand, the lasers used to measure 
the changes in flavoprotein and NADH autofluorescence in these same cells were not 
accompanied with shortening.
To summarise, the KCO diazoxide has significant effects on mitochondrial redox state 
in myocytes however; this response was not observed in C2C12 cells.  Diazoxide, in 
the presence of 3-NPA stimulated flavoprotein oxidation, which was observed as in 
increase  in  flavoprotein  autofluorescence  and  decrease  in NADH  autofluorescence. 
Glibenclamide  did  not  attenuate  this  response.  Using  two  different  methods  to 
evaluate  I  found  that  mitochondria  in  C2C2  cells  depolarised  in  response  to 
diazoxide but there were no  significant changes in A\j/m  with 3-NPA and diazoxide. 
These results suggest that the changes in mitochondrial redox state may not be linked 
to  diazoxide  induced  K Atp   channel  opening  but  more  likely  that  these 
pharmacological  agents  have  non-specific  effects,  which  are  independent  of their 
K atp  channel opening properties.
1763.6  Investigating the function of Kir6.1 in calcium signalling
3.6.1  Ca2+ signalling
I have examined the intracellular localisation of the ATP-sensitive potassium channel 
subunit  Kir6.1  in  immortalised  cell  lines.  Both  endogenous  and  recombinant 
transfected  Kir6.1  are  predominantly  located  in the  ER with  a small  proportion  in 
mitochondria.  The ER is involved in Ca2+ handling.  Given these observations, the 
next  step  was  to  establish  whether  this  localisation  may  have  a  function  in  the 
regulation of Ca  .release and sequestration in cardiac or skeletal muscle.  Ca  is a 
universal  intracellular  messenger  responsible  for  controlling  a  diverse  range  of
cellular processes and it has a major function when its concentration is elevated in the
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cytosolic compartment.  The release of Ca  from intracellular stores is mediated by 
several types of messenger activated channels.
2" b Mammalian  Ca  pumps  fall  into  two  main  classes  of  enzymes:  The  plasma
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membrane Ca  -ATPase (PMCA) pumps Ca  from the cell to regulate the supply of
2+  ^  ^ j
intracellular Ca  via the plasma membrane, while sarco/endoplasmic Ca  ATPases 
(SERCAs)  sequester  Ca  within  intracellular  organelles  such  as  the  sarcoplasmic 
reticulum (SR) in muscle or the ER in non-muscle cells (Bootman et al 2001; Guerirti 
et al  1998).  The threshold of activation of SERCAs by Ca2+ is of the order of 100-
'j*
200nM, so that they set the resting level of cytoplasmic Ca  .  In fast-twitch muscle 
such as skeletal muscle, the SERCA1  isoform is expressed at high levels.  SERCA2 is 
found in slow twitch muscle, SERCA2A is expressed in the heart whereas SERCA3 is 
widely expressed in some  blood cells and purkinje neurons.  There are exchangers 
such as the Na+/Ca2+ exchanger (NCX) that use the Na+ electrochemical gradient to 
diffuse down its concentration gradient across the plasma membrane in exchange for 
Ca2+.  Mitochondria also play a significant role in modulating cytosolic Ca2+ as they
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possess a low affinity, but high capacity Ca  uniporter that can reduce high local Ca 
concentrations and can act as a spatial Ca  buffer (Duchen 2000; 1999).  The entry of 
Ca2+ into mitochondria is driven by the highly polarised membrane potential and this
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feature  of  mitochondria  is  important  because  Ca  accumulation  can  lead  to 
mitochondrial  Ca2+  overload  in  response  to  pathophysiological  events  such  as 
ischaemia, ischaemic reperfusion injury, apoptosis and necrosis (Zucchi et al 2001).
IllThe contraction and relaxation of muscle is regulated by the ionised Ca2+ content of 
the  sarcoplasm.  In  resting  muscle  fibres,  Ca2+  is  stored  in  the  SR  and  muscle 
contraction is initiated by the release of Ca2+ from the intracellular stores.  This can 
happen in two ways.  In cardiac myocytes, Ca2+ is released from the SR after the entry 
of Ca2+ via the L-type Ca2+ channels whilst in skeletal muscle, Ca2+ release is caused 
by  the  electrochemical  coupling  between  the  surface  membrane  and  the  RyR. 
Relaxation of the muscle occurs when Ca2+ is pumped back to the  SR via the Ca2+ 
ATPase.  There are also Ca2+ binding proteins such as calreticulin and calsequesterin
•  91 that will sequester excess Ca  (MacLennan & Wong 1971).  Calsequesterin is unique 
to  SR  and  is  a  high-capacity,  low-affinity  Ca2+  binding  protein  which  is
hydrophobically bonded onto the interior of these vesicles.  However, in non-striated
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and  smooth  muscle  cells,  Ca  release  can  be  mediated  by  receptor  mediated 
mechanisms such as purinergic signalling.
The  P2  Purinergic  receptors  are  classed  into  two  major  groups  P2X  and  P2Y 
receptors.  P2X are ligand-gated ion channels (P2X) and P2Y are G-protein-coupled 
receptors (GPCRs) {Erb et al.  2006; Abbracchio & Burnstock 1994).  P2Y receptors 
are activated by purine and pyrimidine nucleotides and consist of an extracellular N 
terminus with N-glycosylation sites and intracellular C terminus with phosphorylation 
sites.  P2X receptors have two transmembrane domains with intracellular N and C 
terminus, consensus phosphorylation sites and the extracellular loop that contains an 
ATP binding site.  P2Y receptors are vital for regulating cellular processes such as 
cell proliferation, differentiation, apoptosis and metabolism.  The P2X receptors have 
an  important  role  in  generating  nerve  impulses  and  muscle  contraction.  They are 
essentially  ATP-gated  ion  channels  that upon  activation  by  extracellular ATP,  the 
P2X receptor subunit opens and allow the movement of cations across the plasma 
membrane depolarise the cell {Erb et al 2006).  P2X receptors mediate Na+ influx, K+ 
efflux,  and  to  some  degree  Ca2+  influx  which  leads  to  membrane  depolarisation 
{Dubyak & El-Moatassim 1993; Bean 1992).  The events that follow are more poorly 
understood but the net influx of extracellular cations and membrane depolarisation is 
believed to activate voltage-sensitive Ca  channels and Ca  channel, which in turn, 
leads to additional Ca2+ influx and a further increase in cytosolic Ca2+ levels..  Their 
activation  increases  intracellular  Ca2+  ([Ca2+]i)  levels  which  is  responsible  for  the 
activation of a number of intracellular signalling molecules.
1783.6.2  Ca2+ release from the ER/SR in C2C12 cells and rat ventricular myocytes
The skeletal muscle cell line C2C12 was used for this study as these cells can grow 
indefinitely  in  culture  as  undifferentiated  myoblasts.  However,  they  can  also  be 
induced to form well-defined myotubes by growth to confluence followed with serum 
deprivation (Challet et al.  2001).  In muscle development, the ER develops into the 
specialised SR and is characterised by specific receptors responsible for Ca2+ release 
called ryanodine receptors (RyR).  RyR are structurally similar to IP3 receptors and 
are predominantly  expressed  in excitable  cells  such as  striated  muscle as  they  are 
crucial  components  of  the  cascade  leading  to  muscle  contraction.  The  RyR  is 
activated  by  the  plant  alkaloid  ryanodine  at  low  concentrations  (1-10  pM)  and 
irreversibly inhibited at higher concentrations (100  pM).  The receptor can also be 
activated by caffeine (in mM range) as this also increases the sensitivity of RyR to 
Ca2+ ions.
Cells were  loaded  with  5  pM  Fura 2AM and 0.005  % pluronic acid  in a HEPES- 
buffered salt solution (HBSS) for 30 minutes before the medium was replaced with 
fresh recording solution containing 0.5 mM EGTA.  EGTA is a Ca2+ chelator which 
binds to free Ca2+ ions in solution.  If a Ca2+ response was observed in the presence of 
caffeine or ATP, the source of the Ca2+ can be derived from intracellular ER/SR stores 
or extracellularly.  Therefore if a Ca2+ transient is observed, the source of Ca2+ must 
be from internal stores.  This can be through P2Y IP3 receptor mediated pathway or 
via  RyR.  The  cells  were  imaged  using the cooled  CCD  imaging  system  and the 
results are presented as the ratio of excitation at 340 and 380 nm, both with emission 
at  >515  nm.  The  data  presented  is  from  one  coverslip  (one  experiment)  but 
experiments were carried out at least five times from four different cell preparations.
In figure 3.54 (n= 26, total n=  114) non-differentiated C2C12 cells were treated with
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10 pM ATP to induce Ca  release from internal stores.  External ATP activates the 
ligand gated P2Y receptor-mediated pathway; which generates IP3 which binds to IP3 
receptors on the ER to release Ca2+.
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Figure 3.54.  A graph to show the Ca2+ transients in C2C12 cells stimulated with just  10 pM 
ATP (n= 26).
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Figure  3.55.  A  graph  to  show  the  Ca2+  transients  in  C2C12  cells  stimulated  with  1   mM 
caffeine and  10 pM ATP (n= 20).  The cells did not respond to caffeine.
A longer time interval was established between caffeine and ATP application so that when  10 
pM ATP was applied, all cells elicited a Ca2+ response.
180The cells were left for approximately 6 minutes to establish a stable base line before 
10 pM ATP was applied which caused significant Ca2+ transients in all cells.  Despite 
the maintained presence of ATP, the Ca2+ signal recovered over 1  -2 minutes and the 
Ca2+  spikes  disappeared  and  [Ca2+ ],  returned  to  basal  levels.  This  is  through the 
action of the PMCA which can pump Ca2+ extracellularly out of the cell and SERCA 
that allow internal  stores to  start filling again.  The next step was to examine Ca2+  
release from internal stores through RyR with  1   mM caffeine.  Figure 3.55 (n= 20, 
total n= 96) shows the individual traces for C2C12 cells treated with  I  mM caffeine 
and 10 pM ATP.  The cells did not respond to caffeine application but ATP caused 
immediate  Ca2+  transients  via  P2Y  signalling  pathway.  The  lack  of response  to 
caffeine is consistent with the absence of RyRs in the non-differentiated cells.
I then examined the effect of differentiation on the Ca2+ signal in figure 3.56 (n= 40, 
total n= 8 8 ).  C2C12 cells were differentiated for 48 hours with 2 % horse serum and 
visualised under a light microscope to ensure that distinct myotubes were present.  No 
Ca  transients were observed with 1  mM caffeine, but there was a response to 10 pM 
ATP.  Given this observation, I differentiated the cells for a longer period of time.  In 
figure 3.57 (n= 22, total= 98), C2C12 cells were left for approximately four days (96 
hours) to differentiate before they were treated with 1  mM caffeine and 10 pM ATP.
10nM ATP
1mM Caffeine
Differentiated C2C12 - 48hrs
Time (m in utes)
n= 40
Figure  3.56.  A  graph  to  show the Ca2+  transients  in differentiated  C2C12  cells (48  hours). 
The cells were stimulated with  1   mM caffeine and  10 pM ATP (n= 40).
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The cells showed Ca  transients in response to both caffeine and ATP, however it is 
possible to deduce the proportion of cells responding to each agonist therefore it was 
necessary to separate the traces, see figure 3.58.
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Figure  3.57.  A  graph  to  show the Ca2+  transients  in differentiated  C2C12  cells (96  hours). 
The cells were stimulated  with  1   mM  caffeine followed  by  10  pM  ATP (n= 22).  The cells 
showed a response to both caffeine and ATP.
On closer inspection, 41  % of cells only showed ATP induced Ca2+ transients (figure 
3.58A)  whereas  59  %  of the  cells  showed  responses  to  caffeine  and  ATP  (figure 
3.58B).  This  suggests that not all  cells  expressed  RYRs  using this differentiation 
protocol but those that did could respond to caffeine and ATP.  Differentiated cells
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would release Ca  in response to caffeine and the SERCA would pump excess Ca 
back into the SR so the cells were able to release Ca2+ again upon ATP stimulation.
The  rationale  for  using  caffeine was  to  establish  whether these differentiated  cells 
express RyRs and can release Ca  .  A low concentration of caffeine (1 mM) was used 
as this was likely to be a sub-optimal concentration which would open only a fraction 
of the  Ca2+  release  channels  and  permit calcium  release,  but  also  allow some  re­
uptake.  Thus,  the  Ca2+  content  of this  store  could  be  additionally  probed  with  a 
second  agonist  in  this  case  ATP  which  might  act  via  through  an  IP3  dependent 
mechanism.  Ca2+ transients were indeed observed in all cells upon ATP stimulation.
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Figure 3.58.  The Ca2+ transients in figure 3.57 were separated according to their response.  A. 
A graph to show the Ca2+ transients in C2C12 cells in response to  10 pM ATP (n= 9).  B.  A 
graph to show the Ca2+ transients in C2C12 cells response to  1   mM caffeine and  10 pM ATP 
(n=  13).  The response to caffeine was at different times.
To confirm that C2C12 cells did not respond to caffeine because they did not express 
the RyR and it was not a technical issue, I carried out experiments with rat ventricular 
myocytes.  Myocytes express the cardiac RyR2  and therefore release Ca2+ into the 
cytosol  in  response  to  caffeine  (Taur  &  Frishman  2005).  In  figure  3.59,  rat 
ventricular myocytes (n= 7, total= 48) were stimulated with  1   mM caffeine which
183caused the immediate release of Ca2+ from intracellular stores.  The graph shows that 
the rate of recovery is fast, when [Ca2+ Jj levels return to basal levels where there is a 
slight ‘undershoot’ in cells (apart from the yellow trace).  It is the high concentration 
of Ca2+ in the cytosol which creates the driving force for its uptake by the SR.  This is 
a characteristic response observed in myocytes with Ca2+ that is released from internal 
stores (Baro et al 1993).
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Figure  3.59.  A  graph  to  show  the  Ca2+  transients  in  rat  myocytes  in  response  to  1  mM 
caffeine (n= 7).
The data suggest that the ‘differentiated’ C2C12 myotubes did not respond to caffeine 
stimulation because not all of the cells express RyRs.  Therefore, it would be difficult 
to  continue  these  experiments  and  compare  caffeine-induced  Ca2+  transients  in  a 
population of cells that consisted of both non-diflferentiated and differentiated cells if 
only a certain percentage of cells respond to caffeine.  The data accumulated so far are 
summarised in table 3.8.
184Table 3.8.
A table to summarise the relative  increase  in  intracellular Ca2+  levels  in experiments carried 
out throughout this chapter.  The results are presented as means ± SEM.
Cell Type and 
experiment
Agonist Number of cells Ca2+   transient  (Fura-2 
ratio relative increase)
C2C12 1  mM Caffeine n= 66 No response
C2C12 10 pM ATP n= 66 0.4189 ±0.03483
C2C12
(Differentiated)
10 pM ATP
-
U
0.5611 ±0.01499
C2C12
(Differentiated)
1  mM Caffeine n= 44 0.2139 ±0.04141
Myocytes 1  mM Caffeine n= 48 0.2654 ±0.01409
In chapters 3.2 and 3.3, the colocalisation results showed that in C2C12 cells, about 
50 % of Kir6.1  was expressed in the ER.  I then decided to investigate the role of 
Kir6.1  in caffeine and ATP-induced Ca2+ transients in non-differentiated C2C12 cells. 
C2C12 cells were transfected with DN forms of Kir6.1  called DNG->A or DNG— »S. 
The cells were also co-transfected with eGFP so transfected (without Kir6.1) and non 
transfected  (control)  cells  could  be  identified  in  the  same  population  of cells.  A 
transfection  efficiency  of  40  %  or  above  was  observed  under  a  conventional 
fluorescent  microscope  before  cells  were  used.  In  figure  3.60,  C2C12  cells 
transfected with DNG->A were treated with ImM caffeine and 10 pM ATP (Control 
n= 7, total= 41; transfected n= 6 , total  = 39).
As expected, 1  mM caffeine did not induce a response in these non-differentiated cells 
whereas  ATP elicited  immediate Ca2+ transients,  [Ca2+]i  returned to basal  levels in 
under  2  minutes.  However,  the  magnitude  of the  Ca2+ transient  is  smaller  in  the 
transfected cells,  which  suggests that Kir6.1  may have a role  in Ca  release  from 
internal stores.  Although the amplitude of the Ca2+ transients in transfected cells were 
smaller than in non transfected cells, it is apparent from figure 3.60 that the presence 
of eGFP altered Fura-2 measurements.
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Figure 3.60.  A graph to show the Ca2+ transients in C2C12 cells transfected with  DNG->A, 
these  were  stimulated  with  1   mM  caffeine  and  10  pM  ATP.  (Non  transfected  cells  =  7, 
transfected cells = 6).
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Figure 3.61.  A  graph to show the Ca2+ transients  in C2C12 cells transfected  with DNG— >S, 
these  were  stimulated  with  1   mM  caffeine  and  10  pM  ATP.  (Transfected  cells  =  9,  non 
transfected cells =11).
186C2C12 cells were also transfected with DNG-*S, these were also treated with 1   mM 
caffeine and 10 pM ATP, see figure 3.61  (Control n= 11, total= 61; transfected n= 9, 
total =  43).  Again,  these  cells  did  not  respond  to  caffeine  but  ATP  induced  Ca2+ 
transients  in  all  cells.  Again,  the  amplitude  of the  Ca2+  transient  was  smaller  in 
transfected cells.  However, the Fura-2 signal at the start of the experiment was lower 
than in control cells so the Ca2+ transients observed may not be a true response to 
ATP.  In figure 3.62, C2C12 cells were transfected with just eGFP and treated with 1  
mM caffeine and 10 pM ATP (Control n= 13, total = 38; transfected n= 9, total= 32). 
This control experiment was set up to examine whether the presence of eGFP affected 
Ca2f  handling  in  previous  experiments.  If the  absence  of Kir6.1  did  affect  the 
magnitude of Ca2+ transients, then there should be no significant differences in ATP- 
induced Ca  transients in transfected and non transfected cells.  The results in figure 
3.64 showed that the presence of eGFP did indeed depress the magnitude of ATP- 
induced Ca2+ transients.  This suggests that silencing Kir6.1  may not influence Ca2+ 
handling in the ER because the presence of eGFP perturbs the Fura-2 signal.
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Figure 3.62.  A graph to show the Ca2+ transients in C2C12 cells transfected with eGFP these 
were stimulated with  1   mM caffeine and  10 pM ATP. (Transfected cells = 9, non transfected 
cells = 13).
187The  rationale  for  using  a  ratiometric  fluorochrome  such  as  Fura-2  and  not  single 
wavelength dyes such as Fluo-4 was that Ca2+ measurements would be less affected 
by considerations such as dye leakage from the cell and other factors that would affect 
absolute signal levels.  However, eGFP is excited at UV wavelengths and so would 
contribute to an increased background signal in my experiments.  Furthermore, the 
presence of eGFP has been shown subsequently to significantly depress Fura-2 signals 
(Bolsover et al. 2001).  Therefore, it would be difficult to compare fluorescence signal
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intensities as eGFP affects the magnitude of ATP induced Ca  transients.  Because of 
this observation, I measured the kinetics of this response which may be less affected 
by eGFP to test for differences, if any, between control cells, cells transfected with 
eGFP only and those transfected with eGFP and DN for Kir6.1  to examine whether
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Kir6 .1  expression does indeed modulate Ca  dynamics.
The rising rate constants of ATP induced Ca2+ transients were measured in these three 
experiments by calculating the largest rate between successive data points in this rapid 
phase.  It was difficult to compare declining values because the recoveries of the Ca2+ 
transients  were  incomplete.  See  table  3.9.  The  rising  rate  constants  were  then 
analysed  with  one-way  ANOVA  with  Bonferonni  post-tests  to  determine  any 
differences between transfected and non transfected cells for each experiment and I 
also tested  for differences,  if any,  between eGFP and DN  Kir6.1  transfected cells. 
Transfection is a stressful process for cells and it would be advantageous to observe 
the differences between these cells.  The rising rate constants of cells transfected with 
just eGFP were much lower (by 50 %) than their non transfected neighbours p<0.001 
(***).  This is also true for cells that were co-transfected with DN for Kir6.1.  The 
presence  of eGFP  quenches  the  signal  and  slows  down  the  rate  of rising  Ca 
transients but the degree of quenching does not appear to be altered by the presence of 
DNG— >A p>0.05 (NS) and DNG— >S p>0.05 (NS) when compared to cells transfected 
with just  eGFP.  Transfection  is  a  stressful  process  for  cells  therefore  for  future 
experiments, it would advisable to transfect cells with lipofectamine alone or with an 
inert  protein  for  a  control  experiment.  Please  refer  to  chapter  4.0  for  further 
discussion on the limitations in this experiment.
188Table 3.9.
A table to summarise the rate of rise and recovery of ATP induced Ca2 +  transients in C2C12 
cells transfected  with  eGFP,  eGFP  +  DNG— >A  and  eGFP  +  DN-»GS.  The  results  are 
presented as means ± SEM.  (C)= control, (TF)= transfected.
Experiment 
(C2C12 cells)
Rising rate constant 
min' 1
Reference
eGFP only 2.15 ± 0.26(C)  t 
1.07 ±0.21 (TF)
Figure 3.62
eGFP + DNG-+A 1.02 + 0.14(C)  %  
0.61 ±0.11 (TF)
Figure 3.60
eGFP + DNG— >S 0.54 ± 0.06 (C)  U  
0.32 ± 0.06 (TF)
Figure 3.61
t  Rise: eGFP (C) vs. (TF) p<0.001 (***).
%   Rise: eGFP + DNGA (C) vs. (TF) p>0.05 (NS) 
U   Rise: eGFP + DNGS (C) vs. (TF) p>0.05 (NS)
Rise eGFP (TF) vs. eGFP + DNGA (TF)
Rise eGFP (TF) vs. eGFP + DNGS (TF)
1894.0  Discussion
4.1  The distribution of Kir6.1 in immortalised cells lines:
The  main  focus  of this  thesis was to  investigate the  subcellular distribution of ATP- 
sensitive  potassium  subunit  Kir6.1  in  immortalised  cell  lines.  Using  transient 
transfections, I found that a large proportion of Kir6 .1  was expressed in the ER however, 
in the presence of its receptor SUR1, there was very little membrane staining and the 
majority  of the  signal  remained  intracellular.  In  addition  to this,  immunofluorescent 
staining results support the fact that native Kir6 .1   is expressed in the ER to some extent 
in mitochondria.  The latter is an important observation as Kir6.1 may be a component of 
the mitoKATP channel that is hypothesised to be  involved  in  IPC {Suzuki et al.  1997). 
Using two  different  approaches:  i) the  overexpression  of proteins and  ii)  staining for 
endogenous protein, approximately 35-55 % of Kir6.1 was distributed in the ER with 20- 
25 % expressed in mitochondria in immortalised cell lines.
4.2  The evidence for Kir6 .1  in mitochondria
In  my hands,  I  showed  that Kir6.1  is present  in  the ER and  mitochondria  in cardiac, 
skeletal  muscle and  liver cell  lines.  I  did  not investigate the trafficking of Kir6.1  in 
primary cells because of the timescale available and the fact that they are notoriously 
difficult to transfect.  Transient transfections and staining for native Kir6.1 showed that a 
small but significant proportion of Kir6.1 exists in mitochondria in these cell lines.  Using 
the immunofluorescent staining approach,  I then co-stained these cells with the Kir6.1 
antibody and cytochrome C oxidase, a classic marker for mitochondria and detected a 
small proportion of Kir6.1  in mitochondria.  My antibody also detected Kir6.1  in HL-1 
cardiomyocytes  which  is  a  rat  cell  line  however;  I  was  not  able  to  detect  natively 
expressed Kir6 . 1 in freshly dissociated rat ventricular myocytes.
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suggested  that  mitoKATP  channels  would  also  consist  of Kir6.0  and  SUR  subunits. 
Suzuki et al suggested that Kir6 .1   was located in mitochondria based on the immunoblot 
analysis  of mitochondrial  fractions  from  rat  skeletal  muscle  and  liver  from  isolated 
plasma membrane vesicles.  Their antibodies detected Kir6.1 as a 51 and 47 kDa protein. 
My Kir6.1  antibody also detected a band of a similar size (48 kDa) which is consistent 
for the molecular weight  of Kir6.1.  Furthermore,  Garlid’s  group  later  identified two 
proteins at 55 and 63 kDa with mitoKATP activity in mitochondrial fractions (Bajar et al. 
2001; Paucek et al.  1992).  The 63 kDa protein was proposed to be the SUR subunit 
whilst the  55  kDa protein was the pore  forming subunit of the channel.  The 63  kDa 
protein from rat brain was bound to fluorescent glibenclamide and the authors suggested 
that this may be the SUR subunit of the mitoKATP channel.  Recent studies using different 
cell types have confirmed that Kir6.1  is expressed in mitochondria (Lacza et al 2003a, 
2003b).
It has been  reported that  Kir6.1  mRNA  and not Kir6.2 or SUR2A  is only elevated in 
cardiomyocytes  during  metabolic  stress  such  as  ischaemia  (Akao  et  al.  1997). 
Interestingly, one group have reported the clear expression of Kir6.1 and SUR1 in cardiac 
ventricular myocytes with their antibodies (Morrissey et al.  2005).  On the other hand, 
Kir6.1,  Kir6.2 and  SUR2  proteins were also expressed in  mitochondria using Western 
blot analysis (Cuong et al. 2005).  The authors showed that the SUR subunit, which was 
identified  using  green  fluorescent  probe  glibenclamide-BODIPY  colocalised  with 
mitotracker  red  in  rat  myocytes  and  mitochondria  but  SUR1  was  not  present  in 
mitochondria.  The  SUR2A  gene  is  expressed  abundantly  in  cardiac  muscle  so  the 
presence of SUR1  may indicate that the mitoKATP channel does consist of Kir6.1/SUR1 
as Liu et al originally suggested {Liu et al. 2001).  It is possible that a small proportion 
Kir6.1 and SUR1 may form K atp channels but I was unable to detect Kir6.1 at the plasma 
membrane because expression levels were too low.
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expressed strongly in mitochondrial and microsome fractions but weakly on the plasma 
membrane {Zhou et al. 2005).  Interestingly, Kir6.2 was also expressed in the microsome 
fraction but weakly at the plasma membrane and mitochondria.  This is in line with my 
findings  as  I  was  not  able to  detect  any  membrane  staining  in  cells transfected  with 
Kir6.1-GFP and  SUR1.  Furthermore,  Kir6.2-GFP did not  localise in mitochondria in 
HEK293 cells which implies that Kir6.2 is not part of the  m i t o K A T P  channel {Hu et al 
1999).  Kir6.1  has also  been  identified  in rat ventricular myocytes and were localised 
with a mitochondrial marker called MitoFluor red, and anti-Kir6.1 antibodies recognised 
a polypeptide of 48  kDa in  mitochondrial  membrane fractions SUR1  and  SUR2 were 
absent  in  heart  mitochondria,  which  suggest  that  if  Kir6.1  is  part  of the  mitoKA T P 
channel,  it  may  coassemble  with  a  different  sulphonylurea  like  subunit  {Singh  et al. 
2003).  According to the literature, this can either be a SUR1 or even a SUR2 like protein 
{Liu et al 1999).  There is more evidence to support the fact that Kir6.1 and not Kir6.2 is 
the  possible  component  of the  mitoKA T p  channel  though  I  am  not  in  the  position  to 
speculate the exact identity of its sulphonylurea receptor.  Kir6 . 1  may be expressed in 
mitochondria, it but does not imply that it is part of the mitoKA TP channel.
4.3  The evidence against Kir6.1 in mitochondria
There are studies that support the hypothesis that Kir6.1  exists in mitochondria, whether 
it is part of the mitoKA rp channel remains controversial.  In the last eight years, this field 
has taken a new direction as there are now studies that question the existence of mitoKA Tp 
channels.  My data suggests that a significant amount of Kir6 .1   is expressed in the ER 
with a small proportion of Kir6.1  in mitochondria.  Previous studies have suggested that 
Kir6.1/SUR1  K At p   channel  subunits transfected  in  HEK293  cells most resembled the 
native mitoKA xp channel in rabbit myocytes with such channel activity and pharmacology 
{Liu et al  2001).  The presence of SUR1  did not significantly alter the distribution of 
Kir6.1  at the plasma  membrane or mitochondria.  Another group  reported that  GFP- 
tagged Kir6.1, alone or co-expressed with various splice forms of SUR1  did not target to 
mitochondria at all {Hambrock et al 2002).  However, our group has been able to detect
192channel activity in HEK293 cells transfected with Kir6.2-GFP and SUR1.  The mitoKATp 
channels may not exist or may be composed of entirely different subunits which imply 
that Kir6.1 and SUR1 may not form functional channels naturally.
One study examined the molecular composition of K atp  channels with adenoviral gene 
transfer  expressing  wild-type  and  dominant-negative  constructs  of Kir6.1  and  6.2  in 
rabbit ventricular myocytes {Seharaseyon et al.  2000).  Kir6 .1   and Kir6.2 constructs did 
not affect mitoKATp channel activity, as assayed by measuring the changes in flavoprotein 
autofluorescence.  These  results  contradict  the  earlier  proposal  based  on  subcellular 
antibody  localisation  that  Kir6.1  may  be  part  of the  mitoKATp  channel  {Suzuki et al. 
1997).  The authors did not rule out that Kir6.1 may exist in mitochondria but it may not 
heterodimerize with the dominant negative forms.  This may be true for with my results 
as  Kir6.1  was  detected  in  mitochondria  using  transfected  Kir6.1  which  may  not  co- 
assemble with SUR1.  Recent studies have also suggested that neither Kir6.1  nor Kir6.2 
are part of the mitoKATp channel in mitochondria isolated from rabbit and mouse heart 
{Miki et al 2002; Suzuki et al 2002).  Furthermore, Kir6 .1   knockout mice were shown to 
die from sudden cardiac death associated with vasopasm but mitoKATp channel opening 
was not affected by the absence of this K atp  subunit {Miki et al. 2002).
The  original  study which  used  the  immunogold  labelling technique to  investigate  the 
distribution of Kir6.1  was novel at the time {Suzuki et al.  1997).  However, a review by 
Grover  and  Garlid  disputed  the  reliability  of the  Kir6.1  antibody  used  in  this  study 
because there was a possibility that it could bind to other unidentified proteins in the 
sample {Grover & Garlid 2000).  Other Kir6.1  antibodies in different studies have been 
used to identify the location of Kir6 .1   but recent reviews have recognised potential flaws 
in  their data.  For example,  the technical  aspect  of Lacza’s  study  was  questioned  by 
Hanley and Daut’s recent review because the mitochondrial samples used were enriched 
by a factor of 8  in  Western blots increasing the chances of contamination because the 
antibodies  could  cross  react  with  other  proteins.  Kir6.1  and  Kir6.2  also  contained 
mitochondrial  targeting  sequences  which  Hanley  and  Daut  were  not  able  to  verify
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ensure that the endogenous expression of Kir6 .1 in the immortalised were accurate.
Ardehali’s prominent study in 2004 questioned the existence of mitoKATp channels.  The 
authors’  findings  added  further  controversy  to  the  identity  of the  mitoKATp channel 
because  this  multiprotein  complex  that  conferred  mitoKATp activity  consisted  of five 
different mitochondrial proteins including SDH  (Ardehali et al.  2004).  These proteins 
were detected via Western blotting however, Kir6.1  was not detected.  This group later 
examined  this  multiprotein  complex  further and  postulated  that  perhaps  this  complex 
could act upstream and modulate the mitoKATp channel {Ardehali & O’Rourke 2005).
4.4  Putting colocalisation and immunofluorescent staining data together
Kir6 .1  is  expressed  in  tissues  such  as  in  cardiac  muscle,  skeletal  muscle,  liver  and 
pancreas {Inagaki et al  1995c).  I examined the distribution of Kir6.1  in skeletal muscle 
(C2C12), liver (HepG2) and cardiac (HL-1) cell  lines.  The results showed that Kir6.1 
was predominantly located in the ER with a small proportion located in mitochondria.  In 
cells transfected with Kir6.1-GFP and SUR1, Kir6.1  was expected to translocate to the 
membrane because RKR retention motif is masked on both subunits, which promotes exit 
from the ER.  However, Kir6.1  was still ER retained and there was no clear membrane 
staining.  The rationale for transfecting Kir6.1-GFP with SUR1  in my experiments was 
because in Liu’s study, it was reported that the Kir6.1/SUR1  channel closely resembled 
native mitoKATp channels with such pharmacology and single channel conductance at the 
plasma membrane {Liu et al.  2001).  These results are in line with another group where 
the Kir6.1/SUR1 type channel does exist and exhibited channel activity in HEK293 cells. 
In these cells,  K atp   channel  currents were activated  in the presence of diazoxide and 
inhibited by tolbutamide or glibenclamide {Ammala et al. 1996a; 1996b).
A plausible explanation for these observations may be that overexpressing Kir6 .1   would 
lead to a higher proportion of Kir6 .1   being ER retained as there are sufficient functional 
K atp channels already on the plasma membrane.  Most post-translational processes occur
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degradation (.Klausner & Sitia 1990).  However, it is likely that Kir6.1 does not normally 
associate with SUR1 therefore the RKR motif is not masked causing Kir6.1 to be retained 
in the ER.  If I had chosen SUR2A or SUR2B, there may be some translocation to the 
plasma membrane  or possibly  mitochondria as  we  know these  combinations  of K atp 
channel subunits exist in different tissues.  On a technical note, the GFP tag on the Kir6.1 
subunit  could  interfere  with  the  assembly  of  the  K Atp  channel  causing  Kir6 .1  to 
accumulate in the ER.  Furthermore, our group have previously shown that HEK293 cells 
co-transfected with Kir6.1-GFP and SUR2B can form functional channels with distinct 
channel activity at the plasma membrane (Cui & Tinker, unpublished observations).  This 
was not the case because HEK293 cells transfected with Kir6.2-GFP alone did not exit 
the ER but co-transfection with SUR1  showed prominent membrane staining and which 
suggests that the Kir6.1/SUR1  isoform does not exist and form functional channels.  For 
example, Cuong et al did not detect SUR1  in their samples and it is likely more evidence 
to suggest that if Kir6 .1   is part of the m itoK ATP channel, it would associate would a SUR2 
like protein (Lacza et al. 2003, Cuong et al 2005).
Despite this observation, Kir6.1  may exist in other intracellular membranes for example; 
functional KAtp channels have been identified on the nuclear membrane of pancreatic (3 
cells (Quesada et al. 2002).  The majority of Kir6.1  was distributed in the ER and I was 
able to  detect a  small  proportion  of Kir6.1  in  mitochondria.  The  immunofluorescent 
staining data confirmed that  Kir6.1  was  natively expressed  in  these  immortalised cell 
lines.  Concanavalin  A  FITC  mainly stains the  ER but it may also  stain  proteins that 
contain  lectins,  namely  internal  and  non-reducing  terminal  alpha-mannosyl  groups 
therefore it must be taken into consideration that the results obtained in chapter 3.3 that 
show  prominent  ER  staining may  also  stain  parts  of the  Golgi  body.  Kir6.1  is  also 
expressed in mitochondria.  However, its distribution was not altered in the presence of 
SURE  It is possible that there was a small amount of Kir6.1  at the plasma membrane 
which I could not detect and Kir6 .1   may reside in the ER before it is redistributed to the 
plasma membrane.  Although there is now emerging evidence to suggest that a SUR2 like 
protein is more likely to be closely associated with Kir6.1, my colocalisation studies were
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currents as reported by Liu et al (Liu et al 2001).  Its pharmacology is almost identical to 
native mitoKATp channels in this paper indicate that SUR1  may be part of the mitoKATp 
channel.  For example, this channel was activated by diazoxide and this is an important 
observation  because  SUR2A  containing  channels  do  not  respond  to  diazoxide.  In 
addition to this, 5-HD only blocked channel activity in SUR1  containing channels.  P- 
1075 did not activate mitoKA Tpand Kir6.1/SUR1 channels.
From these observations, Kir6 .1   does not appear to be part of the mitoKATp channel and 
the channel in question may be composed of entirely different subunits.  The distribution 
of Kir6.1  in these organelles may have important functional roles.  In the ER, Kir6.1 may 
modulate  Ca  handling  and  the  small  proportion  in  mitochondria  may  modulate 
mitochondrial function.  I then examined the functional consequences of this subcellular 
distribution using siRNA and dominant negatives for Kir6.1.
4.5  The role of Kir6.1 and K a t p  channels in ROS production
The aim of chapter 3.4 was to examine whether K atp channel opening would lead to ROS 
production and in particular, whether K atp channel subunit Kir6 .1  may have a functional 
role in mediating ROS production.  I predicted that the addition of diazoxide would cause 
a  significant  increase  in  ROS  production  due  to  the  opening  of  K atp  channels  and 
glibenclamide would inhibit this response.  The data showed that diazoxide induced the 
oxidation of the ROS indicator dye dichlorohydrofluorescein (H2DCF), hence an increase 
in ROS production in HepG2 and C2C12 cell lines which contain an abundant amount of 
endogenous Kir6 .1.  In addition to this, I observed the inhibitory effects of glibenclamide 
on ROS production, which also implies the involvement of K atp channels.  In agreement 
with my findings, the results of another study showed that diazoxide increased H2DCF 
oxidation in rat ventricular myocytes with 5-HD attenuating this response (Forbes et al 
2001).  On  the  other  hand,  a  similar  study  using  rabbit  cardiomyocytes  showed  no 
changes in fluorescence in response to diazoxide (Cone & Liu 2001).
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functional  K atp   channels  would  exist  in  this  cell  line  (Cui et al.  2001).  Given  this 
observation, 1  did not anticipate changes in ROS production in response to diazoxide and 
glibenclamide in this cell line.  However, diazoxide was able to increase ROS production 
and  glibenclamide  abolished  this  effect.  These  observations  suggest  that  these 
pharmacological agents have K atp  channel independent effects.  Furthermore, the lack of 
functional  K atp  channels in HEK293 cells imply that the responses observed in C2C12 
and HepG2 cell lines may not result from K atp  channel activity or Kir6.1 expression but 
rather the indirect effects of diazoxide and glibenclamide.  The absence of Kir6.1 did not 
alter diazoxide-induced ROS production in HepG2 and HEK293 cells.  The stimulatory 
effect  of diazoxide  and  inhibitory  effect  of glibenclamide  were  more  pronounced  in 
C2C12  cells  lacking  Kir6.1  which  imply  that  these  compounds  do  possess  indirect 
effects.  If Kir6.1  is a component of the mitoKATp channel then the source of ROS must 
be derived from elsewhere such as the respiratory chain or perhaps a mitoKATp channel 
composed of entirely different subunits may be involved in mediating ROS production 
and protection {Ardehali et al. 2004).  My results also showed that ROS production was 
unrelated to Kir6.1 expression.
In support of my  findings, one recent study has confirmed that  K atp  channels are not 
responsible for diazoxide induced ROS production (Drose et al. 2006).  In isolated liver 
and  heart  mitochondria,  diazoxide-induced  ROS  production  and  5-HD  abolished  this 
response.  Drose et al were able to exclude the complete involvement of K atp channels 
because diazoxide could still stimulate ROS production K+ free medium and absence of 
ATP.  In theory,  mitoKATp channels should be opened in the absence of ATP and  K+  
{Garlid &  Paucek 2003).  Furthermore,  the  protective  doses  of diazoxide  stimulated 
mitochondrial  respiration  and  increased  ROS  generation  with  5-HD  attenuating  this 
response {Minners et al. 2007).  Protection was independent of mitoKATp channel activity 
and the data showed that  inhibiting mitochondrial  respiration was a  key  step  in ROS 
signalling.  The authors suggested an alternate hypothesis that mitochondrial respiratory 
inhibition rather than  m ito K ATP  channel opening was the mediating event in diazoxide 
induced protection.
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activates  a  number  of intracellular  messengers  that  lead  to  protection.  It  has  been 
reported that at high doses, diazoxide can act as a weak protonophoric uncoupler rather 
than a KCO (Holmuhamedov et al.  2004; Kowaltowski et al.  2001; Portenhauser et al. 
1971).  Diazoxide and pinacidil are lipophilic and facilitate the transfer of protons across 
the mitochondrial inner membrane; this is consistent with the fact that a high A\j/m  will 
enhance ROS production (Holmuhamedov et al. 2004).  This may also explain the results 
where a burst of ROS was observed perhaps due to the uncoupling rather than channel 
opening properties of diazoxide.  In addition to this, the uncoupler DNP was shown to 
protect  hearts  from  ischaemia  which  strongly  supports  the  notion  that  protonophoric 
uncoupling is another mechanism that can precondition the heart which is independent of 
K atp channels (Minners et al. 2000).  However the list of non specific effects such as the 
ability to enhance mitochondrial swelling, substrate oxidation and cause changes in fatty 
acid metabolism and ROS production suggests that it may not act directly on mitoKATP 
channels.  Garlid originally reported that diazoxide was a specific and potent activator of 
m i t o K ATP channels with half-maximal effect (EC50) at < 3   pM {Garlid et al.  1996).  The 
foundation for using glibenclamide instead of 5-HD in my experiments was because 5- 
HD is a known  substrate for the p-oxidation pathway and possess many other channel 
independent  actions  {Drose  et  al.  2006;  Hanley  et al.  2002,  2003).  However,  these 
pharmacological compounds are not always truly ‘selective’ for K Atp channels and their 
cardioprotective mechanism can be attributed by other mechanisms.
My  data  showed  that  diazoxide  and  glibenclamide  had  significant  effects  on  ROS 
production.  The source of ROS is cellular, I cannot confirm whether it is mitochondrial 
but it can be derived from other intracellular sources such as xanthine oxidase, NADPH 
oxidase or the respiratory chain.  Given more time, further experiments would be carried 
out  in  the  presence  of  specific  inhibitors  for  these  enzymes  to  determine  their 
involvement  in  ROS  production.  For NADPH  oxidase,  diphenylene  iodonium  (DPI) 
would be used to inhibit NADPH oxidase activity whereas xanthine oxidase would be 
inhibited using oxypurinol; this is a metabolite of allopurinol and has preferential binding 
to the reduced  form  of xanthine  oxidase.  If the  source  of ROS  is  derived  from  the
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ROS  production.  However,  DPI  is  known  to  inhibit  the  respiratory  chain,  NADPH 
oxidases and xanthine oxidase (Li &  Trush 1998,  O’ Donnell et al 1994).  To conclude, 
diazoxide induced ROS production was abolished by glibenclamide however, there is no 
link between diazoxide mediated ROS production and Kir6.1 expression.
4.6  The effects of pharmacological agents on mitochondrial redox state
Kir6.1  does not have role in ROS production and diazoxide and glibenclamide possess 
non specific effects that are independent of K atp channels.  Despite this conclusion, K atp 
channels  may  still  exist  in  mitochondria and  their activity can  be  modulated by these 
pharmacological compounds.
Table 4.1.  A table to show the studies that measured the changes  in  flavoprotein  fluorescence 
and  the  effects  of  potassium  channel  opener  diazoxide  and  inhibitor  glibenclamide  on 
mitochondrial redox state.
Journal Cell tvDe Diazoxide 
(100 pM)
Glibenclamide 
(10 pM)
Other
Dha rmacolozical 
agents
Reference
Circulation Rabbit
Ventricular
myocytes
Oxidised
flavoproteins
No effect (but 
may promote 
further
uncoupling of 
mitochondria)
500 pM 5-HD 
blocked diazoxide 
induced 
flavoprotein 
oxidation
Liu  et  al. 
1998
Annals  of  the 
New  York 
Academy  of 
Sciences
Rabbit
Ventricular
myocytes
Oxidised 
flavoproteins 
(P-1075  also 
produced the 
same effect)
n/a 500 pM 5-HD 
blocked diazoxide 
induced 
flavoprotein 
oxidation
Liu  et  al. 
1999
Circulation Rabbit
Ventricular
myocytes
Oxidised
flavoproteins
n/a 500 pM 5-HD 
blocked diazoxide 
induced 
flavoprotein 
oxidation, 30 pM 
HMR1098 did not
Sato  et  al. 
2000
British Journal 
of
Pharmacology
Rat
ventricular
myocytes
No effect n/a n/a Lawrence 
et al. 2001
Journal  of 
Physiology
Guinea  Pig
ventricular
myocytes
No effect n/a n/a Hanley  et 
al. 2002
199The  opening  of mitoKATP  channels  would  alter the  A\j/m   and  uncouple  mitochondria. 
Such dissipation will enhance electron transfer within the respiratory chain leading to the 
net oxidation of the mitochondrial matrix which can be detected by measuring an increase 
in  flavoprotein  autofluorescence.  This technique  is  routinely used  as  an  indicator of 
mitoKATP  channel  activity  and  many  groups  have  used  this  method  to  evaluate  the 
relationship between  m it o K ATP  channel  activity and pharmacological agents (O’ Rourke 
2004; Garlid 1996).  The studies of interest are highlighted in table 4.1.  In my hands, a 
small  amount  of  Kir6.1  was  expressed  in  mitochondria.  Given  this  observation,  I 
investigated  the  possible  effects  of diazoxide  and  glibenclamide  on  mitochondria  by 
measuring the changes in mitochondrial redox state.
My data showed that  100  pM  diazoxide and  10  pM  glibenclamide had no significant 
effect on mitochondrial redox state in C2C12 cells and rat ventricular myocytes.  Despite 
these initial observations, diazoxide significantly increased flavoprotein oxidation when 
myocytes were pre-treated with  1   mM 3-NPA.  This increase in flavoprotein oxidation 
(observed  as  an  increase  in  flavoprotein  autofluorescence  and  reciprocal  decrease  in 
NADH autofluorescence) was completely diazoxide dependent.  Glibenclamide did not 
block this response.  However, I could not reproduce this phenomenon in C2C12 cells. 
My  results  oppose  previously  published  work  because  Marban’s  group  were  able  to 
initiate  flavoprotein oxidation  with  100  pM diazoxide  (Liu et al.  1998).  The authors 
investigated the effects of diazoxide and 5-HD on mitochondrial redox state and sarcKATP 
current in rabbit ventricular myocytes.  These variables were measured simultaneously 
where  100 pM diazoxide increased flavoprotein autofluorescence but failed to activate 
sarcolemmal  currents,  confirming  the  existence  of mitoKATP  channels.  The  selective 
m ito K ATP blocker 5-HD abolished the redox changes induced by diazoxide.
In  my  hands,  the  inhibition  of  SDH  by  3-NPA  was  vital  for  diazoxide  induced 
flavoprotein oxidation.  My results are in  line with two similar studies where  100 pM 
diazoxide alone did not promote flavoprotein oxidation in rat and guinea pig myocytes 
{Hanley et al 2002;  Lawrence  et al.  2001) but disagree  with  the original  findings  of 
Marban’s group {Liu et al 1998).  Subsequent studies conducted by Marban’s group were
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{Sato et al 2000; Sasaki et al.  2000; Liu et al.  1999).  It is important to note that the 
recordings from Marban’s group were obtained from myocytes isolated in Ml99 medium 
but experiments were performed  in glucose-free physiological  salt solution which may 
have  enhanced  the  cells’  ability  to  consume  more  substrates  when  respiration  was 
stimulated with pharmacological agents.  The myocytes used in my experiments were not 
substrate starved which may account for the difference in results.  The variation between 
the studies highlighted in table 4.1  may be linked to experimental conditions or possibly 
even species differences.
My  data  also  showed  that  3-NPA  alone  did  not  affect  flavoprotein  oxidation.  The 
inhibition of SDH by 3-NPA may not be necessary to dissipate the A\j/m  because electrons 
will  continue  to  pass  from  complex  I  to  III,  which  may  explain  why  no  change  in 
flavoprotein autofluorescence was observed in the presence of 3-NPA.  However, 3-NPA 
pre-treatment was essential for diazoxide to stimulate respiration.  Previous work carried 
out  in  our  laboratory  showed  that  1   mM  3-NPA  and  30  pM  diazoxide  induced 
flavoprotein oxidation (Duchen lab, unpublished observations).  In my hands, it was not 
possible to  induce  flavoprotein  oxidation  unless  100  pM  diazoxide was administered. 
Glibenclamide was administered after diazoxide application based on the assumption that 
it  would  inhibit  flavoprotein  oxidation  by  closing the  m ito K ATP  channel  but my  data 
showed that it did not reverse flavoprotein oxidation.  Furthermore, glibenclamide has 
been shown to uncouple mitochondria significantly {Garlid et al.  1997; Szewczyk et al.
1997).  These experiments have shown that 3-NPA and diazoxide were responsible for 
flavoprotein oxidation but this phenomenon does not confirm the involvement of Kir6 .1  
nor mitoKATP channels.  To add further fuel to this controversy, Ardehali’s study found 
that their multiprotein complex was sensitive to KCOs and inhibitors but also to SDH 
inhibitors such as 3-NPA which promoted  m ito K ATP  channel activity and  K+ transport 
{Ardehali et al 2004).
2014.6  The effect of pharmacological agents on A vy™
The A vj/m  is an important factor to measure because the dissipation of A vj/m  is thought to 
lead to an increase in flavoprotein oxidation.  My data showed that  100 pM diazoxide 
caused  mitochondrial  depolarisation  in  C2C12  cells,  whereas  glibenclamide  had  no 
effect.  Similar  effects  of KCOs  have  been  reported  in  isolated  rat  skeletal  muscle 
mitochondria and  intact L6  skeletal myoblasts (Debska et al.  2002).  In other studies, 
C2C12  myoblasts  subjected  to  diazoxide  or  adenosine  treatment  resulted  in  mild 
uncoupling, assayed by the increase in oxygen consumption, small decrease in A\|/m , and 
reduction of cellular ATP levels (Minners et al.  2000).  The authors also reported that 
diazoxide  and  nicorandil  caused  significant  mitochondrial  depolarisation  which  was 
followed by an increase in oxygen consumption in a dose dependent manner; this effect 
was completely inhibited by glibenclamide but partially by 5-HD.  However, the A\j/m . 
did  not  change  in  the  presence  of 3-NPA  and  diazoxide  (which  caused  significant 
flavoprotein  oxidation)  but  there  was  some  uncoupling  effect  upon  glibenclamide 
addition.  The presence of 3-NPA has been confirmed by others to not affect the Ai|/m  
whereas  in  Ardenhali’s  study,  3-NPA  was  able  to  activate  m i t o K A T P   currents  in  lipid 
bilayers (Busija et al. 2005, Ardehali et al. 2004).
Table 4.2.  A table to show the studies that examined the  changes  in  mitochondrial  membrane 
potential (A\j/m) in the presence of potassium channel opener diazoxide.
Journal Cell tvoe Diazoxide 
(100 pM)
Glibenclamide 
(10 pM)
Other compound Reference
British Journal 
of
Pharmacology
Rat
Ventricular
myocytes
No  changes 
in Avj/m
n/a 1  pM FCCP 
collapsed Av|/m
Lawrence 
et al. 2001
Journal  of 
Physiology
Rabbit
Ventricular
myocytes
No  changes 
in Av|/m
n/a 100 pM  DNP 
collapsed Av|/m
Hanley  et 
al. 2002
The data suggest that the changes in flavoprotein autofluorescence are not associated with 
the changes  in  A\|/m .  I  was not able to examine the effects of 3-NPA, diazoxide and 
glibenclamide in rat ventricular myocytes.  The phototoxicity effect of the laser caused
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difficult to take accurate measurements.  The studies of interest are highlighted in table 
4.2.  In my hands, the addition of 1   mM 3-NPA and 100 pM diazoxide did not alter Avpm  
in C2C12 cells, perhaps, the combination of 3-NPA and diazoxide increased respiration 
significantly  (observed  as  an  increase  in  flavoprotein  autofluorescence)  to  restore the 
A\\fm  so the changes in A\|/m  could not detected.  The complete dissipation of the A\j/m  was 
only observed in response to the protonophore FCCP.  Hanley et al’s data agrees with my 
results as they also observed no changes in Avj/m  with  100 pM diazoxide (and  100 pM 
pinacidil)  in  guinea pig ventricular myocytes (Hanley et al 2002).  These findings are 
also in agreement with another group where Avpm  was not affected by the presence of 100 
pM diazoxide (/Mwrence et al. 2001).
4.7  The non-specific effects of Katp channel openers and inhibitors
The decision to use diazoxide and glibenclamide in these experiments was based on their 
specificity and ability to modulate the  m i t o K A T P  channel.  Garlid reported that diazoxide 
had a potency  for mitoKA TP channel about  2 0 0 0 -fold higher than the sarcKA T p channel 
(< Garlid et al.  1996).  Studies in the 1970’s demonstrated the coupling effects of diazoxide 
in heart and liver mitochondria where  150 pM diazoxide caused 60 % inhibition of SDH 
and a decrease  in  pyruvate and  fatty acid oxidation  {Schafer et al.  1971).  Therefore, 
diazoxide may act either to open the mitoKA TP channel or inhibit SDH depending on the 
concentration  used.  My  functional  data  showed  that  these  compounds  possess  non­
specific and toxic effects that are independent of KA T P channels.
In preliminary studies, I was not able to induce flavoprotein oxidation with a low dose of 
diazoxide (50 pM) {unpublished observations).  Liu’s study showed that the increase in 
flavoprotein autofluorescence in rabbit myocytes was due to  100 pM diazoxide {Liu et al
1998).  The  increase  in  flavoprotein  autofluorescence  was  interpreted  as  mitoKA T P 
channel  opening  and  was  a  consequence  of mitochondrial  depolarisation.  This  is  an 
interesting result because it is the low concentration of diazoxide (30 pM) that is reported 
to confer protection in isolated hearts.  However, the increase in flavoprotein oxidation in
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data  (and  studies)  discussed  here  show  that  only  the  higher  dose  of diazoxide  will 
promote  flavoprotein  oxidation  which  is  not  consistent  with  these  observations. 
Furthermore,  Garlid  stressed that a high  dose of diazoxide  (100  pM)  was  higher than 
required  to  open  K Atp   channels  in  Liu’s  study  to  observe  changes  in  flavoprotein 
oxidation.  Therefore  the  results  may  not  be  a  direct  response  to  m i t o K A T P   opening 
because  in  addition,  there was  a  significant time delay of  10-12  minutes  between the 
administration of diazoxide and the start of the signal (Garlid 2000).  This specific time 
delay  is  also  true  for  my  data  but  diazoxide  alone  could  not  increase  flavoprotein 
oxidation unless the cells were pre-treated with 3-NPA.
One advantage of my work is that I was able to measure the changes in flavoprotein and 
NADH  autofluorescence  simultaneously.  My  results  are  in  agreement  with  Hanley’s 
study  where  they  also  observed  no  effect  of  100  pM  diazoxide  on  flavoprotein 
autofluorescence in guinea pig ventricular myocytes.  They also stated that the inhibition 
of  SDH  was  important  for  flavoprotein  oxidation  which  operates  independently  of 
mitoKA Tp channels (Hanley et al.  2002).  A  recent study examining the crystal structure 
of avian complex II protein showed that 3-NPA irreversibly inactivates complex II upon 
oxidation  by  forming  permanent  covalent  bonds  to  modify  its  catalytic  machinery 
(Huang et al.  2006).  This  supports  the  hypothesis  that  SDH  may  modulate  mitoKATp 
channels  because when  SDH  is  inhibited, the addition of diazoxide may still  activate a 
mitoKA TP  channel  or  act  independently  on  neighbouring  proteins  to  activate  signal 
transduction pathways that increase rate of respiration (Ardehali & O’Rourke 2005).
Glibenclamide significantly reduced diazoxide  induced ROS production  which  initially 
suggested  the  involvement of K Atp  channels.  Glibenclamide  had no  major effects on 
mitochondrial  redox  state  in  C2C12  cells  but  in  rat  myocytes,  glibenclamide  did  not 
block  the  rate  of  flavoprotein  oxidation  which  suggests  that  it  may  not  act  on 
mitochondrial redox state.  Gibenclamide has non-specific effects; it is a potent inhibitor 
of carnitine palmitoyltransferase which reduces the rate of fatty acid oxidation perhaps 
contributing to  increased  flavoprotein  oxidation  {Cook  1987).  This  may  explain  why
204glibenclamide did not block flavoprotein autofluorescence in my rat myocytes and this is 
also  true  of Liu’s  original  study  in  rabbit  myocytes  because  the  rate  of flavoprotein 
oxidation  was  maintained  {Liu  et  al.  1998).  However,  at  higher  concentrations, 
glibenclamide can  inhibit other members of the ABC  family of transport proteins and 
chloride  channels  (Payen  et  al.  2001;  Rabe  et al.  1995).  The  uncoupling  effects  of 
glibenclamide may not be due to enhanced H+ pumping to maintain the v|/m  but rather the 
increase in permeability to Cf which results in K+ influx {Fernandes et al. 2004).
In  Liu’s  study,  the  data  showed  that  5-HD  abolished  diazoxide  induced  flavoprotein 
autofluorescence but this was not used for my experiments because of its many and non­
specific  side  effects.  Various  groups  have  reported  5-HD  to  affect  sarcKATP  channel 
currents  in  myocytes  induced  by  cromakalim  and  pinacidil  whereas  glibenclamide 
abolished this effect {Sato et al.  1998; McCullough et al.  1991).  Furthermore, Notsu and 
co-workers  showed  5-HD  could  also  block  K Atp   channel  activity  in  cardiomyocytes 
subjected to metabolic inhibition; this suggests that it is not particularly selective for the 
mitoKArp channel {Notsu et al.  1992a and b).  Like all fatty acids, 5-HD is catalysed by 
acyl-CoA synthethase to 5-HD CoA which can be further metabolised in rat mitochondria 
{Lim et al.  2002).  This questions the reliability of their data because 5-HD in substrate 
free conditions  is metabolised by the p-oxidation pathway and fatty acid oxidation can 
induce flavoprotein oxidation {Hanley et al. 2002; 2003;  Vuorinen et al.  1995).
4.8  The controversies surrounding the mitoKATP channel
In this section, 1  will aim to examine my data and discuss the evidence for the  m i t o K A T P  
channel.  The pharmacological compounds used to probe the function of Kir6.1  are not 
always selective for  K Atp  channels.  In particular, my data question the assumption that 
sensitivity to diazoxide and glibenclamide implies the involvement of mitoKATp channels. 
Diazoxide  is a cardioprotective agent  because  it  initiates  mitochondrial  depolarisation, 
conserves cellular ATP and limits Ca2+ uptake {Holmuhamedov et al  1999).  Marban’s 
earlier studies showed that diazoxide increased mitochondrial oxidation and this piece of 
evidence was interpreted as m i t o K A T P  channel opening.  Once the A'Pm dissipates, there is
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production.  However,  the  relationship  between  mitochondrial  uncoupling,  A T*™   and 
flavoprotein  oxidation  are not always related  because  it  is  possible to cause oxidation 
without  depolarisation.  This  has  been  demonstrated  with  my  work  because  my  data 
showed that the changes in flavoprotein oxidation and Av|/m  do not go hand in hand and it 
is unclear whether these two variables are closely linked.
In  support of my  findings,  Brennan and  colleagues showed that  low concentrations of 
FCCP  (100  nM)  caused  flavoprotein  oxidation  without  mitochondrial  depolarisation 
whereas  higher  concentrations  of  FCCP  (300  nM)  caused  significant  depolarisation 
which can be detrimental (Brennan et al.  2006b).  Furthermore this group showed that 
FCCP  was  able  to  promote  protection  and  protection  was  dependent  on  ROS  but 
independent of K a tp  channels.  The evidence for this showed that the  sarcK ATP channel 
was  not  activated  and  protection  was  not  abolished  by  glibenclamide  and  5-HD. 
Myocytes  can  oppose  mitochondrial  depolarisation  by  increasing  electron  transport 
through the respiratory chain by depleting creatine phosphate (Brennan et al. 2006a).
The  opening  of  the  m ito K ATP  channels  has  been  reported  to  have  little  effect  on 
respiration, \j/m , or Ca  uptake but had pronounced effects on matrix and intermembrane 
space volumes (Kowaltowski et al. 2001).  The influx and magnitude of K+ was too small 
to influence respiration and A\j/m .  Since pharmacological preconditioning with diazoxide 
is  usually  credited  with  mitoKATp  channel  opening,  an  alternative  explanation  for the 
cardioprotective effect of these drugs was required.  One school  of thought is that the 
potential role of m ito K ATP  channels  is  its direct interaction with the components of the 
electron transport chain.  For example, the inhibition of respiratory chain enzyme SDH 
may  induce  a  conformational  change  in  the  protein  complex  that  is  accompanied  by 
mitochondrial swelling; this mechanism may protect mitochondria from metabolic stress 
and offer protection by conserving energy and ATP stores.
These  observations  lead  investigators to  believe  that  inhibiting  respiration  rather than 
K atp channel activation may be the underlying mechanism responsible in preconditioning
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inhibiting SDH  but SDH  inhibitors such as 3-NPA and malonate have been reported to 
attenuate  metabolic  stress  and  promote  cardioprotection  in  the  heart (Horiguchi et al. 
2003;  Ozcan et al.  2002;  Ockaili et al.  2001).  Recently, one study reported diazoxide 
inhibited  succinate  supported  respiration  which  promoted  ROS  production  in  C2C12 
myotubes.  Interestingly, this response was achieved independently of mitoKATp channels 
(Minners et al 2007).  In support of my data, the recent study published by Drose et al 
questioned  the  protective  role  of diazoxide  in  cardioprotection  (Drose  et  al.  2006). 
Diazoxide  induced  ROS  production  in  isolated  liver  and  heart  mitochondria  but  this 
response was still observed in the absence of ATP and K+  which strongly suggests that 
ROS production was not the result of K a t p  channel opening.
Diazoxide at cardioprotective concentrations may not induce mitochondrial oxidation or 
depolarisation.  (Lawrence  et al .2001).  The other mechanisms  may be  linked  to the 
changes in mitochondrial matrix volume or the generation of ROS rather than  m ito K ATP 
channel opening (Pain et al 2000).  In addition, Hanley et al showed diazoxide had  K A t p  
channel  independent  targets  in  the  heart  and  it  may  be  the  partial  inhibition  of the 
respiratory chain that  leads to an  increase in  ROS production (Hanley et al.  2002).  In 
light of my results, diazoxide will stimulate respiration in cells pre-treated with 3-NPA. 
However, the changes in flavoprotein autofluorescence and A\j/m  did not correlate which 
suggest that  these  compounds  had  no  effect on  the  m ito K ATp  channel.  Despite these 
observations, the partial  inhibition of the respiratory chain may increase the transfer of 
electrons which was detected as increase in flavoprotein oxidation.  Another possibility is 
that the channel may already be opened but the influx of K+ into the matrix was too small 
to  influence Ai|/m  but  instead promote the close  interaction between components of the 
electron transport chain such as SDH and  m ito K ATP channel.  These results suggest that 
the  changes  in  A\j/m   and  flavoprotein  oxidation  are  not  inevitable  consequences  of 
diazoxide application in intact cardiac myocytes, and that the mitoKATp channel may not 
be the  essential  component of the  mechanism  that provides protection.  The evidence 
from my studies suggests that these pharmacological compounds may offer protection via 
a different mechanism that is independent of K a t p  channels.
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4.9  Ca  signalling and K atp channels-what is the connection?
Kir6.1  is expressed in the ER of cardiac and skeletal muscle as well as liver cell lines.  I 
investigated  the  possible  role  of  Kir6.1  in  Ca2+  handling  with  the  ratiometric  Ca2+  
indicator Fura-2 in C2C12 cells.  I also examined Ca2+ release in rat myocytes because 
these  cells  express  RYR  and  elicit  Ca2+  transients  in  response  to  caffeine.  Ca2+  is 
important for controlling a number of cellular processes and  [Ca2+]i is regulated by the 
entry of external Ca2+ (influx) and its release from internal stores.  Once Ca2+ has carried 
out its signalling functions, the high concentration of Ca2+ is rapidly restored by the Ca2+ 
pumps, PMCA and SERCAs as well as secondary active transporters such as NCX.  The 
opening  of  a  K Atp  channel  in  intracellular  membranes  such  as  the  ER/SR  and 
mitochondria may have a significant impact on cytosolic Ca2+ levels.  K+  is vital for the 
normal  electrical  activity  of  cardiac  muscle  as  the  K+   gradient  is  responsible  for 
maintaining the resting membrane potential and is critical for the repolarisation of the cell 
membrane  when  an  action  potential  has  been  elicted.  The  role  of K+   in  excitation- 
contraction  (EC)  coupling  is  unclear  but  there  are  K +  channels  in  the  cardiac  SR 
membrane similar to those  in the sarcolemma {Hill et al.  1989).  However, there is no 
evidence for K atp channel expression in the ER/SR.
Ca2+  overload  has  been  linked  to  the  damage  caused  by  ischaemic  reperfusion  and 
mechanisms  that  reduce  the  rate  of  Ca2+  release  or  deplete  Ca2+  stores  are 
cardioprotective.  One such mechanism involves the opening of K Atp channels in the SR 
which  may promote Ca2+ release and change Ca2+ transients that can  prevent SR Ca2+
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accumulation during cytosolic Ca  overload.  More importantly, it has been shown that
i
cytosolic Ca  overload occurs during myocardial ischaemic injury (Gettes et al.  1991). 
In cardiac tissue, the release of Ca2+ from the SR will interfere with the transmembrane 
potential which can inhibit its own release and prevent muscle contraction.  It has been 
suggested  that the  opening  of the  SR  KAtp channel  allows  K+  moves  in  the  opposite 
direction to Ca2+ across the SR membrane during the uptake and release of Ca2+ by the
208•  •  2 -F SR  to  prevent  the  development  of large  charge  imbalances which  could  inhibit  Ca 
movement.  This mechanism  is based on the ‘charge compensation’ theory mediated by 
the movement of K+ and Cf  in the SR which maintains electroneutrality (Kourie et al. 
1997;  Tinker et al  1992;  Labarca et al.  1980).  IPC is often associated with decreased 
calcium  release  from  the  SR  regulating  contractility.  One  study  showed  that
2~F  • preconditioning still occurred when the SR was unable to accumulate Ca  (by using a 
low  dose  of ryanodine  to  block  the  channel).  These  observations  suggested  that  the 
changes  in  SR  calcium  release  are  not essential  in  the  mechanism  of preconditioning 
(Cave & Garlick 2000).  Furthermore,  K atp channels had no defined role in contractility 
and Ca2+ release in voltage clamped cells (Tokuno et al 1999).
2+   • Many studies have shown that ATP can stimulate the release of Ca  specifically  from 
intracellular  stores  (FJ-Moatassim  et  al.  1992;  Inscho  et  al.  1996).  My  C2C12  cells 
showed a robust response to  10  pM  ATP with significant Ca2+ transients.  EGTA was 
included in low Ca2+ extracellular solutions so that the Ca2+  responses observed would be 
derived  from  internal  stores  presumably  via  purinergic  P2Y  signalling  pathway. 
However, caffeine did  not  induce Ca  transients  in these cells.  The next step  was to 
differentiate the cells into distinct myotubes to express RYR.  Caffeine should then elicit 
significant  Ca2+  transients  by  activating  RYR  however,  this  was  not  the  case.  The 
population of cells were differentiated for five days but caffeine-induced Ca2+ transients 
were only observed in 51  % of cells.  The Ca2+  stores were partially emptied using this 
low  concentration  of caffeine  and  so  it  was  possible  for re-uptake  into  the  SR.  The 
rationale for using  1   mM caffeine as opposed to  10 mM was because I did not want to 
deplete stores and additional stimulation with ATP would elicit further Ca2+  release.
For future experiments, staining the ‘differentiated’ cells for RyRs may help determine if 
the myotubes  in my study had expressed mature and sufficient RyRs.  To confirm that 
caffeine dependent RYR Ca  release could be measured, rat myocytes were also treated 
with the same caffeine  stock  solution and all  cells responded  immediately by eliciting 
Ca2+ transients.  The next step was to examine if Kir6.1  expression was related to Ca2+ 
release  therefore  C2C12  cells  were  co-transfected  with  DN  for  Kir6.1  and  eGFP  to
209identify transfected cells.  However, there were limitations with these experiments.  Fura- 
2 was excited by IJV light (340/380 nm) whereas blue light would predominantly excite 
eGFP.  The initial results showed that Kir6.1  may play a small role in modulating ATP- 
induced Ca2+ release from the ER/SR because smaller Ca2+ transients were observed in 
cells without Kir6.1.  However, the magnitude of Ca2+ transients in cells transfected with 
just eGFP were also affected.  The Fura-2 ratio in the resting state was lower in eGFP- 
expressing  cells  than  in  their  non  expressing  neighbours.  This  was  an  important
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observation because it showed that the presence of eGFP affected [Ca  ]i measurements 
and made it difficult to determine if transfection itself alter Ca2+ transients.
It has been  reported  that eGFP can  seriously contaminate Ca2+ (Fura-2) measurements 
(Bolsover et al.  2001).  According to the authors, the excitation and emission spectra of 
GFP and its variants are very broad, contributing to cross-talk between the fluorescence 
signals from GFP and the fluorescent Ca2+ indicator.  The excitation spectra of both Fura- 
2 and eGFP  were measured and a small  but rather significant short wavelength tail  of 
eGFP excitation spectrum (350 nm) was present and so the molecule would be excited by 
the 380 nm UV light used to excite Fura-2.  The light that is emitted from eGFP would 
thus reduce the 340/380 Ratio.  Therefore the [Ca2+]j measured was lower than expected. 
Given  this  observation,  I  then  examined  the  kinetics  of the  Ca2+  transients  in  eGFP 
containing cells and found that the signal was quenched and the rising rate constants were 
significantly  lower  than  their  non-transfected  counterparts.  It  was  not  possible  to 
measure the falling rate constants because Ca2+ transients did not make a full recovery. 
Statistical  analysis  showed  that  the  Ca2+   transients  in  cells  transfected  with  DNs  and 
eGFP  were  similar  and  knocking  out  Kir6.1  protein  expression  did  not  prevent  ATP 
induced Ca2+ transients and co-transfection with eGFP did not affect the cell’s ability to
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release Ca  .  However, transfection itself is a stressful procedure and it would have been 
advantageous to include a control experiment (with just lipofectamine or an inert protein) 
to demonstrate that it had not affected the Ca2+ transients.
In conclusion,  I  have demonstrated that eGFP alone does contaminate the Fura-2  ratio 
therefore direct comparisons could not be made between the two cell populations.  To
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my  hands,  I  was  not  able  to  demonstrate  whether  Kir6.1  plays  a  prominent  role  in 
modulating  Ca2+  dynamics.  I  cannot  deduce  if Kir6.1  has  a modulatory  role  in  Ca2+ 
release from internal stores though it is also possible that Kir6.1  may still have a function 
in the ER.  Given the opportunity, to facilitate the measurement of rate constants, 1  would 
increase the sampling rate and use other dyes where there is no detectable contamination 
of the Ca  indicator signal  by the  fluorescent protein.  For example,  blue  fluorescent 
protein could be used with the Ca2+ indicator Fura Red and eGFP could be used with the 
Ca2+ indicator X-Rhod 1.
4.10  Overall conclusion
The  ATP-sensitive  potassium  channel  subunit  Kir6.1  is  predominantly  distributed  in 
intracellular organelles such as the ER and to some extent in mitochondria.  Kir6.1  was 
overexpressed  in  immortalised  cell  lines  and  colocalisation  studies  showed  that  the 
majority of Kir6.1  was located in the ER.  However, the presence of SUR1  did not affect 
the distribution of Kir6.1  and its translocation to the plasma membrane.  It is possible that 
overexpressing Kir6.1  in these cell lines would cause excess Kir6.1 to be ER retained, as 
there are  functional  K atp  channels already  present at the membrane.  Kir6.1  has been 
proposed to be a major component of the controversial  m ito K ATP channel.  Although the 
molecular  identity  of this channel  still  remains elusive,  immunofluorescent staining  in 
cardiac,  skeletal  muscle and  liver cell  lines showed that Kir6.1  was present in the ER 
with a small  but significant amount  in mitochondria.  In addition, several groups have 
identified  endogenous  Kir6.1  in  primary  cardiomyocytes  but  I  was  not  able  to  detect 
natively expressed Kir6.1  in rat myocytes.
The localisation of Kir6.1  is hypothesised to be central to its role in cardioprotection and
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may modulate cellular respiration and Ca  handling.  Since 1997, several publications in 
this field have implicated that  m it o K ATP  channel  opening is a crucial step in  ischaemic 
preconditioning.  I  showed  that  a  small  proportion  of  Kir6.1  was  expressed  in 
mitochondria but this data alone was not sufficient to confirm that Kir6.1  was part of the
211mitoKMP channel.  The potential role of Kir6.1  was also examined in immortalised cell 
lines and in rat ventricular myocytes.  Firstly, I measured the changes in ROS levels in 
C2C12 and HepG2 cell lines which express native Kir6.1.  The data initially suggested 
that  Katp  channels  were  involved  because  diazoxide  significantly  increased  ROS 
production  whereas  glibenclamide  abolished  this  effect.  However,  in  the  absence  of 
Kir6.1  using siRNA and DNs for Kir6.1  and in HEK293 cells that do not express Kir6.1, 
the  same responses were observed.  These  results revealed that these pharmacological 
compounds  may  have  other  intracellular  targets  that  may  influence  cellular  ROS 
production.  Furthermore, it has been demonstrated recently that diazoxide induced ROS 
production is not related to K Atp channels.
The  effects  of  diazoxide  and  glibenclamide  were  also  examined  on  mitochondrial 
function  by  measuring the changes  in mitochondrial  redox state and  Ai|/m .  The results 
showed  that  3-NPA  pre-treatment  (and  SDH  inhibition)  was  an  essential  step  for 
diazoxide to stimulate flavoprotein oxidation  in rat ventricular myocytes.  In my hands, 
Kir6.1  was  absent  in  these  myocytes  whereas  the  C2C12  cell  line  expressed  Kir6.1. 
However, these cells showed no changes in flavoprotein oxidation and A\j/m  in response 
to  3-NPA  and  diazoxide.  Despite  these  observations,  the  changes  in  Avpm   did  not 
correlate with the changes in flavoprotein oxidation which suggested that these variables 
were not linked and the effects observed were independent of K atp channels.  Diazoxide 
may  offer  protection  by  partially  inhibiting  the  respiratory  chain  which  may  alter 
mitochondrial  function.  Recently,  emerging  evidence  has  added  further  fuel  to  the 
identity of the mitoKATp channel by identifying a multiprotein complex which exhibited 
m ito K ATP  channel  activity.  This  complex  did  not  contain  Kir6.1.  M R oK atp  channel 
opening may facilitate the influx of K+ into the matrix and induce mitochondrial swelling 
to promote the close interaction of proteins in the electron transport chain such as SDH 
and mitoKATp channel to initiate protection.
Finally, as the majority of Kir6.1  resides in the ER, Kir6.1  was postulated to have a vital 
role in Ca2+ handling.  In C2C12 cells, ATP induced Ca2+ release from the ER.  In the 
absence of Kir6.1,  the magnitude of ATP  induced Ca2+ transients were smaller but on
212closer inspection, it was revealed that the presence of eGFP that was used to assess the 
transfection efficiency seriously contaminated the Ca2+ (Fura 2) signal.  The presence of 
eGFP  altered  the  emission  spectrum  and  the  entire  Fura-2  ratio.  Suppressing  Kir6.1 
expression  did  not  affect  the  cell’s  ability  to  release  Ca2+  but  I  cannot  deduce  a 
conclusion  from  these  results.  From  my observations,  the potassium  channel  subunit 
Kir6.1  is  predominantly  distributed  in  the  ER  but  also  exists  in  mitochondria. 
Pharmacological  agents  such as diazoxide and glibenclamide have non-specific effects 
and  my  data  show  that  Kir6.1  does  not  appear to  have  a  role  in  ROS  production  or 
mitochondrial  function which suggests that it may not be a component of the  m i t o K A T P  
channel.
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